<LCTL_TEXT lang="spa">
<DOC grammar="none" id="L0C04CVK8" lang="spa" raw_text_char_length="18772" raw_text_md5="abdeb46403c9861ddda7c85bd377613f" tokenization="tokenization_parameters.v5.0">
<TEXT>
<SEG end_char="115" id="segment-0" start_char="1">
<ORIGINAL_TEXT>Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19</ORIGINAL_TEXT>
<TOKEN end_char="7" id="token-0-0" morph="none" pos="word" start_char="1">Lilly's</TOKEN>
<TOKEN end_char="20" id="token-0-1" morph="none" pos="word" start_char="9">bamlanivimab</TOKEN>
<TOKEN end_char="24" id="token-0-2" morph="none" pos="word" start_char="22">and</TOKEN>
<TOKEN end_char="35" id="token-0-3" morph="none" pos="word" start_char="26">etesevimab</TOKEN>
<TOKEN end_char="44" id="token-0-4" morph="none" pos="word" start_char="37">together</TOKEN>
<TOKEN end_char="52" id="token-0-5" morph="none" pos="word" start_char="46">reduced</TOKEN>
<TOKEN end_char="69" id="token-0-6" morph="none" pos="word" start_char="54">hospitalizations</TOKEN>
<TOKEN end_char="73" id="token-0-7" morph="none" pos="word" start_char="71">and</TOKEN>
<TOKEN end_char="79" id="token-0-8" morph="none" pos="word" start_char="75">death</TOKEN>
<TOKEN end_char="82" id="token-0-9" morph="none" pos="word" start_char="81">in</TOKEN>
<TOKEN end_char="88" id="token-0-10" morph="none" pos="word" start_char="84">Phase</TOKEN>
<TOKEN end_char="90" id="token-0-11" morph="none" pos="word" start_char="90">3</TOKEN>
<TOKEN end_char="96" id="token-0-12" morph="none" pos="word" start_char="92">trial</TOKEN>
<TOKEN end_char="100" id="token-0-13" morph="none" pos="word" start_char="98">for</TOKEN>
<TOKEN end_char="106" id="token-0-14" morph="none" pos="word" start_char="102">early</TOKEN>
<TOKEN end_char="115" id="token-0-15" morph="none" pos="unknown" start_char="108">COVID-19</TOKEN>
</SEG>
<SEG end_char="417" id="segment-1" start_char="121">
<ORIGINAL_TEXT>- New data show therapy reduced risk of hospitalizations and death by 87 percent - Second positive Phase 3 trial readout for bamlanivimab and etesevimab together - Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorized in U.S. and several countries around the world</ORIGINAL_TEXT>
<TOKEN end_char="121" id="token-1-0" morph="none" pos="punct" start_char="121">-</TOKEN>
<TOKEN end_char="125" id="token-1-1" morph="none" pos="word" start_char="123">New</TOKEN>
<TOKEN end_char="130" id="token-1-2" morph="none" pos="word" start_char="127">data</TOKEN>
<TOKEN end_char="135" id="token-1-3" morph="none" pos="word" start_char="132">show</TOKEN>
<TOKEN end_char="143" id="token-1-4" morph="none" pos="word" start_char="137">therapy</TOKEN>
<TOKEN end_char="151" id="token-1-5" morph="none" pos="word" start_char="145">reduced</TOKEN>
<TOKEN end_char="156" id="token-1-6" morph="none" pos="word" start_char="153">risk</TOKEN>
<TOKEN end_char="159" id="token-1-7" morph="none" pos="word" start_char="158">of</TOKEN>
<TOKEN end_char="176" id="token-1-8" morph="none" pos="word" start_char="161">hospitalizations</TOKEN>
<TOKEN end_char="180" id="token-1-9" morph="none" pos="word" start_char="178">and</TOKEN>
<TOKEN end_char="186" id="token-1-10" morph="none" pos="word" start_char="182">death</TOKEN>
<TOKEN end_char="189" id="token-1-11" morph="none" pos="word" start_char="188">by</TOKEN>
<TOKEN end_char="192" id="token-1-12" morph="none" pos="word" start_char="191">87</TOKEN>
<TOKEN end_char="200" id="token-1-13" morph="none" pos="word" start_char="194">percent</TOKEN>
<TOKEN end_char="202" id="token-1-14" morph="none" pos="punct" start_char="202">-</TOKEN>
<TOKEN end_char="209" id="token-1-15" morph="none" pos="word" start_char="204">Second</TOKEN>
<TOKEN end_char="218" id="token-1-16" morph="none" pos="word" start_char="211">positive</TOKEN>
<TOKEN end_char="224" id="token-1-17" morph="none" pos="word" start_char="220">Phase</TOKEN>
<TOKEN end_char="226" id="token-1-18" morph="none" pos="word" start_char="226">3</TOKEN>
<TOKEN end_char="232" id="token-1-19" morph="none" pos="word" start_char="228">trial</TOKEN>
<TOKEN end_char="240" id="token-1-20" morph="none" pos="word" start_char="234">readout</TOKEN>
<TOKEN end_char="244" id="token-1-21" morph="none" pos="word" start_char="242">for</TOKEN>
<TOKEN end_char="257" id="token-1-22" morph="none" pos="word" start_char="246">bamlanivimab</TOKEN>
<TOKEN end_char="261" id="token-1-23" morph="none" pos="word" start_char="259">and</TOKEN>
<TOKEN end_char="272" id="token-1-24" morph="none" pos="word" start_char="263">etesevimab</TOKEN>
<TOKEN end_char="281" id="token-1-25" morph="none" pos="word" start_char="274">together</TOKEN>
<TOKEN end_char="283" id="token-1-26" morph="none" pos="punct" start_char="283">-</TOKEN>
<TOKEN end_char="291" id="token-1-27" morph="none" pos="word" start_char="285">Results</TOKEN>
<TOKEN end_char="299" id="token-1-28" morph="none" pos="word" start_char="293">support</TOKEN>
<TOKEN end_char="303" id="token-1-29" morph="none" pos="word" start_char="301">use</TOKEN>
<TOKEN end_char="306" id="token-1-30" morph="none" pos="word" start_char="305">of</TOKEN>
<TOKEN end_char="319" id="token-1-31" morph="none" pos="word" start_char="308">bamlanivimab</TOKEN>
<TOKEN end_char="323" id="token-1-32" morph="none" pos="word" start_char="321">700</TOKEN>
<TOKEN end_char="326" id="token-1-33" morph="none" pos="word" start_char="325">mg</TOKEN>
<TOKEN end_char="330" id="token-1-34" morph="none" pos="word" start_char="328">and</TOKEN>
<TOKEN end_char="341" id="token-1-35" morph="none" pos="word" start_char="332">etesevimab</TOKEN>
<TOKEN end_char="346" id="token-1-36" morph="none" pos="word" start_char="343">1400</TOKEN>
<TOKEN end_char="349" id="token-1-37" morph="none" pos="word" start_char="348">mg</TOKEN>
<TOKEN end_char="350" id="token-1-38" morph="none" pos="punct" start_char="350">,</TOKEN>
<TOKEN end_char="354" id="token-1-39" morph="none" pos="word" start_char="352">the</TOKEN>
<TOKEN end_char="359" id="token-1-40" morph="none" pos="word" start_char="356">dose</TOKEN>
<TOKEN end_char="370" id="token-1-41" morph="none" pos="word" start_char="361">authorized</TOKEN>
<TOKEN end_char="373" id="token-1-42" morph="none" pos="word" start_char="372">in</TOKEN>
<TOKEN end_char="377" id="token-1-43" morph="none" pos="unknown" start_char="375">U.S</TOKEN>
<TOKEN end_char="378" id="token-1-44" morph="none" pos="punct" start_char="378">.</TOKEN>
<TOKEN end_char="382" id="token-1-45" morph="none" pos="word" start_char="380">and</TOKEN>
<TOKEN end_char="390" id="token-1-46" morph="none" pos="word" start_char="384">several</TOKEN>
<TOKEN end_char="400" id="token-1-47" morph="none" pos="word" start_char="392">countries</TOKEN>
<TOKEN end_char="407" id="token-1-48" morph="none" pos="word" start_char="402">around</TOKEN>
<TOKEN end_char="411" id="token-1-49" morph="none" pos="word" start_char="409">the</TOKEN>
<TOKEN end_char="417" id="token-1-50" morph="none" pos="word" start_char="413">world</TOKEN>
</SEG>
<SEG end_char="823" id="segment-2" start_char="420">
<ORIGINAL_TEXT>INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="431" id="token-2-0" morph="none" pos="word" start_char="420">INDIANAPOLIS</TOKEN>
<TOKEN end_char="432" id="token-2-1" morph="none" pos="punct" start_char="432">,</TOKEN>
<TOKEN end_char="438" id="token-2-2" morph="none" pos="word" start_char="434">March</TOKEN>
<TOKEN end_char="441" id="token-2-3" morph="none" pos="word" start_char="440">10</TOKEN>
<TOKEN end_char="442" id="token-2-4" morph="none" pos="punct" start_char="442">,</TOKEN>
<TOKEN end_char="447" id="token-2-5" morph="none" pos="word" start_char="444">2021</TOKEN>
<TOKEN end_char="449" id="token-2-6" morph="none" pos="punct" start_char="449">/</TOKEN>
<TOKEN end_char="459" id="token-2-7" morph="none" pos="word" start_char="450">PRNewswire</TOKEN>
<TOKEN end_char="460" id="token-2-8" morph="none" pos="punct" start_char="460">/</TOKEN>
<TOKEN end_char="463" id="token-2-9" morph="none" pos="punct" start_char="462">--</TOKEN>
<TOKEN end_char="467" id="token-2-10" morph="none" pos="word" start_char="465">Eli</TOKEN>
<TOKEN end_char="473" id="token-2-11" morph="none" pos="word" start_char="469">Lilly</TOKEN>
<TOKEN end_char="477" id="token-2-12" morph="none" pos="word" start_char="475">and</TOKEN>
<TOKEN end_char="485" id="token-2-13" morph="none" pos="word" start_char="479">Company</TOKEN>
<TOKEN end_char="487" id="token-2-14" morph="none" pos="punct" start_char="487">(</TOKEN>
<TOKEN end_char="491" id="token-2-15" morph="none" pos="word" start_char="488">NYSE</TOKEN>
<TOKEN end_char="492" id="token-2-16" morph="none" pos="punct" start_char="492">:</TOKEN>
<TOKEN end_char="496" id="token-2-17" morph="none" pos="word" start_char="494">LLY</TOKEN>
<TOKEN end_char="497" id="token-2-18" morph="none" pos="punct" start_char="497">)</TOKEN>
<TOKEN end_char="503" id="token-2-19" morph="none" pos="word" start_char="499">today</TOKEN>
<TOKEN end_char="513" id="token-2-20" morph="none" pos="word" start_char="505">announced</TOKEN>
<TOKEN end_char="517" id="token-2-21" morph="none" pos="word" start_char="515">new</TOKEN>
<TOKEN end_char="522" id="token-2-22" morph="none" pos="word" start_char="519">data</TOKEN>
<TOKEN end_char="527" id="token-2-23" morph="none" pos="word" start_char="524">from</TOKEN>
<TOKEN end_char="531" id="token-2-24" morph="none" pos="word" start_char="529">the</TOKEN>
<TOKEN end_char="542" id="token-2-25" morph="none" pos="word" start_char="533">randomized</TOKEN>
<TOKEN end_char="543" id="token-2-26" morph="none" pos="punct" start_char="543">,</TOKEN>
<TOKEN end_char="556" id="token-2-27" morph="none" pos="unknown" start_char="545">double-blind</TOKEN>
<TOKEN end_char="557" id="token-2-28" morph="none" pos="punct" start_char="557">,</TOKEN>
<TOKEN end_char="576" id="token-2-29" morph="none" pos="unknown" start_char="559">placebo-controlled</TOKEN>
<TOKEN end_char="584" id="token-2-30" morph="none" pos="unknown" start_char="578">BLAZE-1</TOKEN>
<TOKEN end_char="590" id="token-2-31" morph="none" pos="word" start_char="586">Phase</TOKEN>
<TOKEN end_char="592" id="token-2-32" morph="none" pos="word" start_char="592">3</TOKEN>
<TOKEN end_char="598" id="token-2-33" morph="none" pos="word" start_char="594">study</TOKEN>
<TOKEN end_char="599" id="token-2-34" morph="none" pos="punct" start_char="599">,</TOKEN>
<TOKEN end_char="613" id="token-2-35" morph="none" pos="word" start_char="601">demonstrating</TOKEN>
<TOKEN end_char="626" id="token-2-36" morph="none" pos="word" start_char="615">bamlanivimab</TOKEN>
<TOKEN end_char="628" id="token-2-37" morph="none" pos="punct" start_char="628">(</TOKEN>
<TOKEN end_char="637" id="token-2-38" morph="none" pos="unknown" start_char="629">LY-CoV555</TOKEN>
<TOKEN end_char="638" id="token-2-39" morph="none" pos="punct" start_char="638">)</TOKEN>
<TOKEN end_char="642" id="token-2-40" morph="none" pos="word" start_char="640">700</TOKEN>
<TOKEN end_char="645" id="token-2-41" morph="none" pos="word" start_char="644">mg</TOKEN>
<TOKEN end_char="649" id="token-2-42" morph="none" pos="word" start_char="647">and</TOKEN>
<TOKEN end_char="660" id="token-2-43" morph="none" pos="word" start_char="651">etesevimab</TOKEN>
<TOKEN end_char="662" id="token-2-44" morph="none" pos="punct" start_char="662">(</TOKEN>
<TOKEN end_char="671" id="token-2-45" morph="none" pos="unknown" start_char="663">LY-CoV016</TOKEN>
<TOKEN end_char="672" id="token-2-46" morph="none" pos="punct" start_char="672">)</TOKEN>
<TOKEN end_char="677" id="token-2-47" morph="none" pos="word" start_char="674">1400</TOKEN>
<TOKEN end_char="680" id="token-2-48" morph="none" pos="word" start_char="679">mg</TOKEN>
<TOKEN end_char="689" id="token-2-49" morph="none" pos="word" start_char="682">together</TOKEN>
<TOKEN end_char="703" id="token-2-50" morph="none" pos="word" start_char="691">significantly</TOKEN>
<TOKEN end_char="711" id="token-2-51" morph="none" pos="word" start_char="705">reduced</TOKEN>
<TOKEN end_char="720" id="token-2-52" morph="none" pos="unknown" start_char="713">COVID-19</TOKEN>
<TOKEN end_char="728" id="token-2-53" morph="none" pos="word" start_char="722">related</TOKEN>
<TOKEN end_char="745" id="token-2-54" morph="none" pos="word" start_char="730">hospitalizations</TOKEN>
<TOKEN end_char="749" id="token-2-55" morph="none" pos="word" start_char="747">and</TOKEN>
<TOKEN end_char="756" id="token-2-56" morph="none" pos="word" start_char="751">deaths</TOKEN>
<TOKEN end_char="759" id="token-2-57" morph="none" pos="punct" start_char="758">("</TOKEN>
<TOKEN end_char="765" id="token-2-58" morph="none" pos="word" start_char="760">events</TOKEN>
<TOKEN end_char="767" id="token-2-59" morph="none" pos="punct" start_char="766">")</TOKEN>
<TOKEN end_char="770" id="token-2-60" morph="none" pos="word" start_char="769">in</TOKEN>
<TOKEN end_char="780" id="token-2-61" morph="none" pos="unknown" start_char="772">high-risk</TOKEN>
<TOKEN end_char="789" id="token-2-62" morph="none" pos="word" start_char="782">patients</TOKEN>
<TOKEN end_char="798" id="token-2-63" morph="none" pos="word" start_char="791">recently</TOKEN>
<TOKEN end_char="808" id="token-2-64" morph="none" pos="word" start_char="800">diagnosed</TOKEN>
<TOKEN end_char="813" id="token-2-65" morph="none" pos="word" start_char="810">with</TOKEN>
<TOKEN end_char="822" id="token-2-66" morph="none" pos="unknown" start_char="815">COVID-19</TOKEN>
<TOKEN end_char="823" id="token-2-67" morph="none" pos="punct" start_char="823">.</TOKEN>
</SEG>
<SEG end_char="1141" id="segment-3" start_char="825">
<ORIGINAL_TEXT>These results provide additional efficacy and safety data that support the use of the dose recently granted both Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) and a positive scientific opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).</ORIGINAL_TEXT>
<TOKEN end_char="829" id="token-3-0" morph="none" pos="word" start_char="825">These</TOKEN>
<TOKEN end_char="837" id="token-3-1" morph="none" pos="word" start_char="831">results</TOKEN>
<TOKEN end_char="845" id="token-3-2" morph="none" pos="word" start_char="839">provide</TOKEN>
<TOKEN end_char="856" id="token-3-3" morph="none" pos="word" start_char="847">additional</TOKEN>
<TOKEN end_char="865" id="token-3-4" morph="none" pos="word" start_char="858">efficacy</TOKEN>
<TOKEN end_char="869" id="token-3-5" morph="none" pos="word" start_char="867">and</TOKEN>
<TOKEN end_char="876" id="token-3-6" morph="none" pos="word" start_char="871">safety</TOKEN>
<TOKEN end_char="881" id="token-3-7" morph="none" pos="word" start_char="878">data</TOKEN>
<TOKEN end_char="886" id="token-3-8" morph="none" pos="word" start_char="883">that</TOKEN>
<TOKEN end_char="894" id="token-3-9" morph="none" pos="word" start_char="888">support</TOKEN>
<TOKEN end_char="898" id="token-3-10" morph="none" pos="word" start_char="896">the</TOKEN>
<TOKEN end_char="902" id="token-3-11" morph="none" pos="word" start_char="900">use</TOKEN>
<TOKEN end_char="905" id="token-3-12" morph="none" pos="word" start_char="904">of</TOKEN>
<TOKEN end_char="909" id="token-3-13" morph="none" pos="word" start_char="907">the</TOKEN>
<TOKEN end_char="914" id="token-3-14" morph="none" pos="word" start_char="911">dose</TOKEN>
<TOKEN end_char="923" id="token-3-15" morph="none" pos="word" start_char="916">recently</TOKEN>
<TOKEN end_char="931" id="token-3-16" morph="none" pos="word" start_char="925">granted</TOKEN>
<TOKEN end_char="936" id="token-3-17" morph="none" pos="word" start_char="933">both</TOKEN>
<TOKEN end_char="946" id="token-3-18" morph="none" pos="word" start_char="938">Emergency</TOKEN>
<TOKEN end_char="950" id="token-3-19" morph="none" pos="word" start_char="948">Use</TOKEN>
<TOKEN end_char="964" id="token-3-20" morph="none" pos="word" start_char="952">Authorization</TOKEN>
<TOKEN end_char="967" id="token-3-21" morph="none" pos="word" start_char="966">by</TOKEN>
<TOKEN end_char="971" id="token-3-22" morph="none" pos="word" start_char="969">the</TOKEN>
<TOKEN end_char="975" id="token-3-23" morph="none" pos="unknown" start_char="973">U.S</TOKEN>
<TOKEN end_char="976" id="token-3-24" morph="none" pos="punct" start_char="976">.</TOKEN>
<TOKEN end_char="981" id="token-3-25" morph="none" pos="word" start_char="978">Food</TOKEN>
<TOKEN end_char="985" id="token-3-26" morph="none" pos="word" start_char="983">and</TOKEN>
<TOKEN end_char="990" id="token-3-27" morph="none" pos="word" start_char="987">Drug</TOKEN>
<TOKEN end_char="1005" id="token-3-28" morph="none" pos="word" start_char="992">Administration</TOKEN>
<TOKEN end_char="1007" id="token-3-29" morph="none" pos="punct" start_char="1007">(</TOKEN>
<TOKEN end_char="1010" id="token-3-30" morph="none" pos="word" start_char="1008">FDA</TOKEN>
<TOKEN end_char="1011" id="token-3-31" morph="none" pos="punct" start_char="1011">)</TOKEN>
<TOKEN end_char="1015" id="token-3-32" morph="none" pos="word" start_char="1013">and</TOKEN>
<TOKEN end_char="1017" id="token-3-33" morph="none" pos="word" start_char="1017">a</TOKEN>
<TOKEN end_char="1026" id="token-3-34" morph="none" pos="word" start_char="1019">positive</TOKEN>
<TOKEN end_char="1037" id="token-3-35" morph="none" pos="word" start_char="1028">scientific</TOKEN>
<TOKEN end_char="1045" id="token-3-36" morph="none" pos="word" start_char="1039">opinion</TOKEN>
<TOKEN end_char="1048" id="token-3-37" morph="none" pos="word" start_char="1047">by</TOKEN>
<TOKEN end_char="1052" id="token-3-38" morph="none" pos="word" start_char="1050">the</TOKEN>
<TOKEN end_char="1061" id="token-3-39" morph="none" pos="word" start_char="1054">European</TOKEN>
<TOKEN end_char="1071" id="token-3-40" morph="none" pos="word" start_char="1063">Medicines</TOKEN>
<TOKEN end_char="1080" id="token-3-41" morph="none" pos="word" start_char="1073">Agency's</TOKEN>
<TOKEN end_char="1082" id="token-3-42" morph="none" pos="punct" start_char="1082">(</TOKEN>
<TOKEN end_char="1085" id="token-3-43" morph="none" pos="word" start_char="1083">EMA</TOKEN>
<TOKEN end_char="1086" id="token-3-44" morph="none" pos="punct" start_char="1086">)</TOKEN>
<TOKEN end_char="1096" id="token-3-45" morph="none" pos="word" start_char="1088">Committee</TOKEN>
<TOKEN end_char="1100" id="token-3-46" morph="none" pos="word" start_char="1098">for</TOKEN>
<TOKEN end_char="1110" id="token-3-47" morph="none" pos="word" start_char="1102">Medicinal</TOKEN>
<TOKEN end_char="1119" id="token-3-48" morph="none" pos="word" start_char="1112">Products</TOKEN>
<TOKEN end_char="1123" id="token-3-49" morph="none" pos="word" start_char="1121">for</TOKEN>
<TOKEN end_char="1129" id="token-3-50" morph="none" pos="word" start_char="1125">Human</TOKEN>
<TOKEN end_char="1133" id="token-3-51" morph="none" pos="word" start_char="1131">Use</TOKEN>
<TOKEN end_char="1135" id="token-3-52" morph="none" pos="punct" start_char="1135">(</TOKEN>
<TOKEN end_char="1139" id="token-3-53" morph="none" pos="word" start_char="1136">CHMP</TOKEN>
<TOKEN end_char="1141" id="token-3-54" morph="none" pos="punct" start_char="1140">).</TOKEN>
</SEG>
<SEG end_char="1293" id="segment-4" start_char="1144">
<ORIGINAL_TEXT>This new Phase 3 cohort of BLAZE-1 included 769 high-risk patients, aged 12 and older with mild to moderate COVID-19 (therapy: n=511; placebo: n=258).</ORIGINAL_TEXT>
<TOKEN end_char="1147" id="token-4-0" morph="none" pos="word" start_char="1144">This</TOKEN>
<TOKEN end_char="1151" id="token-4-1" morph="none" pos="word" start_char="1149">new</TOKEN>
<TOKEN end_char="1157" id="token-4-2" morph="none" pos="word" start_char="1153">Phase</TOKEN>
<TOKEN end_char="1159" id="token-4-3" morph="none" pos="word" start_char="1159">3</TOKEN>
<TOKEN end_char="1166" id="token-4-4" morph="none" pos="word" start_char="1161">cohort</TOKEN>
<TOKEN end_char="1169" id="token-4-5" morph="none" pos="word" start_char="1168">of</TOKEN>
<TOKEN end_char="1177" id="token-4-6" morph="none" pos="unknown" start_char="1171">BLAZE-1</TOKEN>
<TOKEN end_char="1186" id="token-4-7" morph="none" pos="word" start_char="1179">included</TOKEN>
<TOKEN end_char="1190" id="token-4-8" morph="none" pos="word" start_char="1188">769</TOKEN>
<TOKEN end_char="1200" id="token-4-9" morph="none" pos="unknown" start_char="1192">high-risk</TOKEN>
<TOKEN end_char="1209" id="token-4-10" morph="none" pos="word" start_char="1202">patients</TOKEN>
<TOKEN end_char="1210" id="token-4-11" morph="none" pos="punct" start_char="1210">,</TOKEN>
<TOKEN end_char="1215" id="token-4-12" morph="none" pos="word" start_char="1212">aged</TOKEN>
<TOKEN end_char="1218" id="token-4-13" morph="none" pos="word" start_char="1217">12</TOKEN>
<TOKEN end_char="1222" id="token-4-14" morph="none" pos="word" start_char="1220">and</TOKEN>
<TOKEN end_char="1228" id="token-4-15" morph="none" pos="word" start_char="1224">older</TOKEN>
<TOKEN end_char="1233" id="token-4-16" morph="none" pos="word" start_char="1230">with</TOKEN>
<TOKEN end_char="1238" id="token-4-17" morph="none" pos="word" start_char="1235">mild</TOKEN>
<TOKEN end_char="1241" id="token-4-18" morph="none" pos="word" start_char="1240">to</TOKEN>
<TOKEN end_char="1250" id="token-4-19" morph="none" pos="word" start_char="1243">moderate</TOKEN>
<TOKEN end_char="1259" id="token-4-20" morph="none" pos="unknown" start_char="1252">COVID-19</TOKEN>
<TOKEN end_char="1261" id="token-4-21" morph="none" pos="punct" start_char="1261">(</TOKEN>
<TOKEN end_char="1268" id="token-4-22" morph="none" pos="word" start_char="1262">therapy</TOKEN>
<TOKEN end_char="1269" id="token-4-23" morph="none" pos="punct" start_char="1269">:</TOKEN>
<TOKEN end_char="1275" id="token-4-24" morph="none" pos="unknown" start_char="1271">n=511</TOKEN>
<TOKEN end_char="1276" id="token-4-25" morph="none" pos="punct" start_char="1276">;</TOKEN>
<TOKEN end_char="1284" id="token-4-26" morph="none" pos="word" start_char="1278">placebo</TOKEN>
<TOKEN end_char="1285" id="token-4-27" morph="none" pos="punct" start_char="1285">:</TOKEN>
<TOKEN end_char="1291" id="token-4-28" morph="none" pos="unknown" start_char="1287">n=258</TOKEN>
<TOKEN end_char="1293" id="token-4-29" morph="none" pos="punct" start_char="1292">).</TOKEN>
</SEG>
<SEG end_char="1459" id="segment-5" start_char="1295">
<ORIGINAL_TEXT>There were four events in patients taking bamlanivimab with etesevimab and 15 events in patients taking placebo, representing an 87 percent risk reduction (p0.0001).</ORIGINAL_TEXT>
<TOKEN end_char="1299" id="token-5-0" morph="none" pos="word" start_char="1295">There</TOKEN>
<TOKEN end_char="1304" id="token-5-1" morph="none" pos="word" start_char="1301">were</TOKEN>
<TOKEN end_char="1309" id="token-5-2" morph="none" pos="word" start_char="1306">four</TOKEN>
<TOKEN end_char="1316" id="token-5-3" morph="none" pos="word" start_char="1311">events</TOKEN>
<TOKEN end_char="1319" id="token-5-4" morph="none" pos="word" start_char="1318">in</TOKEN>
<TOKEN end_char="1328" id="token-5-5" morph="none" pos="word" start_char="1321">patients</TOKEN>
<TOKEN end_char="1335" id="token-5-6" morph="none" pos="word" start_char="1330">taking</TOKEN>
<TOKEN end_char="1348" id="token-5-7" morph="none" pos="word" start_char="1337">bamlanivimab</TOKEN>
<TOKEN end_char="1353" id="token-5-8" morph="none" pos="word" start_char="1350">with</TOKEN>
<TOKEN end_char="1364" id="token-5-9" morph="none" pos="word" start_char="1355">etesevimab</TOKEN>
<TOKEN end_char="1368" id="token-5-10" morph="none" pos="word" start_char="1366">and</TOKEN>
<TOKEN end_char="1371" id="token-5-11" morph="none" pos="word" start_char="1370">15</TOKEN>
<TOKEN end_char="1378" id="token-5-12" morph="none" pos="word" start_char="1373">events</TOKEN>
<TOKEN end_char="1381" id="token-5-13" morph="none" pos="word" start_char="1380">in</TOKEN>
<TOKEN end_char="1390" id="token-5-14" morph="none" pos="word" start_char="1383">patients</TOKEN>
<TOKEN end_char="1397" id="token-5-15" morph="none" pos="word" start_char="1392">taking</TOKEN>
<TOKEN end_char="1405" id="token-5-16" morph="none" pos="word" start_char="1399">placebo</TOKEN>
<TOKEN end_char="1406" id="token-5-17" morph="none" pos="punct" start_char="1406">,</TOKEN>
<TOKEN end_char="1419" id="token-5-18" morph="none" pos="word" start_char="1408">representing</TOKEN>
<TOKEN end_char="1422" id="token-5-19" morph="none" pos="word" start_char="1421">an</TOKEN>
<TOKEN end_char="1425" id="token-5-20" morph="none" pos="word" start_char="1424">87</TOKEN>
<TOKEN end_char="1433" id="token-5-21" morph="none" pos="word" start_char="1427">percent</TOKEN>
<TOKEN end_char="1438" id="token-5-22" morph="none" pos="word" start_char="1435">risk</TOKEN>
<TOKEN end_char="1448" id="token-5-23" morph="none" pos="word" start_char="1440">reduction</TOKEN>
<TOKEN end_char="1450" id="token-5-24" morph="none" pos="punct" start_char="1450">(</TOKEN>
<TOKEN end_char="1457" id="token-5-25" morph="none" pos="unknown" start_char="1451">p0.0001</TOKEN>
<TOKEN end_char="1459" id="token-5-26" morph="none" pos="punct" start_char="1458">).</TOKEN>
</SEG>
<SEG end_char="1581" id="segment-6" start_char="1461">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on key secondary endpoints.</ORIGINAL_TEXT>
<TOKEN end_char="1472" id="token-6-0" morph="none" pos="word" start_char="1461">Bamlanivimab</TOKEN>
<TOKEN end_char="1476" id="token-6-1" morph="none" pos="word" start_char="1474">and</TOKEN>
<TOKEN end_char="1487" id="token-6-2" morph="none" pos="word" start_char="1478">etesevimab</TOKEN>
<TOKEN end_char="1496" id="token-6-3" morph="none" pos="word" start_char="1489">together</TOKEN>
<TOKEN end_char="1501" id="token-6-4" morph="none" pos="word" start_char="1498">also</TOKEN>
<TOKEN end_char="1514" id="token-6-5" morph="none" pos="word" start_char="1503">demonstrated</TOKEN>
<TOKEN end_char="1528" id="token-6-6" morph="none" pos="word" start_char="1516">statistically</TOKEN>
<TOKEN end_char="1540" id="token-6-7" morph="none" pos="word" start_char="1530">significant</TOKEN>
<TOKEN end_char="1553" id="token-6-8" morph="none" pos="word" start_char="1542">improvements</TOKEN>
<TOKEN end_char="1556" id="token-6-9" morph="none" pos="word" start_char="1555">on</TOKEN>
<TOKEN end_char="1560" id="token-6-10" morph="none" pos="word" start_char="1558">key</TOKEN>
<TOKEN end_char="1570" id="token-6-11" morph="none" pos="word" start_char="1562">secondary</TOKEN>
<TOKEN end_char="1580" id="token-6-12" morph="none" pos="word" start_char="1572">endpoints</TOKEN>
<TOKEN end_char="1581" id="token-6-13" morph="none" pos="punct" start_char="1581">.</TOKEN>
</SEG>
<SEG end_char="1924" id="segment-7" start_char="1583">
<ORIGINAL_TEXT>These results are consistent with those seen in other data sets from BLAZE-1: in the previous Phase 3 cohort, bamlanivimab 2800 mg with etesevimab 2800 mg reduced the risk of hospitalizations and deaths by 70 percent and in the Phase 2 cohort, bamlanivimab alone reduced the risk of hospitalizations and ER visits by approximately 70 percent.</ORIGINAL_TEXT>
<TOKEN end_char="1587" id="token-7-0" morph="none" pos="word" start_char="1583">These</TOKEN>
<TOKEN end_char="1595" id="token-7-1" morph="none" pos="word" start_char="1589">results</TOKEN>
<TOKEN end_char="1599" id="token-7-2" morph="none" pos="word" start_char="1597">are</TOKEN>
<TOKEN end_char="1610" id="token-7-3" morph="none" pos="word" start_char="1601">consistent</TOKEN>
<TOKEN end_char="1615" id="token-7-4" morph="none" pos="word" start_char="1612">with</TOKEN>
<TOKEN end_char="1621" id="token-7-5" morph="none" pos="word" start_char="1617">those</TOKEN>
<TOKEN end_char="1626" id="token-7-6" morph="none" pos="word" start_char="1623">seen</TOKEN>
<TOKEN end_char="1629" id="token-7-7" morph="none" pos="word" start_char="1628">in</TOKEN>
<TOKEN end_char="1635" id="token-7-8" morph="none" pos="word" start_char="1631">other</TOKEN>
<TOKEN end_char="1640" id="token-7-9" morph="none" pos="word" start_char="1637">data</TOKEN>
<TOKEN end_char="1645" id="token-7-10" morph="none" pos="word" start_char="1642">sets</TOKEN>
<TOKEN end_char="1650" id="token-7-11" morph="none" pos="word" start_char="1647">from</TOKEN>
<TOKEN end_char="1658" id="token-7-12" morph="none" pos="unknown" start_char="1652">BLAZE-1</TOKEN>
<TOKEN end_char="1659" id="token-7-13" morph="none" pos="punct" start_char="1659">:</TOKEN>
<TOKEN end_char="1662" id="token-7-14" morph="none" pos="word" start_char="1661">in</TOKEN>
<TOKEN end_char="1666" id="token-7-15" morph="none" pos="word" start_char="1664">the</TOKEN>
<TOKEN end_char="1675" id="token-7-16" morph="none" pos="word" start_char="1668">previous</TOKEN>
<TOKEN end_char="1681" id="token-7-17" morph="none" pos="word" start_char="1677">Phase</TOKEN>
<TOKEN end_char="1683" id="token-7-18" morph="none" pos="word" start_char="1683">3</TOKEN>
<TOKEN end_char="1690" id="token-7-19" morph="none" pos="word" start_char="1685">cohort</TOKEN>
<TOKEN end_char="1691" id="token-7-20" morph="none" pos="punct" start_char="1691">,</TOKEN>
<TOKEN end_char="1704" id="token-7-21" morph="none" pos="word" start_char="1693">bamlanivimab</TOKEN>
<TOKEN end_char="1709" id="token-7-22" morph="none" pos="word" start_char="1706">2800</TOKEN>
<TOKEN end_char="1712" id="token-7-23" morph="none" pos="word" start_char="1711">mg</TOKEN>
<TOKEN end_char="1717" id="token-7-24" morph="none" pos="word" start_char="1714">with</TOKEN>
<TOKEN end_char="1728" id="token-7-25" morph="none" pos="word" start_char="1719">etesevimab</TOKEN>
<TOKEN end_char="1733" id="token-7-26" morph="none" pos="word" start_char="1730">2800</TOKEN>
<TOKEN end_char="1736" id="token-7-27" morph="none" pos="word" start_char="1735">mg</TOKEN>
<TOKEN end_char="1744" id="token-7-28" morph="none" pos="word" start_char="1738">reduced</TOKEN>
<TOKEN end_char="1748" id="token-7-29" morph="none" pos="word" start_char="1746">the</TOKEN>
<TOKEN end_char="1753" id="token-7-30" morph="none" pos="word" start_char="1750">risk</TOKEN>
<TOKEN end_char="1756" id="token-7-31" morph="none" pos="word" start_char="1755">of</TOKEN>
<TOKEN end_char="1773" id="token-7-32" morph="none" pos="word" start_char="1758">hospitalizations</TOKEN>
<TOKEN end_char="1777" id="token-7-33" morph="none" pos="word" start_char="1775">and</TOKEN>
<TOKEN end_char="1784" id="token-7-34" morph="none" pos="word" start_char="1779">deaths</TOKEN>
<TOKEN end_char="1787" id="token-7-35" morph="none" pos="word" start_char="1786">by</TOKEN>
<TOKEN end_char="1790" id="token-7-36" morph="none" pos="word" start_char="1789">70</TOKEN>
<TOKEN end_char="1798" id="token-7-37" morph="none" pos="word" start_char="1792">percent</TOKEN>
<TOKEN end_char="1802" id="token-7-38" morph="none" pos="word" start_char="1800">and</TOKEN>
<TOKEN end_char="1805" id="token-7-39" morph="none" pos="word" start_char="1804">in</TOKEN>
<TOKEN end_char="1809" id="token-7-40" morph="none" pos="word" start_char="1807">the</TOKEN>
<TOKEN end_char="1815" id="token-7-41" morph="none" pos="word" start_char="1811">Phase</TOKEN>
<TOKEN end_char="1817" id="token-7-42" morph="none" pos="word" start_char="1817">2</TOKEN>
<TOKEN end_char="1824" id="token-7-43" morph="none" pos="word" start_char="1819">cohort</TOKEN>
<TOKEN end_char="1825" id="token-7-44" morph="none" pos="punct" start_char="1825">,</TOKEN>
<TOKEN end_char="1838" id="token-7-45" morph="none" pos="word" start_char="1827">bamlanivimab</TOKEN>
<TOKEN end_char="1844" id="token-7-46" morph="none" pos="word" start_char="1840">alone</TOKEN>
<TOKEN end_char="1852" id="token-7-47" morph="none" pos="word" start_char="1846">reduced</TOKEN>
<TOKEN end_char="1856" id="token-7-48" morph="none" pos="word" start_char="1854">the</TOKEN>
<TOKEN end_char="1861" id="token-7-49" morph="none" pos="word" start_char="1858">risk</TOKEN>
<TOKEN end_char="1864" id="token-7-50" morph="none" pos="word" start_char="1863">of</TOKEN>
<TOKEN end_char="1881" id="token-7-51" morph="none" pos="word" start_char="1866">hospitalizations</TOKEN>
<TOKEN end_char="1885" id="token-7-52" morph="none" pos="word" start_char="1883">and</TOKEN>
<TOKEN end_char="1888" id="token-7-53" morph="none" pos="word" start_char="1887">ER</TOKEN>
<TOKEN end_char="1895" id="token-7-54" morph="none" pos="word" start_char="1890">visits</TOKEN>
<TOKEN end_char="1898" id="token-7-55" morph="none" pos="word" start_char="1897">by</TOKEN>
<TOKEN end_char="1912" id="token-7-56" morph="none" pos="word" start_char="1900">approximately</TOKEN>
<TOKEN end_char="1915" id="token-7-57" morph="none" pos="word" start_char="1914">70</TOKEN>
<TOKEN end_char="1923" id="token-7-58" morph="none" pos="word" start_char="1917">percent</TOKEN>
<TOKEN end_char="1924" id="token-7-59" morph="none" pos="punct" start_char="1924">.</TOKEN>
</SEG>
<SEG end_char="2039" id="segment-8" start_char="1926">
<ORIGINAL_TEXT>The viral load reductions were also consistent with what was observed in the previous Phase 3 cohort of the study.</ORIGINAL_TEXT>
<TOKEN end_char="1928" id="token-8-0" morph="none" pos="word" start_char="1926">The</TOKEN>
<TOKEN end_char="1934" id="token-8-1" morph="none" pos="word" start_char="1930">viral</TOKEN>
<TOKEN end_char="1939" id="token-8-2" morph="none" pos="word" start_char="1936">load</TOKEN>
<TOKEN end_char="1950" id="token-8-3" morph="none" pos="word" start_char="1941">reductions</TOKEN>
<TOKEN end_char="1955" id="token-8-4" morph="none" pos="word" start_char="1952">were</TOKEN>
<TOKEN end_char="1960" id="token-8-5" morph="none" pos="word" start_char="1957">also</TOKEN>
<TOKEN end_char="1971" id="token-8-6" morph="none" pos="word" start_char="1962">consistent</TOKEN>
<TOKEN end_char="1976" id="token-8-7" morph="none" pos="word" start_char="1973">with</TOKEN>
<TOKEN end_char="1981" id="token-8-8" morph="none" pos="word" start_char="1978">what</TOKEN>
<TOKEN end_char="1985" id="token-8-9" morph="none" pos="word" start_char="1983">was</TOKEN>
<TOKEN end_char="1994" id="token-8-10" morph="none" pos="word" start_char="1987">observed</TOKEN>
<TOKEN end_char="1997" id="token-8-11" morph="none" pos="word" start_char="1996">in</TOKEN>
<TOKEN end_char="2001" id="token-8-12" morph="none" pos="word" start_char="1999">the</TOKEN>
<TOKEN end_char="2010" id="token-8-13" morph="none" pos="word" start_char="2003">previous</TOKEN>
<TOKEN end_char="2016" id="token-8-14" morph="none" pos="word" start_char="2012">Phase</TOKEN>
<TOKEN end_char="2018" id="token-8-15" morph="none" pos="word" start_char="2018">3</TOKEN>
<TOKEN end_char="2025" id="token-8-16" morph="none" pos="word" start_char="2020">cohort</TOKEN>
<TOKEN end_char="2028" id="token-8-17" morph="none" pos="word" start_char="2027">of</TOKEN>
<TOKEN end_char="2032" id="token-8-18" morph="none" pos="word" start_char="2030">the</TOKEN>
<TOKEN end_char="2038" id="token-8-19" morph="none" pos="word" start_char="2034">study</TOKEN>
<TOKEN end_char="2039" id="token-8-20" morph="none" pos="punct" start_char="2039">.</TOKEN>
</SEG>
<SEG end_char="2291" id="segment-9" start_char="2042">
<ORIGINAL_TEXT>In this new Phase 3 cohort, there were four deaths total, all of which were deemed related to COVID-19 and all of which occurred in patients taking placebo; no deaths occurred in patients receiving treatment with bamlanivimab and etesevimab together.</ORIGINAL_TEXT>
<TOKEN end_char="2043" id="token-9-0" morph="none" pos="word" start_char="2042">In</TOKEN>
<TOKEN end_char="2048" id="token-9-1" morph="none" pos="word" start_char="2045">this</TOKEN>
<TOKEN end_char="2052" id="token-9-2" morph="none" pos="word" start_char="2050">new</TOKEN>
<TOKEN end_char="2058" id="token-9-3" morph="none" pos="word" start_char="2054">Phase</TOKEN>
<TOKEN end_char="2060" id="token-9-4" morph="none" pos="word" start_char="2060">3</TOKEN>
<TOKEN end_char="2067" id="token-9-5" morph="none" pos="word" start_char="2062">cohort</TOKEN>
<TOKEN end_char="2068" id="token-9-6" morph="none" pos="punct" start_char="2068">,</TOKEN>
<TOKEN end_char="2074" id="token-9-7" morph="none" pos="word" start_char="2070">there</TOKEN>
<TOKEN end_char="2079" id="token-9-8" morph="none" pos="word" start_char="2076">were</TOKEN>
<TOKEN end_char="2084" id="token-9-9" morph="none" pos="word" start_char="2081">four</TOKEN>
<TOKEN end_char="2091" id="token-9-10" morph="none" pos="word" start_char="2086">deaths</TOKEN>
<TOKEN end_char="2097" id="token-9-11" morph="none" pos="word" start_char="2093">total</TOKEN>
<TOKEN end_char="2098" id="token-9-12" morph="none" pos="punct" start_char="2098">,</TOKEN>
<TOKEN end_char="2102" id="token-9-13" morph="none" pos="word" start_char="2100">all</TOKEN>
<TOKEN end_char="2105" id="token-9-14" morph="none" pos="word" start_char="2104">of</TOKEN>
<TOKEN end_char="2111" id="token-9-15" morph="none" pos="word" start_char="2107">which</TOKEN>
<TOKEN end_char="2116" id="token-9-16" morph="none" pos="word" start_char="2113">were</TOKEN>
<TOKEN end_char="2123" id="token-9-17" morph="none" pos="word" start_char="2118">deemed</TOKEN>
<TOKEN end_char="2131" id="token-9-18" morph="none" pos="word" start_char="2125">related</TOKEN>
<TOKEN end_char="2134" id="token-9-19" morph="none" pos="word" start_char="2133">to</TOKEN>
<TOKEN end_char="2143" id="token-9-20" morph="none" pos="unknown" start_char="2136">COVID-19</TOKEN>
<TOKEN end_char="2147" id="token-9-21" morph="none" pos="word" start_char="2145">and</TOKEN>
<TOKEN end_char="2151" id="token-9-22" morph="none" pos="word" start_char="2149">all</TOKEN>
<TOKEN end_char="2154" id="token-9-23" morph="none" pos="word" start_char="2153">of</TOKEN>
<TOKEN end_char="2160" id="token-9-24" morph="none" pos="word" start_char="2156">which</TOKEN>
<TOKEN end_char="2169" id="token-9-25" morph="none" pos="word" start_char="2162">occurred</TOKEN>
<TOKEN end_char="2172" id="token-9-26" morph="none" pos="word" start_char="2171">in</TOKEN>
<TOKEN end_char="2181" id="token-9-27" morph="none" pos="word" start_char="2174">patients</TOKEN>
<TOKEN end_char="2188" id="token-9-28" morph="none" pos="word" start_char="2183">taking</TOKEN>
<TOKEN end_char="2196" id="token-9-29" morph="none" pos="word" start_char="2190">placebo</TOKEN>
<TOKEN end_char="2197" id="token-9-30" morph="none" pos="punct" start_char="2197">;</TOKEN>
<TOKEN end_char="2200" id="token-9-31" morph="none" pos="word" start_char="2199">no</TOKEN>
<TOKEN end_char="2207" id="token-9-32" morph="none" pos="word" start_char="2202">deaths</TOKEN>
<TOKEN end_char="2216" id="token-9-33" morph="none" pos="word" start_char="2209">occurred</TOKEN>
<TOKEN end_char="2219" id="token-9-34" morph="none" pos="word" start_char="2218">in</TOKEN>
<TOKEN end_char="2228" id="token-9-35" morph="none" pos="word" start_char="2221">patients</TOKEN>
<TOKEN end_char="2238" id="token-9-36" morph="none" pos="word" start_char="2230">receiving</TOKEN>
<TOKEN end_char="2248" id="token-9-37" morph="none" pos="word" start_char="2240">treatment</TOKEN>
<TOKEN end_char="2253" id="token-9-38" morph="none" pos="word" start_char="2250">with</TOKEN>
<TOKEN end_char="2266" id="token-9-39" morph="none" pos="word" start_char="2255">bamlanivimab</TOKEN>
<TOKEN end_char="2270" id="token-9-40" morph="none" pos="word" start_char="2268">and</TOKEN>
<TOKEN end_char="2281" id="token-9-41" morph="none" pos="word" start_char="2272">etesevimab</TOKEN>
<TOKEN end_char="2290" id="token-9-42" morph="none" pos="word" start_char="2283">together</TOKEN>
<TOKEN end_char="2291" id="token-9-43" morph="none" pos="punct" start_char="2291">.</TOKEN>
</SEG>
<SEG end_char="2556" id="segment-10" start_char="2293">
<ORIGINAL_TEXT>Across the two Phase 3 cohorts of the study that have been analyzed to date, there have been no deaths in patients receiving treatment with bamlanivimab and etesevimab together, and 14 deaths in patients receiving placebo, 13 of which were deemed COVID-19 related.</ORIGINAL_TEXT>
<TOKEN end_char="2298" id="token-10-0" morph="none" pos="word" start_char="2293">Across</TOKEN>
<TOKEN end_char="2302" id="token-10-1" morph="none" pos="word" start_char="2300">the</TOKEN>
<TOKEN end_char="2306" id="token-10-2" morph="none" pos="word" start_char="2304">two</TOKEN>
<TOKEN end_char="2312" id="token-10-3" morph="none" pos="word" start_char="2308">Phase</TOKEN>
<TOKEN end_char="2314" id="token-10-4" morph="none" pos="word" start_char="2314">3</TOKEN>
<TOKEN end_char="2322" id="token-10-5" morph="none" pos="word" start_char="2316">cohorts</TOKEN>
<TOKEN end_char="2325" id="token-10-6" morph="none" pos="word" start_char="2324">of</TOKEN>
<TOKEN end_char="2329" id="token-10-7" morph="none" pos="word" start_char="2327">the</TOKEN>
<TOKEN end_char="2335" id="token-10-8" morph="none" pos="word" start_char="2331">study</TOKEN>
<TOKEN end_char="2340" id="token-10-9" morph="none" pos="word" start_char="2337">that</TOKEN>
<TOKEN end_char="2345" id="token-10-10" morph="none" pos="word" start_char="2342">have</TOKEN>
<TOKEN end_char="2350" id="token-10-11" morph="none" pos="word" start_char="2347">been</TOKEN>
<TOKEN end_char="2359" id="token-10-12" morph="none" pos="word" start_char="2352">analyzed</TOKEN>
<TOKEN end_char="2362" id="token-10-13" morph="none" pos="word" start_char="2361">to</TOKEN>
<TOKEN end_char="2367" id="token-10-14" morph="none" pos="word" start_char="2364">date</TOKEN>
<TOKEN end_char="2368" id="token-10-15" morph="none" pos="punct" start_char="2368">,</TOKEN>
<TOKEN end_char="2374" id="token-10-16" morph="none" pos="word" start_char="2370">there</TOKEN>
<TOKEN end_char="2379" id="token-10-17" morph="none" pos="word" start_char="2376">have</TOKEN>
<TOKEN end_char="2384" id="token-10-18" morph="none" pos="word" start_char="2381">been</TOKEN>
<TOKEN end_char="2387" id="token-10-19" morph="none" pos="word" start_char="2386">no</TOKEN>
<TOKEN end_char="2394" id="token-10-20" morph="none" pos="word" start_char="2389">deaths</TOKEN>
<TOKEN end_char="2397" id="token-10-21" morph="none" pos="word" start_char="2396">in</TOKEN>
<TOKEN end_char="2406" id="token-10-22" morph="none" pos="word" start_char="2399">patients</TOKEN>
<TOKEN end_char="2416" id="token-10-23" morph="none" pos="word" start_char="2408">receiving</TOKEN>
<TOKEN end_char="2426" id="token-10-24" morph="none" pos="word" start_char="2418">treatment</TOKEN>
<TOKEN end_char="2431" id="token-10-25" morph="none" pos="word" start_char="2428">with</TOKEN>
<TOKEN end_char="2444" id="token-10-26" morph="none" pos="word" start_char="2433">bamlanivimab</TOKEN>
<TOKEN end_char="2448" id="token-10-27" morph="none" pos="word" start_char="2446">and</TOKEN>
<TOKEN end_char="2459" id="token-10-28" morph="none" pos="word" start_char="2450">etesevimab</TOKEN>
<TOKEN end_char="2468" id="token-10-29" morph="none" pos="word" start_char="2461">together</TOKEN>
<TOKEN end_char="2469" id="token-10-30" morph="none" pos="punct" start_char="2469">,</TOKEN>
<TOKEN end_char="2473" id="token-10-31" morph="none" pos="word" start_char="2471">and</TOKEN>
<TOKEN end_char="2476" id="token-10-32" morph="none" pos="word" start_char="2475">14</TOKEN>
<TOKEN end_char="2483" id="token-10-33" morph="none" pos="word" start_char="2478">deaths</TOKEN>
<TOKEN end_char="2486" id="token-10-34" morph="none" pos="word" start_char="2485">in</TOKEN>
<TOKEN end_char="2495" id="token-10-35" morph="none" pos="word" start_char="2488">patients</TOKEN>
<TOKEN end_char="2505" id="token-10-36" morph="none" pos="word" start_char="2497">receiving</TOKEN>
<TOKEN end_char="2513" id="token-10-37" morph="none" pos="word" start_char="2507">placebo</TOKEN>
<TOKEN end_char="2514" id="token-10-38" morph="none" pos="punct" start_char="2514">,</TOKEN>
<TOKEN end_char="2517" id="token-10-39" morph="none" pos="word" start_char="2516">13</TOKEN>
<TOKEN end_char="2520" id="token-10-40" morph="none" pos="word" start_char="2519">of</TOKEN>
<TOKEN end_char="2526" id="token-10-41" morph="none" pos="word" start_char="2522">which</TOKEN>
<TOKEN end_char="2531" id="token-10-42" morph="none" pos="word" start_char="2528">were</TOKEN>
<TOKEN end_char="2538" id="token-10-43" morph="none" pos="word" start_char="2533">deemed</TOKEN>
<TOKEN end_char="2547" id="token-10-44" morph="none" pos="unknown" start_char="2540">COVID-19</TOKEN>
<TOKEN end_char="2555" id="token-10-45" morph="none" pos="word" start_char="2549">related</TOKEN>
<TOKEN end_char="2556" id="token-10-46" morph="none" pos="punct" start_char="2556">.</TOKEN>
</SEG>
<SEG end_char="2742" id="segment-11" start_char="2558">
<ORIGINAL_TEXT>In this data set, the safety profile of bamlanivimab and etesevimab together was consistent with observations from other Phase 1, Phase 2 and Phase 3 trials evaluating these antibodies.</ORIGINAL_TEXT>
<TOKEN end_char="2559" id="token-11-0" morph="none" pos="word" start_char="2558">In</TOKEN>
<TOKEN end_char="2564" id="token-11-1" morph="none" pos="word" start_char="2561">this</TOKEN>
<TOKEN end_char="2569" id="token-11-2" morph="none" pos="word" start_char="2566">data</TOKEN>
<TOKEN end_char="2573" id="token-11-3" morph="none" pos="word" start_char="2571">set</TOKEN>
<TOKEN end_char="2574" id="token-11-4" morph="none" pos="punct" start_char="2574">,</TOKEN>
<TOKEN end_char="2578" id="token-11-5" morph="none" pos="word" start_char="2576">the</TOKEN>
<TOKEN end_char="2585" id="token-11-6" morph="none" pos="word" start_char="2580">safety</TOKEN>
<TOKEN end_char="2593" id="token-11-7" morph="none" pos="word" start_char="2587">profile</TOKEN>
<TOKEN end_char="2596" id="token-11-8" morph="none" pos="word" start_char="2595">of</TOKEN>
<TOKEN end_char="2609" id="token-11-9" morph="none" pos="word" start_char="2598">bamlanivimab</TOKEN>
<TOKEN end_char="2613" id="token-11-10" morph="none" pos="word" start_char="2611">and</TOKEN>
<TOKEN end_char="2624" id="token-11-11" morph="none" pos="word" start_char="2615">etesevimab</TOKEN>
<TOKEN end_char="2633" id="token-11-12" morph="none" pos="word" start_char="2626">together</TOKEN>
<TOKEN end_char="2637" id="token-11-13" morph="none" pos="word" start_char="2635">was</TOKEN>
<TOKEN end_char="2648" id="token-11-14" morph="none" pos="word" start_char="2639">consistent</TOKEN>
<TOKEN end_char="2653" id="token-11-15" morph="none" pos="word" start_char="2650">with</TOKEN>
<TOKEN end_char="2666" id="token-11-16" morph="none" pos="word" start_char="2655">observations</TOKEN>
<TOKEN end_char="2671" id="token-11-17" morph="none" pos="word" start_char="2668">from</TOKEN>
<TOKEN end_char="2677" id="token-11-18" morph="none" pos="word" start_char="2673">other</TOKEN>
<TOKEN end_char="2683" id="token-11-19" morph="none" pos="word" start_char="2679">Phase</TOKEN>
<TOKEN end_char="2685" id="token-11-20" morph="none" pos="word" start_char="2685">1</TOKEN>
<TOKEN end_char="2686" id="token-11-21" morph="none" pos="punct" start_char="2686">,</TOKEN>
<TOKEN end_char="2692" id="token-11-22" morph="none" pos="word" start_char="2688">Phase</TOKEN>
<TOKEN end_char="2694" id="token-11-23" morph="none" pos="word" start_char="2694">2</TOKEN>
<TOKEN end_char="2698" id="token-11-24" morph="none" pos="word" start_char="2696">and</TOKEN>
<TOKEN end_char="2704" id="token-11-25" morph="none" pos="word" start_char="2700">Phase</TOKEN>
<TOKEN end_char="2706" id="token-11-26" morph="none" pos="word" start_char="2706">3</TOKEN>
<TOKEN end_char="2713" id="token-11-27" morph="none" pos="word" start_char="2708">trials</TOKEN>
<TOKEN end_char="2724" id="token-11-28" morph="none" pos="word" start_char="2715">evaluating</TOKEN>
<TOKEN end_char="2730" id="token-11-29" morph="none" pos="word" start_char="2726">these</TOKEN>
<TOKEN end_char="2741" id="token-11-30" morph="none" pos="word" start_char="2732">antibodies</TOKEN>
<TOKEN end_char="2742" id="token-11-31" morph="none" pos="punct" start_char="2742">.</TOKEN>
</SEG>
<SEG end_char="2794" id="segment-12" start_char="2745">
<ORIGINAL_TEXT>Figure 1: Time to COVID-19 related hospitalization</ORIGINAL_TEXT>
<TOKEN end_char="2750" id="token-12-0" morph="none" pos="word" start_char="2745">Figure</TOKEN>
<TOKEN end_char="2752" id="token-12-1" morph="none" pos="word" start_char="2752">1</TOKEN>
<TOKEN end_char="2753" id="token-12-2" morph="none" pos="punct" start_char="2753">:</TOKEN>
<TOKEN end_char="2758" id="token-12-3" morph="none" pos="word" start_char="2755">Time</TOKEN>
<TOKEN end_char="2761" id="token-12-4" morph="none" pos="word" start_char="2760">to</TOKEN>
<TOKEN end_char="2770" id="token-12-5" morph="none" pos="unknown" start_char="2763">COVID-19</TOKEN>
<TOKEN end_char="2778" id="token-12-6" morph="none" pos="word" start_char="2772">related</TOKEN>
<TOKEN end_char="2794" id="token-12-7" morph="none" pos="word" start_char="2780">hospitalization</TOKEN>
</SEG>
<SEG end_char="2932" id="segment-13" start_char="2798">
<ORIGINAL_TEXT>"These positive results reinforce our previous findings and support the authorized dose of bamlanivimab 700 mg with etesevimab 1400 mg.</ORIGINAL_TEXT>
<TOKEN end_char="2798" id="token-13-0" morph="none" pos="punct" start_char="2798">"</TOKEN>
<TOKEN end_char="2803" id="token-13-1" morph="none" pos="word" start_char="2799">These</TOKEN>
<TOKEN end_char="2812" id="token-13-2" morph="none" pos="word" start_char="2805">positive</TOKEN>
<TOKEN end_char="2820" id="token-13-3" morph="none" pos="word" start_char="2814">results</TOKEN>
<TOKEN end_char="2830" id="token-13-4" morph="none" pos="word" start_char="2822">reinforce</TOKEN>
<TOKEN end_char="2834" id="token-13-5" morph="none" pos="word" start_char="2832">our</TOKEN>
<TOKEN end_char="2843" id="token-13-6" morph="none" pos="word" start_char="2836">previous</TOKEN>
<TOKEN end_char="2852" id="token-13-7" morph="none" pos="word" start_char="2845">findings</TOKEN>
<TOKEN end_char="2856" id="token-13-8" morph="none" pos="word" start_char="2854">and</TOKEN>
<TOKEN end_char="2864" id="token-13-9" morph="none" pos="word" start_char="2858">support</TOKEN>
<TOKEN end_char="2868" id="token-13-10" morph="none" pos="word" start_char="2866">the</TOKEN>
<TOKEN end_char="2879" id="token-13-11" morph="none" pos="word" start_char="2870">authorized</TOKEN>
<TOKEN end_char="2884" id="token-13-12" morph="none" pos="word" start_char="2881">dose</TOKEN>
<TOKEN end_char="2887" id="token-13-13" morph="none" pos="word" start_char="2886">of</TOKEN>
<TOKEN end_char="2900" id="token-13-14" morph="none" pos="word" start_char="2889">bamlanivimab</TOKEN>
<TOKEN end_char="2904" id="token-13-15" morph="none" pos="word" start_char="2902">700</TOKEN>
<TOKEN end_char="2907" id="token-13-16" morph="none" pos="word" start_char="2906">mg</TOKEN>
<TOKEN end_char="2912" id="token-13-17" morph="none" pos="word" start_char="2909">with</TOKEN>
<TOKEN end_char="2923" id="token-13-18" morph="none" pos="word" start_char="2914">etesevimab</TOKEN>
<TOKEN end_char="2928" id="token-13-19" morph="none" pos="word" start_char="2925">1400</TOKEN>
<TOKEN end_char="2931" id="token-13-20" morph="none" pos="word" start_char="2930">mg</TOKEN>
<TOKEN end_char="2932" id="token-13-21" morph="none" pos="punct" start_char="2932">.</TOKEN>
</SEG>
<SEG end_char="3461" id="segment-14" start_char="2934">
<ORIGINAL_TEXT>These compelling data  in addition to the recent EUA from FDA, the CHMP decision from EMA and the recommendation for the therapy in the National Institutes of Health's COVID-19 Treatment Guidelines  give healthcare providers additional information regarding the use of bamlanivimab and etesevimab together as a potentially life-saving treatment to help those most at risk for severe complications of COVID-19," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories.</ORIGINAL_TEXT>
<TOKEN end_char="2938" id="token-14-0" morph="none" pos="word" start_char="2934">These</TOKEN>
<TOKEN end_char="2949" id="token-14-1" morph="none" pos="word" start_char="2940">compelling</TOKEN>
<TOKEN end_char="2954" id="token-14-2" morph="none" pos="word" start_char="2951">data</TOKEN>
<TOKEN end_char="2956" id="token-14-3" morph="none" pos="punct" start_char="2956"></TOKEN>
<TOKEN end_char="2959" id="token-14-4" morph="none" pos="word" start_char="2958">in</TOKEN>
<TOKEN end_char="2968" id="token-14-5" morph="none" pos="word" start_char="2961">addition</TOKEN>
<TOKEN end_char="2971" id="token-14-6" morph="none" pos="word" start_char="2970">to</TOKEN>
<TOKEN end_char="2975" id="token-14-7" morph="none" pos="word" start_char="2973">the</TOKEN>
<TOKEN end_char="2982" id="token-14-8" morph="none" pos="word" start_char="2977">recent</TOKEN>
<TOKEN end_char="2986" id="token-14-9" morph="none" pos="word" start_char="2984">EUA</TOKEN>
<TOKEN end_char="2991" id="token-14-10" morph="none" pos="word" start_char="2988">from</TOKEN>
<TOKEN end_char="2995" id="token-14-11" morph="none" pos="word" start_char="2993">FDA</TOKEN>
<TOKEN end_char="2996" id="token-14-12" morph="none" pos="punct" start_char="2996">,</TOKEN>
<TOKEN end_char="3000" id="token-14-13" morph="none" pos="word" start_char="2998">the</TOKEN>
<TOKEN end_char="3005" id="token-14-14" morph="none" pos="word" start_char="3002">CHMP</TOKEN>
<TOKEN end_char="3014" id="token-14-15" morph="none" pos="word" start_char="3007">decision</TOKEN>
<TOKEN end_char="3019" id="token-14-16" morph="none" pos="word" start_char="3016">from</TOKEN>
<TOKEN end_char="3023" id="token-14-17" morph="none" pos="word" start_char="3021">EMA</TOKEN>
<TOKEN end_char="3027" id="token-14-18" morph="none" pos="word" start_char="3025">and</TOKEN>
<TOKEN end_char="3031" id="token-14-19" morph="none" pos="word" start_char="3029">the</TOKEN>
<TOKEN end_char="3046" id="token-14-20" morph="none" pos="word" start_char="3033">recommendation</TOKEN>
<TOKEN end_char="3050" id="token-14-21" morph="none" pos="word" start_char="3048">for</TOKEN>
<TOKEN end_char="3054" id="token-14-22" morph="none" pos="word" start_char="3052">the</TOKEN>
<TOKEN end_char="3062" id="token-14-23" morph="none" pos="word" start_char="3056">therapy</TOKEN>
<TOKEN end_char="3065" id="token-14-24" morph="none" pos="word" start_char="3064">in</TOKEN>
<TOKEN end_char="3069" id="token-14-25" morph="none" pos="word" start_char="3067">the</TOKEN>
<TOKEN end_char="3078" id="token-14-26" morph="none" pos="word" start_char="3071">National</TOKEN>
<TOKEN end_char="3089" id="token-14-27" morph="none" pos="word" start_char="3080">Institutes</TOKEN>
<TOKEN end_char="3092" id="token-14-28" morph="none" pos="word" start_char="3091">of</TOKEN>
<TOKEN end_char="3101" id="token-14-29" morph="none" pos="word" start_char="3094">Health's</TOKEN>
<TOKEN end_char="3110" id="token-14-30" morph="none" pos="unknown" start_char="3103">COVID-19</TOKEN>
<TOKEN end_char="3120" id="token-14-31" morph="none" pos="word" start_char="3112">Treatment</TOKEN>
<TOKEN end_char="3131" id="token-14-32" morph="none" pos="word" start_char="3122">Guidelines</TOKEN>
<TOKEN end_char="3133" id="token-14-33" morph="none" pos="punct" start_char="3133"></TOKEN>
<TOKEN end_char="3138" id="token-14-34" morph="none" pos="word" start_char="3135">give</TOKEN>
<TOKEN end_char="3149" id="token-14-35" morph="none" pos="word" start_char="3140">healthcare</TOKEN>
<TOKEN end_char="3159" id="token-14-36" morph="none" pos="word" start_char="3151">providers</TOKEN>
<TOKEN end_char="3170" id="token-14-37" morph="none" pos="word" start_char="3161">additional</TOKEN>
<TOKEN end_char="3182" id="token-14-38" morph="none" pos="word" start_char="3172">information</TOKEN>
<TOKEN end_char="3192" id="token-14-39" morph="none" pos="word" start_char="3184">regarding</TOKEN>
<TOKEN end_char="3196" id="token-14-40" morph="none" pos="word" start_char="3194">the</TOKEN>
<TOKEN end_char="3200" id="token-14-41" morph="none" pos="word" start_char="3198">use</TOKEN>
<TOKEN end_char="3203" id="token-14-42" morph="none" pos="word" start_char="3202">of</TOKEN>
<TOKEN end_char="3216" id="token-14-43" morph="none" pos="word" start_char="3205">bamlanivimab</TOKEN>
<TOKEN end_char="3220" id="token-14-44" morph="none" pos="word" start_char="3218">and</TOKEN>
<TOKEN end_char="3231" id="token-14-45" morph="none" pos="word" start_char="3222">etesevimab</TOKEN>
<TOKEN end_char="3240" id="token-14-46" morph="none" pos="word" start_char="3233">together</TOKEN>
<TOKEN end_char="3243" id="token-14-47" morph="none" pos="word" start_char="3242">as</TOKEN>
<TOKEN end_char="3245" id="token-14-48" morph="none" pos="word" start_char="3245">a</TOKEN>
<TOKEN end_char="3257" id="token-14-49" morph="none" pos="word" start_char="3247">potentially</TOKEN>
<TOKEN end_char="3269" id="token-14-50" morph="none" pos="unknown" start_char="3259">life-saving</TOKEN>
<TOKEN end_char="3279" id="token-14-51" morph="none" pos="word" start_char="3271">treatment</TOKEN>
<TOKEN end_char="3282" id="token-14-52" morph="none" pos="word" start_char="3281">to</TOKEN>
<TOKEN end_char="3287" id="token-14-53" morph="none" pos="word" start_char="3284">help</TOKEN>
<TOKEN end_char="3293" id="token-14-54" morph="none" pos="word" start_char="3289">those</TOKEN>
<TOKEN end_char="3298" id="token-14-55" morph="none" pos="word" start_char="3295">most</TOKEN>
<TOKEN end_char="3301" id="token-14-56" morph="none" pos="word" start_char="3300">at</TOKEN>
<TOKEN end_char="3306" id="token-14-57" morph="none" pos="word" start_char="3303">risk</TOKEN>
<TOKEN end_char="3310" id="token-14-58" morph="none" pos="word" start_char="3308">for</TOKEN>
<TOKEN end_char="3317" id="token-14-59" morph="none" pos="word" start_char="3312">severe</TOKEN>
<TOKEN end_char="3331" id="token-14-60" morph="none" pos="word" start_char="3319">complications</TOKEN>
<TOKEN end_char="3334" id="token-14-61" morph="none" pos="word" start_char="3333">of</TOKEN>
<TOKEN end_char="3343" id="token-14-62" morph="none" pos="unknown" start_char="3336">COVID-19</TOKEN>
<TOKEN end_char="3345" id="token-14-63" morph="none" pos="punct" start_char="3344">,"</TOKEN>
<TOKEN end_char="3350" id="token-14-64" morph="none" pos="word" start_char="3347">said</TOKEN>
<TOKEN end_char="3357" id="token-14-65" morph="none" pos="word" start_char="3352">Daniel</TOKEN>
<TOKEN end_char="3368" id="token-14-66" morph="none" pos="word" start_char="3359">Skovronsky</TOKEN>
<TOKEN end_char="3369" id="token-14-67" morph="none" pos="punct" start_char="3369">,</TOKEN>
<TOKEN end_char="3373" id="token-14-68" morph="none" pos="unknown" start_char="3371">M.D</TOKEN>
<TOKEN end_char="3375" id="token-14-69" morph="none" pos="punct" start_char="3374">.,</TOKEN>
<TOKEN end_char="3380" id="token-14-70" morph="none" pos="unknown" start_char="3377">Ph.D</TOKEN>
<TOKEN end_char="3382" id="token-14-71" morph="none" pos="punct" start_char="3381">.,</TOKEN>
<TOKEN end_char="3390" id="token-14-72" morph="none" pos="word" start_char="3384">Lilly's</TOKEN>
<TOKEN end_char="3396" id="token-14-73" morph="none" pos="word" start_char="3392">chief</TOKEN>
<TOKEN end_char="3407" id="token-14-74" morph="none" pos="word" start_char="3398">scientific</TOKEN>
<TOKEN end_char="3415" id="token-14-75" morph="none" pos="word" start_char="3409">officer</TOKEN>
<TOKEN end_char="3419" id="token-14-76" morph="none" pos="word" start_char="3417">and</TOKEN>
<TOKEN end_char="3429" id="token-14-77" morph="none" pos="word" start_char="3421">president</TOKEN>
<TOKEN end_char="3432" id="token-14-78" morph="none" pos="word" start_char="3431">of</TOKEN>
<TOKEN end_char="3438" id="token-14-79" morph="none" pos="word" start_char="3434">Lilly</TOKEN>
<TOKEN end_char="3447" id="token-14-80" morph="none" pos="word" start_char="3440">Research</TOKEN>
<TOKEN end_char="3460" id="token-14-81" morph="none" pos="word" start_char="3449">Laboratories</TOKEN>
<TOKEN end_char="3461" id="token-14-82" morph="none" pos="punct" start_char="3461">.</TOKEN>
</SEG>
<SEG end_char="3728" id="segment-15" start_char="3463">
<ORIGINAL_TEXT>"The consistent results observed in multiple cohorts of this trial over several months, even as new strains of COVID-19 have emerged, indicate bamlanivimab with etesevimab maintains its effects against a range of variants, particularly those circulating in the U.S."</ORIGINAL_TEXT>
<TOKEN end_char="3463" id="token-15-0" morph="none" pos="punct" start_char="3463">"</TOKEN>
<TOKEN end_char="3466" id="token-15-1" morph="none" pos="word" start_char="3464">The</TOKEN>
<TOKEN end_char="3477" id="token-15-2" morph="none" pos="word" start_char="3468">consistent</TOKEN>
<TOKEN end_char="3485" id="token-15-3" morph="none" pos="word" start_char="3479">results</TOKEN>
<TOKEN end_char="3494" id="token-15-4" morph="none" pos="word" start_char="3487">observed</TOKEN>
<TOKEN end_char="3497" id="token-15-5" morph="none" pos="word" start_char="3496">in</TOKEN>
<TOKEN end_char="3506" id="token-15-6" morph="none" pos="word" start_char="3499">multiple</TOKEN>
<TOKEN end_char="3514" id="token-15-7" morph="none" pos="word" start_char="3508">cohorts</TOKEN>
<TOKEN end_char="3517" id="token-15-8" morph="none" pos="word" start_char="3516">of</TOKEN>
<TOKEN end_char="3522" id="token-15-9" morph="none" pos="word" start_char="3519">this</TOKEN>
<TOKEN end_char="3528" id="token-15-10" morph="none" pos="word" start_char="3524">trial</TOKEN>
<TOKEN end_char="3533" id="token-15-11" morph="none" pos="word" start_char="3530">over</TOKEN>
<TOKEN end_char="3541" id="token-15-12" morph="none" pos="word" start_char="3535">several</TOKEN>
<TOKEN end_char="3548" id="token-15-13" morph="none" pos="word" start_char="3543">months</TOKEN>
<TOKEN end_char="3549" id="token-15-14" morph="none" pos="punct" start_char="3549">,</TOKEN>
<TOKEN end_char="3554" id="token-15-15" morph="none" pos="word" start_char="3551">even</TOKEN>
<TOKEN end_char="3557" id="token-15-16" morph="none" pos="word" start_char="3556">as</TOKEN>
<TOKEN end_char="3561" id="token-15-17" morph="none" pos="word" start_char="3559">new</TOKEN>
<TOKEN end_char="3569" id="token-15-18" morph="none" pos="word" start_char="3563">strains</TOKEN>
<TOKEN end_char="3572" id="token-15-19" morph="none" pos="word" start_char="3571">of</TOKEN>
<TOKEN end_char="3581" id="token-15-20" morph="none" pos="unknown" start_char="3574">COVID-19</TOKEN>
<TOKEN end_char="3586" id="token-15-21" morph="none" pos="word" start_char="3583">have</TOKEN>
<TOKEN end_char="3594" id="token-15-22" morph="none" pos="word" start_char="3588">emerged</TOKEN>
<TOKEN end_char="3595" id="token-15-23" morph="none" pos="punct" start_char="3595">,</TOKEN>
<TOKEN end_char="3604" id="token-15-24" morph="none" pos="word" start_char="3597">indicate</TOKEN>
<TOKEN end_char="3617" id="token-15-25" morph="none" pos="word" start_char="3606">bamlanivimab</TOKEN>
<TOKEN end_char="3622" id="token-15-26" morph="none" pos="word" start_char="3619">with</TOKEN>
<TOKEN end_char="3633" id="token-15-27" morph="none" pos="word" start_char="3624">etesevimab</TOKEN>
<TOKEN end_char="3643" id="token-15-28" morph="none" pos="word" start_char="3635">maintains</TOKEN>
<TOKEN end_char="3647" id="token-15-29" morph="none" pos="word" start_char="3645">its</TOKEN>
<TOKEN end_char="3655" id="token-15-30" morph="none" pos="word" start_char="3649">effects</TOKEN>
<TOKEN end_char="3663" id="token-15-31" morph="none" pos="word" start_char="3657">against</TOKEN>
<TOKEN end_char="3665" id="token-15-32" morph="none" pos="word" start_char="3665">a</TOKEN>
<TOKEN end_char="3671" id="token-15-33" morph="none" pos="word" start_char="3667">range</TOKEN>
<TOKEN end_char="3674" id="token-15-34" morph="none" pos="word" start_char="3673">of</TOKEN>
<TOKEN end_char="3683" id="token-15-35" morph="none" pos="word" start_char="3676">variants</TOKEN>
<TOKEN end_char="3684" id="token-15-36" morph="none" pos="punct" start_char="3684">,</TOKEN>
<TOKEN end_char="3697" id="token-15-37" morph="none" pos="word" start_char="3686">particularly</TOKEN>
<TOKEN end_char="3703" id="token-15-38" morph="none" pos="word" start_char="3699">those</TOKEN>
<TOKEN end_char="3715" id="token-15-39" morph="none" pos="word" start_char="3705">circulating</TOKEN>
<TOKEN end_char="3718" id="token-15-40" morph="none" pos="word" start_char="3717">in</TOKEN>
<TOKEN end_char="3722" id="token-15-41" morph="none" pos="word" start_char="3720">the</TOKEN>
<TOKEN end_char="3726" id="token-15-42" morph="none" pos="unknown" start_char="3724">U.S</TOKEN>
<TOKEN end_char="3728" id="token-15-43" morph="none" pos="punct" start_char="3727">."</TOKEN>
</SEG>
<SEG end_char="3874" id="segment-16" start_char="3731">
<ORIGINAL_TEXT>Lilly continues to engage with global regulators to make bamlanivimab alone and bamlanivimab and etesevimab together available around the world.</ORIGINAL_TEXT>
<TOKEN end_char="3735" id="token-16-0" morph="none" pos="word" start_char="3731">Lilly</TOKEN>
<TOKEN end_char="3745" id="token-16-1" morph="none" pos="word" start_char="3737">continues</TOKEN>
<TOKEN end_char="3748" id="token-16-2" morph="none" pos="word" start_char="3747">to</TOKEN>
<TOKEN end_char="3755" id="token-16-3" morph="none" pos="word" start_char="3750">engage</TOKEN>
<TOKEN end_char="3760" id="token-16-4" morph="none" pos="word" start_char="3757">with</TOKEN>
<TOKEN end_char="3767" id="token-16-5" morph="none" pos="word" start_char="3762">global</TOKEN>
<TOKEN end_char="3778" id="token-16-6" morph="none" pos="word" start_char="3769">regulators</TOKEN>
<TOKEN end_char="3781" id="token-16-7" morph="none" pos="word" start_char="3780">to</TOKEN>
<TOKEN end_char="3786" id="token-16-8" morph="none" pos="word" start_char="3783">make</TOKEN>
<TOKEN end_char="3799" id="token-16-9" morph="none" pos="word" start_char="3788">bamlanivimab</TOKEN>
<TOKEN end_char="3805" id="token-16-10" morph="none" pos="word" start_char="3801">alone</TOKEN>
<TOKEN end_char="3809" id="token-16-11" morph="none" pos="word" start_char="3807">and</TOKEN>
<TOKEN end_char="3822" id="token-16-12" morph="none" pos="word" start_char="3811">bamlanivimab</TOKEN>
<TOKEN end_char="3826" id="token-16-13" morph="none" pos="word" start_char="3824">and</TOKEN>
<TOKEN end_char="3837" id="token-16-14" morph="none" pos="word" start_char="3828">etesevimab</TOKEN>
<TOKEN end_char="3846" id="token-16-15" morph="none" pos="word" start_char="3839">together</TOKEN>
<TOKEN end_char="3856" id="token-16-16" morph="none" pos="word" start_char="3848">available</TOKEN>
<TOKEN end_char="3863" id="token-16-17" morph="none" pos="word" start_char="3858">around</TOKEN>
<TOKEN end_char="3867" id="token-16-18" morph="none" pos="word" start_char="3865">the</TOKEN>
<TOKEN end_char="3873" id="token-16-19" morph="none" pos="word" start_char="3869">world</TOKEN>
<TOKEN end_char="3874" id="token-16-20" morph="none" pos="punct" start_char="3874">.</TOKEN>
</SEG>
<SEG end_char="4052" id="segment-17" start_char="3876">
<ORIGINAL_TEXT>Bamlanivimab alone and bamlanivimab with etesevimab together are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union.</ORIGINAL_TEXT>
<TOKEN end_char="3887" id="token-17-0" morph="none" pos="word" start_char="3876">Bamlanivimab</TOKEN>
<TOKEN end_char="3893" id="token-17-1" morph="none" pos="word" start_char="3889">alone</TOKEN>
<TOKEN end_char="3897" id="token-17-2" morph="none" pos="word" start_char="3895">and</TOKEN>
<TOKEN end_char="3910" id="token-17-3" morph="none" pos="word" start_char="3899">bamlanivimab</TOKEN>
<TOKEN end_char="3915" id="token-17-4" morph="none" pos="word" start_char="3912">with</TOKEN>
<TOKEN end_char="3926" id="token-17-5" morph="none" pos="word" start_char="3917">etesevimab</TOKEN>
<TOKEN end_char="3935" id="token-17-6" morph="none" pos="word" start_char="3928">together</TOKEN>
<TOKEN end_char="3939" id="token-17-7" morph="none" pos="word" start_char="3937">are</TOKEN>
<TOKEN end_char="3950" id="token-17-8" morph="none" pos="word" start_char="3941">authorized</TOKEN>
<TOKEN end_char="3956" id="token-17-9" morph="none" pos="word" start_char="3952">under</TOKEN>
<TOKEN end_char="3974" id="token-17-10" morph="none" pos="unknown" start_char="3958">special/emergency</TOKEN>
<TOKEN end_char="3983" id="token-17-11" morph="none" pos="word" start_char="3976">pathways</TOKEN>
<TOKEN end_char="3984" id="token-17-12" morph="none" pos="punct" start_char="3984">,</TOKEN>
<TOKEN end_char="3987" id="token-17-13" morph="none" pos="word" start_char="3986">in</TOKEN>
<TOKEN end_char="3991" id="token-17-14" morph="none" pos="word" start_char="3989">the</TOKEN>
<TOKEN end_char="3999" id="token-17-15" morph="none" pos="word" start_char="3993">context</TOKEN>
<TOKEN end_char="4002" id="token-17-16" morph="none" pos="word" start_char="4001">of</TOKEN>
<TOKEN end_char="4006" id="token-17-17" morph="none" pos="word" start_char="4004">the</TOKEN>
<TOKEN end_char="4015" id="token-17-18" morph="none" pos="word" start_char="4008">pandemic</TOKEN>
<TOKEN end_char="4016" id="token-17-19" morph="none" pos="punct" start_char="4016">,</TOKEN>
<TOKEN end_char="4019" id="token-17-20" morph="none" pos="word" start_char="4018">in</TOKEN>
<TOKEN end_char="4023" id="token-17-21" morph="none" pos="word" start_char="4021">the</TOKEN>
<TOKEN end_char="4027" id="token-17-22" morph="none" pos="unknown" start_char="4025">U.S</TOKEN>
<TOKEN end_char="4028" id="token-17-23" morph="none" pos="punct" start_char="4028">.</TOKEN>
<TOKEN end_char="4032" id="token-17-24" morph="none" pos="word" start_char="4030">and</TOKEN>
<TOKEN end_char="4036" id="token-17-25" morph="none" pos="word" start_char="4034">the</TOKEN>
<TOKEN end_char="4045" id="token-17-26" morph="none" pos="word" start_char="4038">European</TOKEN>
<TOKEN end_char="4051" id="token-17-27" morph="none" pos="word" start_char="4047">Union</TOKEN>
<TOKEN end_char="4052" id="token-17-28" morph="none" pos="punct" start_char="4052">.</TOKEN>
</SEG>
<SEG end_char="4206" id="segment-18" start_char="4054">
<ORIGINAL_TEXT>In addition, bamlanivimab alone is authorized for emergency use in Canada, Panama, Kuwait, the UAE, Israel, Rwanda, Morocco and numerous other countries.</ORIGINAL_TEXT>
<TOKEN end_char="4055" id="token-18-0" morph="none" pos="word" start_char="4054">In</TOKEN>
<TOKEN end_char="4064" id="token-18-1" morph="none" pos="word" start_char="4057">addition</TOKEN>
<TOKEN end_char="4065" id="token-18-2" morph="none" pos="punct" start_char="4065">,</TOKEN>
<TOKEN end_char="4078" id="token-18-3" morph="none" pos="word" start_char="4067">bamlanivimab</TOKEN>
<TOKEN end_char="4084" id="token-18-4" morph="none" pos="word" start_char="4080">alone</TOKEN>
<TOKEN end_char="4087" id="token-18-5" morph="none" pos="word" start_char="4086">is</TOKEN>
<TOKEN end_char="4098" id="token-18-6" morph="none" pos="word" start_char="4089">authorized</TOKEN>
<TOKEN end_char="4102" id="token-18-7" morph="none" pos="word" start_char="4100">for</TOKEN>
<TOKEN end_char="4112" id="token-18-8" morph="none" pos="word" start_char="4104">emergency</TOKEN>
<TOKEN end_char="4116" id="token-18-9" morph="none" pos="word" start_char="4114">use</TOKEN>
<TOKEN end_char="4119" id="token-18-10" morph="none" pos="word" start_char="4118">in</TOKEN>
<TOKEN end_char="4126" id="token-18-11" morph="none" pos="word" start_char="4121">Canada</TOKEN>
<TOKEN end_char="4127" id="token-18-12" morph="none" pos="punct" start_char="4127">,</TOKEN>
<TOKEN end_char="4134" id="token-18-13" morph="none" pos="word" start_char="4129">Panama</TOKEN>
<TOKEN end_char="4135" id="token-18-14" morph="none" pos="punct" start_char="4135">,</TOKEN>
<TOKEN end_char="4142" id="token-18-15" morph="none" pos="word" start_char="4137">Kuwait</TOKEN>
<TOKEN end_char="4143" id="token-18-16" morph="none" pos="punct" start_char="4143">,</TOKEN>
<TOKEN end_char="4147" id="token-18-17" morph="none" pos="word" start_char="4145">the</TOKEN>
<TOKEN end_char="4151" id="token-18-18" morph="none" pos="word" start_char="4149">UAE</TOKEN>
<TOKEN end_char="4152" id="token-18-19" morph="none" pos="punct" start_char="4152">,</TOKEN>
<TOKEN end_char="4159" id="token-18-20" morph="none" pos="word" start_char="4154">Israel</TOKEN>
<TOKEN end_char="4160" id="token-18-21" morph="none" pos="punct" start_char="4160">,</TOKEN>
<TOKEN end_char="4167" id="token-18-22" morph="none" pos="word" start_char="4162">Rwanda</TOKEN>
<TOKEN end_char="4168" id="token-18-23" morph="none" pos="punct" start_char="4168">,</TOKEN>
<TOKEN end_char="4176" id="token-18-24" morph="none" pos="word" start_char="4170">Morocco</TOKEN>
<TOKEN end_char="4180" id="token-18-25" morph="none" pos="word" start_char="4178">and</TOKEN>
<TOKEN end_char="4189" id="token-18-26" morph="none" pos="word" start_char="4182">numerous</TOKEN>
<TOKEN end_char="4195" id="token-18-27" morph="none" pos="word" start_char="4191">other</TOKEN>
<TOKEN end_char="4205" id="token-18-28" morph="none" pos="word" start_char="4197">countries</TOKEN>
<TOKEN end_char="4206" id="token-18-29" morph="none" pos="punct" start_char="4206">.</TOKEN>
</SEG>
<SEG end_char="4346" id="segment-19" start_char="4208">
<ORIGINAL_TEXT>Through Lilly's work with the Bill Melinda Gates Foundation, Lilly is providing doses of bamlanivimab free of charge in Rwanda and Morocco.</ORIGINAL_TEXT>
<TOKEN end_char="4214" id="token-19-0" morph="none" pos="word" start_char="4208">Through</TOKEN>
<TOKEN end_char="4222" id="token-19-1" morph="none" pos="word" start_char="4216">Lilly's</TOKEN>
<TOKEN end_char="4227" id="token-19-2" morph="none" pos="word" start_char="4224">work</TOKEN>
<TOKEN end_char="4232" id="token-19-3" morph="none" pos="word" start_char="4229">with</TOKEN>
<TOKEN end_char="4236" id="token-19-4" morph="none" pos="word" start_char="4234">the</TOKEN>
<TOKEN end_char="4241" id="token-19-5" morph="none" pos="word" start_char="4238">Bill</TOKEN>
<TOKEN end_char="4249" id="token-19-6" morph="none" pos="word" start_char="4243">Melinda</TOKEN>
<TOKEN end_char="4255" id="token-19-7" morph="none" pos="word" start_char="4251">Gates</TOKEN>
<TOKEN end_char="4266" id="token-19-8" morph="none" pos="word" start_char="4257">Foundation</TOKEN>
<TOKEN end_char="4267" id="token-19-9" morph="none" pos="punct" start_char="4267">,</TOKEN>
<TOKEN end_char="4273" id="token-19-10" morph="none" pos="word" start_char="4269">Lilly</TOKEN>
<TOKEN end_char="4276" id="token-19-11" morph="none" pos="word" start_char="4275">is</TOKEN>
<TOKEN end_char="4286" id="token-19-12" morph="none" pos="word" start_char="4278">providing</TOKEN>
<TOKEN end_char="4292" id="token-19-13" morph="none" pos="word" start_char="4288">doses</TOKEN>
<TOKEN end_char="4295" id="token-19-14" morph="none" pos="word" start_char="4294">of</TOKEN>
<TOKEN end_char="4308" id="token-19-15" morph="none" pos="word" start_char="4297">bamlanivimab</TOKEN>
<TOKEN end_char="4313" id="token-19-16" morph="none" pos="word" start_char="4310">free</TOKEN>
<TOKEN end_char="4316" id="token-19-17" morph="none" pos="word" start_char="4315">of</TOKEN>
<TOKEN end_char="4323" id="token-19-18" morph="none" pos="word" start_char="4318">charge</TOKEN>
<TOKEN end_char="4326" id="token-19-19" morph="none" pos="word" start_char="4325">in</TOKEN>
<TOKEN end_char="4333" id="token-19-20" morph="none" pos="word" start_char="4328">Rwanda</TOKEN>
<TOKEN end_char="4337" id="token-19-21" morph="none" pos="word" start_char="4335">and</TOKEN>
<TOKEN end_char="4345" id="token-19-22" morph="none" pos="word" start_char="4339">Morocco</TOKEN>
<TOKEN end_char="4346" id="token-19-23" morph="none" pos="punct" start_char="4346">.</TOKEN>
</SEG>
<SEG end_char="4631" id="segment-20" start_char="4349">
<ORIGINAL_TEXT>For more information about the use of bamlanivimab alone or bamlanivimab and etesevimab together for the treatment of mild to moderate COVID-19 in high-risk patients under the FDA's emergency use authorization, contact Lilly's 24-hour support line at 1-855-LillyC19 (1-855-545-5921).</ORIGINAL_TEXT>
<TOKEN end_char="4351" id="token-20-0" morph="none" pos="word" start_char="4349">For</TOKEN>
<TOKEN end_char="4356" id="token-20-1" morph="none" pos="word" start_char="4353">more</TOKEN>
<TOKEN end_char="4368" id="token-20-2" morph="none" pos="word" start_char="4358">information</TOKEN>
<TOKEN end_char="4374" id="token-20-3" morph="none" pos="word" start_char="4370">about</TOKEN>
<TOKEN end_char="4378" id="token-20-4" morph="none" pos="word" start_char="4376">the</TOKEN>
<TOKEN end_char="4382" id="token-20-5" morph="none" pos="word" start_char="4380">use</TOKEN>
<TOKEN end_char="4385" id="token-20-6" morph="none" pos="word" start_char="4384">of</TOKEN>
<TOKEN end_char="4398" id="token-20-7" morph="none" pos="word" start_char="4387">bamlanivimab</TOKEN>
<TOKEN end_char="4404" id="token-20-8" morph="none" pos="word" start_char="4400">alone</TOKEN>
<TOKEN end_char="4407" id="token-20-9" morph="none" pos="word" start_char="4406">or</TOKEN>
<TOKEN end_char="4420" id="token-20-10" morph="none" pos="word" start_char="4409">bamlanivimab</TOKEN>
<TOKEN end_char="4424" id="token-20-11" morph="none" pos="word" start_char="4422">and</TOKEN>
<TOKEN end_char="4435" id="token-20-12" morph="none" pos="word" start_char="4426">etesevimab</TOKEN>
<TOKEN end_char="4444" id="token-20-13" morph="none" pos="word" start_char="4437">together</TOKEN>
<TOKEN end_char="4448" id="token-20-14" morph="none" pos="word" start_char="4446">for</TOKEN>
<TOKEN end_char="4452" id="token-20-15" morph="none" pos="word" start_char="4450">the</TOKEN>
<TOKEN end_char="4462" id="token-20-16" morph="none" pos="word" start_char="4454">treatment</TOKEN>
<TOKEN end_char="4465" id="token-20-17" morph="none" pos="word" start_char="4464">of</TOKEN>
<TOKEN end_char="4470" id="token-20-18" morph="none" pos="word" start_char="4467">mild</TOKEN>
<TOKEN end_char="4473" id="token-20-19" morph="none" pos="word" start_char="4472">to</TOKEN>
<TOKEN end_char="4482" id="token-20-20" morph="none" pos="word" start_char="4475">moderate</TOKEN>
<TOKEN end_char="4491" id="token-20-21" morph="none" pos="unknown" start_char="4484">COVID-19</TOKEN>
<TOKEN end_char="4494" id="token-20-22" morph="none" pos="word" start_char="4493">in</TOKEN>
<TOKEN end_char="4504" id="token-20-23" morph="none" pos="unknown" start_char="4496">high-risk</TOKEN>
<TOKEN end_char="4513" id="token-20-24" morph="none" pos="word" start_char="4506">patients</TOKEN>
<TOKEN end_char="4519" id="token-20-25" morph="none" pos="word" start_char="4515">under</TOKEN>
<TOKEN end_char="4523" id="token-20-26" morph="none" pos="word" start_char="4521">the</TOKEN>
<TOKEN end_char="4529" id="token-20-27" morph="none" pos="word" start_char="4525">FDA's</TOKEN>
<TOKEN end_char="4539" id="token-20-28" morph="none" pos="word" start_char="4531">emergency</TOKEN>
<TOKEN end_char="4543" id="token-20-29" morph="none" pos="word" start_char="4541">use</TOKEN>
<TOKEN end_char="4557" id="token-20-30" morph="none" pos="word" start_char="4545">authorization</TOKEN>
<TOKEN end_char="4558" id="token-20-31" morph="none" pos="punct" start_char="4558">,</TOKEN>
<TOKEN end_char="4566" id="token-20-32" morph="none" pos="word" start_char="4560">contact</TOKEN>
<TOKEN end_char="4574" id="token-20-33" morph="none" pos="word" start_char="4568">Lilly's</TOKEN>
<TOKEN end_char="4582" id="token-20-34" morph="none" pos="unknown" start_char="4576">24-hour</TOKEN>
<TOKEN end_char="4590" id="token-20-35" morph="none" pos="word" start_char="4584">support</TOKEN>
<TOKEN end_char="4595" id="token-20-36" morph="none" pos="word" start_char="4592">line</TOKEN>
<TOKEN end_char="4598" id="token-20-37" morph="none" pos="word" start_char="4597">at</TOKEN>
<TOKEN end_char="4613" id="token-20-38" morph="none" pos="unknown" start_char="4600">1-855-LillyC19</TOKEN>
<TOKEN end_char="4615" id="token-20-39" morph="none" pos="punct" start_char="4615">(</TOKEN>
<TOKEN end_char="4629" id="token-20-40" morph="none" pos="unknown" start_char="4616">1-855-545-5921</TOKEN>
<TOKEN end_char="4631" id="token-20-41" morph="none" pos="punct" start_char="4630">).</TOKEN>
</SEG>
<SEG end_char="4752" id="segment-21" start_char="4633">
<ORIGINAL_TEXT>Patients and physicians can visit lillyantibody.com to learn more, including how to find a potential treatment location.</ORIGINAL_TEXT>
<TOKEN end_char="4640" id="token-21-0" morph="none" pos="word" start_char="4633">Patients</TOKEN>
<TOKEN end_char="4644" id="token-21-1" morph="none" pos="word" start_char="4642">and</TOKEN>
<TOKEN end_char="4655" id="token-21-2" morph="none" pos="word" start_char="4646">physicians</TOKEN>
<TOKEN end_char="4659" id="token-21-3" morph="none" pos="word" start_char="4657">can</TOKEN>
<TOKEN end_char="4665" id="token-21-4" morph="none" pos="word" start_char="4661">visit</TOKEN>
<TOKEN end_char="4683" id="token-21-5" morph="none" pos="unknown" start_char="4667">lillyantibody.com</TOKEN>
<TOKEN end_char="4686" id="token-21-6" morph="none" pos="word" start_char="4685">to</TOKEN>
<TOKEN end_char="4692" id="token-21-7" morph="none" pos="word" start_char="4688">learn</TOKEN>
<TOKEN end_char="4697" id="token-21-8" morph="none" pos="word" start_char="4694">more</TOKEN>
<TOKEN end_char="4698" id="token-21-9" morph="none" pos="punct" start_char="4698">,</TOKEN>
<TOKEN end_char="4708" id="token-21-10" morph="none" pos="word" start_char="4700">including</TOKEN>
<TOKEN end_char="4712" id="token-21-11" morph="none" pos="word" start_char="4710">how</TOKEN>
<TOKEN end_char="4715" id="token-21-12" morph="none" pos="word" start_char="4714">to</TOKEN>
<TOKEN end_char="4720" id="token-21-13" morph="none" pos="word" start_char="4717">find</TOKEN>
<TOKEN end_char="4722" id="token-21-14" morph="none" pos="word" start_char="4722">a</TOKEN>
<TOKEN end_char="4732" id="token-21-15" morph="none" pos="word" start_char="4724">potential</TOKEN>
<TOKEN end_char="4742" id="token-21-16" morph="none" pos="word" start_char="4734">treatment</TOKEN>
<TOKEN end_char="4751" id="token-21-17" morph="none" pos="word" start_char="4744">location</TOKEN>
<TOKEN end_char="4752" id="token-21-18" morph="none" pos="punct" start_char="4752">.</TOKEN>
</SEG>
<SEG end_char="4835" id="segment-22" start_char="4755">
<ORIGINAL_TEXT>For media resources, including product images and fact sheets, please click here.</ORIGINAL_TEXT>
<TOKEN end_char="4757" id="token-22-0" morph="none" pos="word" start_char="4755">For</TOKEN>
<TOKEN end_char="4763" id="token-22-1" morph="none" pos="word" start_char="4759">media</TOKEN>
<TOKEN end_char="4773" id="token-22-2" morph="none" pos="word" start_char="4765">resources</TOKEN>
<TOKEN end_char="4774" id="token-22-3" morph="none" pos="punct" start_char="4774">,</TOKEN>
<TOKEN end_char="4784" id="token-22-4" morph="none" pos="word" start_char="4776">including</TOKEN>
<TOKEN end_char="4792" id="token-22-5" morph="none" pos="word" start_char="4786">product</TOKEN>
<TOKEN end_char="4799" id="token-22-6" morph="none" pos="word" start_char="4794">images</TOKEN>
<TOKEN end_char="4803" id="token-22-7" morph="none" pos="word" start_char="4801">and</TOKEN>
<TOKEN end_char="4808" id="token-22-8" morph="none" pos="word" start_char="4805">fact</TOKEN>
<TOKEN end_char="4815" id="token-22-9" morph="none" pos="word" start_char="4810">sheets</TOKEN>
<TOKEN end_char="4816" id="token-22-10" morph="none" pos="punct" start_char="4816">,</TOKEN>
<TOKEN end_char="4823" id="token-22-11" morph="none" pos="word" start_char="4818">please</TOKEN>
<TOKEN end_char="4829" id="token-22-12" morph="none" pos="word" start_char="4825">click</TOKEN>
<TOKEN end_char="4834" id="token-22-13" morph="none" pos="word" start_char="4831">here</TOKEN>
<TOKEN end_char="4835" id="token-22-14" morph="none" pos="punct" start_char="4835">.</TOKEN>
</SEG>
<SEG end_char="4924" id="segment-23" start_char="4838">
<ORIGINAL_TEXT>Important Information about bamlanivimab alone and bamlanivimab and etesevimab together</ORIGINAL_TEXT>
<TOKEN end_char="4846" id="token-23-0" morph="none" pos="word" start_char="4838">Important</TOKEN>
<TOKEN end_char="4858" id="token-23-1" morph="none" pos="word" start_char="4848">Information</TOKEN>
<TOKEN end_char="4864" id="token-23-2" morph="none" pos="word" start_char="4860">about</TOKEN>
<TOKEN end_char="4877" id="token-23-3" morph="none" pos="word" start_char="4866">bamlanivimab</TOKEN>
<TOKEN end_char="4883" id="token-23-4" morph="none" pos="word" start_char="4879">alone</TOKEN>
<TOKEN end_char="4887" id="token-23-5" morph="none" pos="word" start_char="4885">and</TOKEN>
<TOKEN end_char="4900" id="token-23-6" morph="none" pos="word" start_char="4889">bamlanivimab</TOKEN>
<TOKEN end_char="4904" id="token-23-7" morph="none" pos="word" start_char="4902">and</TOKEN>
<TOKEN end_char="4915" id="token-23-8" morph="none" pos="word" start_char="4906">etesevimab</TOKEN>
<TOKEN end_char="4924" id="token-23-9" morph="none" pos="word" start_char="4917">together</TOKEN>
</SEG>
<SEG end_char="5033" id="segment-24" start_char="4928">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together and bamlanivimab alone have not been approved by the FDA for any use.</ORIGINAL_TEXT>
<TOKEN end_char="4939" id="token-24-0" morph="none" pos="word" start_char="4928">Bamlanivimab</TOKEN>
<TOKEN end_char="4943" id="token-24-1" morph="none" pos="word" start_char="4941">and</TOKEN>
<TOKEN end_char="4954" id="token-24-2" morph="none" pos="word" start_char="4945">etesevimab</TOKEN>
<TOKEN end_char="4963" id="token-24-3" morph="none" pos="word" start_char="4956">together</TOKEN>
<TOKEN end_char="4967" id="token-24-4" morph="none" pos="word" start_char="4965">and</TOKEN>
<TOKEN end_char="4980" id="token-24-5" morph="none" pos="word" start_char="4969">bamlanivimab</TOKEN>
<TOKEN end_char="4986" id="token-24-6" morph="none" pos="word" start_char="4982">alone</TOKEN>
<TOKEN end_char="4991" id="token-24-7" morph="none" pos="word" start_char="4988">have</TOKEN>
<TOKEN end_char="4995" id="token-24-8" morph="none" pos="word" start_char="4993">not</TOKEN>
<TOKEN end_char="5000" id="token-24-9" morph="none" pos="word" start_char="4997">been</TOKEN>
<TOKEN end_char="5009" id="token-24-10" morph="none" pos="word" start_char="5002">approved</TOKEN>
<TOKEN end_char="5012" id="token-24-11" morph="none" pos="word" start_char="5011">by</TOKEN>
<TOKEN end_char="5016" id="token-24-12" morph="none" pos="word" start_char="5014">the</TOKEN>
<TOKEN end_char="5020" id="token-24-13" morph="none" pos="word" start_char="5018">FDA</TOKEN>
<TOKEN end_char="5024" id="token-24-14" morph="none" pos="word" start_char="5022">for</TOKEN>
<TOKEN end_char="5028" id="token-24-15" morph="none" pos="word" start_char="5026">any</TOKEN>
<TOKEN end_char="5032" id="token-24-16" morph="none" pos="word" start_char="5030">use</TOKEN>
<TOKEN end_char="5033" id="token-24-17" morph="none" pos="punct" start_char="5033">.</TOKEN>
</SEG>
<SEG end_char="5165" id="segment-25" start_char="5035">
<ORIGINAL_TEXT>It is not known if bamlanivimab and etesevimab together or bamlanivimab alone are safe and effective for the treatment of COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="5036" id="token-25-0" morph="none" pos="word" start_char="5035">It</TOKEN>
<TOKEN end_char="5039" id="token-25-1" morph="none" pos="word" start_char="5038">is</TOKEN>
<TOKEN end_char="5043" id="token-25-2" morph="none" pos="word" start_char="5041">not</TOKEN>
<TOKEN end_char="5049" id="token-25-3" morph="none" pos="word" start_char="5045">known</TOKEN>
<TOKEN end_char="5052" id="token-25-4" morph="none" pos="word" start_char="5051">if</TOKEN>
<TOKEN end_char="5065" id="token-25-5" morph="none" pos="word" start_char="5054">bamlanivimab</TOKEN>
<TOKEN end_char="5069" id="token-25-6" morph="none" pos="word" start_char="5067">and</TOKEN>
<TOKEN end_char="5080" id="token-25-7" morph="none" pos="word" start_char="5071">etesevimab</TOKEN>
<TOKEN end_char="5089" id="token-25-8" morph="none" pos="word" start_char="5082">together</TOKEN>
<TOKEN end_char="5092" id="token-25-9" morph="none" pos="word" start_char="5091">or</TOKEN>
<TOKEN end_char="5105" id="token-25-10" morph="none" pos="word" start_char="5094">bamlanivimab</TOKEN>
<TOKEN end_char="5111" id="token-25-11" morph="none" pos="word" start_char="5107">alone</TOKEN>
<TOKEN end_char="5115" id="token-25-12" morph="none" pos="word" start_char="5113">are</TOKEN>
<TOKEN end_char="5120" id="token-25-13" morph="none" pos="word" start_char="5117">safe</TOKEN>
<TOKEN end_char="5124" id="token-25-14" morph="none" pos="word" start_char="5122">and</TOKEN>
<TOKEN end_char="5134" id="token-25-15" morph="none" pos="word" start_char="5126">effective</TOKEN>
<TOKEN end_char="5138" id="token-25-16" morph="none" pos="word" start_char="5136">for</TOKEN>
<TOKEN end_char="5142" id="token-25-17" morph="none" pos="word" start_char="5140">the</TOKEN>
<TOKEN end_char="5152" id="token-25-18" morph="none" pos="word" start_char="5144">treatment</TOKEN>
<TOKEN end_char="5155" id="token-25-19" morph="none" pos="word" start_char="5154">of</TOKEN>
<TOKEN end_char="5164" id="token-25-20" morph="none" pos="unknown" start_char="5157">COVID-19</TOKEN>
<TOKEN end_char="5165" id="token-25-21" morph="none" pos="punct" start_char="5165">.</TOKEN>
</SEG>
<SEG end_char="5512" id="segment-26" start_char="5168">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together and bamlanivimab alone are authorized under Emergency Use Authorization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under Section 564(b)(1) of the Act, 21 U.S.C  360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</ORIGINAL_TEXT>
<TOKEN end_char="5179" id="token-26-0" morph="none" pos="word" start_char="5168">Bamlanivimab</TOKEN>
<TOKEN end_char="5183" id="token-26-1" morph="none" pos="word" start_char="5181">and</TOKEN>
<TOKEN end_char="5194" id="token-26-2" morph="none" pos="word" start_char="5185">etesevimab</TOKEN>
<TOKEN end_char="5203" id="token-26-3" morph="none" pos="word" start_char="5196">together</TOKEN>
<TOKEN end_char="5207" id="token-26-4" morph="none" pos="word" start_char="5205">and</TOKEN>
<TOKEN end_char="5220" id="token-26-5" morph="none" pos="word" start_char="5209">bamlanivimab</TOKEN>
<TOKEN end_char="5226" id="token-26-6" morph="none" pos="word" start_char="5222">alone</TOKEN>
<TOKEN end_char="5230" id="token-26-7" morph="none" pos="word" start_char="5228">are</TOKEN>
<TOKEN end_char="5241" id="token-26-8" morph="none" pos="word" start_char="5232">authorized</TOKEN>
<TOKEN end_char="5247" id="token-26-9" morph="none" pos="word" start_char="5243">under</TOKEN>
<TOKEN end_char="5257" id="token-26-10" morph="none" pos="word" start_char="5249">Emergency</TOKEN>
<TOKEN end_char="5261" id="token-26-11" morph="none" pos="word" start_char="5259">Use</TOKEN>
<TOKEN end_char="5275" id="token-26-12" morph="none" pos="word" start_char="5263">Authorization</TOKEN>
<TOKEN end_char="5280" id="token-26-13" morph="none" pos="word" start_char="5277">only</TOKEN>
<TOKEN end_char="5284" id="token-26-14" morph="none" pos="word" start_char="5282">for</TOKEN>
<TOKEN end_char="5288" id="token-26-15" morph="none" pos="word" start_char="5286">the</TOKEN>
<TOKEN end_char="5297" id="token-26-16" morph="none" pos="word" start_char="5290">duration</TOKEN>
<TOKEN end_char="5300" id="token-26-17" morph="none" pos="word" start_char="5299">of</TOKEN>
<TOKEN end_char="5304" id="token-26-18" morph="none" pos="word" start_char="5302">the</TOKEN>
<TOKEN end_char="5316" id="token-26-19" morph="none" pos="word" start_char="5306">declaration</TOKEN>
<TOKEN end_char="5321" id="token-26-20" morph="none" pos="word" start_char="5318">that</TOKEN>
<TOKEN end_char="5335" id="token-26-21" morph="none" pos="word" start_char="5323">circumstances</TOKEN>
<TOKEN end_char="5341" id="token-26-22" morph="none" pos="word" start_char="5337">exist</TOKEN>
<TOKEN end_char="5352" id="token-26-23" morph="none" pos="word" start_char="5343">justifying</TOKEN>
<TOKEN end_char="5356" id="token-26-24" morph="none" pos="word" start_char="5354">the</TOKEN>
<TOKEN end_char="5370" id="token-26-25" morph="none" pos="word" start_char="5358">authorization</TOKEN>
<TOKEN end_char="5373" id="token-26-26" morph="none" pos="word" start_char="5372">of</TOKEN>
<TOKEN end_char="5377" id="token-26-27" morph="none" pos="word" start_char="5375">the</TOKEN>
<TOKEN end_char="5387" id="token-26-28" morph="none" pos="word" start_char="5379">emergency</TOKEN>
<TOKEN end_char="5391" id="token-26-29" morph="none" pos="word" start_char="5389">use</TOKEN>
<TOKEN end_char="5397" id="token-26-30" morph="none" pos="word" start_char="5393">under</TOKEN>
<TOKEN end_char="5405" id="token-26-31" morph="none" pos="word" start_char="5399">Section</TOKEN>
<TOKEN end_char="5414" id="token-26-32" morph="none" pos="unknown" start_char="5407">564(b)(1</TOKEN>
<TOKEN end_char="5415" id="token-26-33" morph="none" pos="punct" start_char="5415">)</TOKEN>
<TOKEN end_char="5418" id="token-26-34" morph="none" pos="word" start_char="5417">of</TOKEN>
<TOKEN end_char="5422" id="token-26-35" morph="none" pos="word" start_char="5420">the</TOKEN>
<TOKEN end_char="5426" id="token-26-36" morph="none" pos="word" start_char="5424">Act</TOKEN>
<TOKEN end_char="5427" id="token-26-37" morph="none" pos="punct" start_char="5427">,</TOKEN>
<TOKEN end_char="5430" id="token-26-38" morph="none" pos="word" start_char="5429">21</TOKEN>
<TOKEN end_char="5436" id="token-26-39" morph="none" pos="unknown" start_char="5432">U.S.C</TOKEN>
<TOKEN end_char="5438" id="token-26-40" morph="none" pos="punct" start_char="5438"></TOKEN>
<TOKEN end_char="5452" id="token-26-41" morph="none" pos="unknown" start_char="5440">360bbb-3(b)(1</TOKEN>
<TOKEN end_char="5454" id="token-26-42" morph="none" pos="punct" start_char="5453">),</TOKEN>
<TOKEN end_char="5461" id="token-26-43" morph="none" pos="word" start_char="5456">unless</TOKEN>
<TOKEN end_char="5465" id="token-26-44" morph="none" pos="word" start_char="5463">the</TOKEN>
<TOKEN end_char="5479" id="token-26-45" morph="none" pos="word" start_char="5467">authorization</TOKEN>
<TOKEN end_char="5482" id="token-26-46" morph="none" pos="word" start_char="5481">is</TOKEN>
<TOKEN end_char="5493" id="token-26-47" morph="none" pos="word" start_char="5484">terminated</TOKEN>
<TOKEN end_char="5496" id="token-26-48" morph="none" pos="word" start_char="5495">or</TOKEN>
<TOKEN end_char="5504" id="token-26-49" morph="none" pos="word" start_char="5498">revoked</TOKEN>
<TOKEN end_char="5511" id="token-26-50" morph="none" pos="word" start_char="5506">sooner</TOKEN>
<TOKEN end_char="5512" id="token-26-51" morph="none" pos="punct" start_char="5512">.</TOKEN>
</SEG>
<SEG end_char="5703" id="segment-27" start_char="5515">
<ORIGINAL_TEXT>Healthcare providers should review the Fact Sheet for information on the authorized use of bamlanivimab and etesevimab together and bamlanivimab alone and mandatory requirements of the EUA.</ORIGINAL_TEXT>
<TOKEN end_char="5524" id="token-27-0" morph="none" pos="word" start_char="5515">Healthcare</TOKEN>
<TOKEN end_char="5534" id="token-27-1" morph="none" pos="word" start_char="5526">providers</TOKEN>
<TOKEN end_char="5541" id="token-27-2" morph="none" pos="word" start_char="5536">should</TOKEN>
<TOKEN end_char="5548" id="token-27-3" morph="none" pos="word" start_char="5543">review</TOKEN>
<TOKEN end_char="5552" id="token-27-4" morph="none" pos="word" start_char="5550">the</TOKEN>
<TOKEN end_char="5557" id="token-27-5" morph="none" pos="word" start_char="5554">Fact</TOKEN>
<TOKEN end_char="5563" id="token-27-6" morph="none" pos="word" start_char="5559">Sheet</TOKEN>
<TOKEN end_char="5567" id="token-27-7" morph="none" pos="word" start_char="5565">for</TOKEN>
<TOKEN end_char="5579" id="token-27-8" morph="none" pos="word" start_char="5569">information</TOKEN>
<TOKEN end_char="5582" id="token-27-9" morph="none" pos="word" start_char="5581">on</TOKEN>
<TOKEN end_char="5586" id="token-27-10" morph="none" pos="word" start_char="5584">the</TOKEN>
<TOKEN end_char="5597" id="token-27-11" morph="none" pos="word" start_char="5588">authorized</TOKEN>
<TOKEN end_char="5601" id="token-27-12" morph="none" pos="word" start_char="5599">use</TOKEN>
<TOKEN end_char="5604" id="token-27-13" morph="none" pos="word" start_char="5603">of</TOKEN>
<TOKEN end_char="5617" id="token-27-14" morph="none" pos="word" start_char="5606">bamlanivimab</TOKEN>
<TOKEN end_char="5621" id="token-27-15" morph="none" pos="word" start_char="5619">and</TOKEN>
<TOKEN end_char="5632" id="token-27-16" morph="none" pos="word" start_char="5623">etesevimab</TOKEN>
<TOKEN end_char="5641" id="token-27-17" morph="none" pos="word" start_char="5634">together</TOKEN>
<TOKEN end_char="5645" id="token-27-18" morph="none" pos="word" start_char="5643">and</TOKEN>
<TOKEN end_char="5658" id="token-27-19" morph="none" pos="word" start_char="5647">bamlanivimab</TOKEN>
<TOKEN end_char="5664" id="token-27-20" morph="none" pos="word" start_char="5660">alone</TOKEN>
<TOKEN end_char="5668" id="token-27-21" morph="none" pos="word" start_char="5666">and</TOKEN>
<TOKEN end_char="5678" id="token-27-22" morph="none" pos="word" start_char="5670">mandatory</TOKEN>
<TOKEN end_char="5691" id="token-27-23" morph="none" pos="word" start_char="5680">requirements</TOKEN>
<TOKEN end_char="5694" id="token-27-24" morph="none" pos="word" start_char="5693">of</TOKEN>
<TOKEN end_char="5698" id="token-27-25" morph="none" pos="word" start_char="5696">the</TOKEN>
<TOKEN end_char="5702" id="token-27-26" morph="none" pos="word" start_char="5700">EUA</TOKEN>
<TOKEN end_char="5703" id="token-27-27" morph="none" pos="punct" start_char="5703">.</TOKEN>
</SEG>
<SEG end_char="5898" id="segment-28" start_char="5705">
<ORIGINAL_TEXT>Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents and Caregivers (English) (Spanish) for bamlanivimab and etesevimab together.</ORIGINAL_TEXT>
<TOKEN end_char="5710" id="token-28-0" morph="none" pos="word" start_char="5705">Please</TOKEN>
<TOKEN end_char="5714" id="token-28-1" morph="none" pos="word" start_char="5712">see</TOKEN>
<TOKEN end_char="5718" id="token-28-2" morph="none" pos="word" start_char="5716">the</TOKEN>
<TOKEN end_char="5722" id="token-28-3" morph="none" pos="word" start_char="5720">FDA</TOKEN>
<TOKEN end_char="5729" id="token-28-4" morph="none" pos="word" start_char="5724">Letter</TOKEN>
<TOKEN end_char="5732" id="token-28-5" morph="none" pos="word" start_char="5731">of</TOKEN>
<TOKEN end_char="5746" id="token-28-6" morph="none" pos="word" start_char="5734">Authorization</TOKEN>
<TOKEN end_char="5747" id="token-28-7" morph="none" pos="punct" start_char="5747">,</TOKEN>
<TOKEN end_char="5752" id="token-28-8" morph="none" pos="word" start_char="5749">Fact</TOKEN>
<TOKEN end_char="5758" id="token-28-9" morph="none" pos="word" start_char="5754">Sheet</TOKEN>
<TOKEN end_char="5762" id="token-28-10" morph="none" pos="word" start_char="5760">for</TOKEN>
<TOKEN end_char="5773" id="token-28-11" morph="none" pos="word" start_char="5764">Healthcare</TOKEN>
<TOKEN end_char="5783" id="token-28-12" morph="none" pos="word" start_char="5775">Providers</TOKEN>
<TOKEN end_char="5784" id="token-28-13" morph="none" pos="punct" start_char="5784">,</TOKEN>
<TOKEN end_char="5788" id="token-28-14" morph="none" pos="word" start_char="5786">and</TOKEN>
<TOKEN end_char="5793" id="token-28-15" morph="none" pos="word" start_char="5790">Fact</TOKEN>
<TOKEN end_char="5799" id="token-28-16" morph="none" pos="word" start_char="5795">Sheet</TOKEN>
<TOKEN end_char="5803" id="token-28-17" morph="none" pos="word" start_char="5801">for</TOKEN>
<TOKEN end_char="5812" id="token-28-18" morph="none" pos="word" start_char="5805">Patients</TOKEN>
<TOKEN end_char="5813" id="token-28-19" morph="none" pos="punct" start_char="5813">,</TOKEN>
<TOKEN end_char="5821" id="token-28-20" morph="none" pos="word" start_char="5815">Parents</TOKEN>
<TOKEN end_char="5825" id="token-28-21" morph="none" pos="word" start_char="5823">and</TOKEN>
<TOKEN end_char="5836" id="token-28-22" morph="none" pos="word" start_char="5827">Caregivers</TOKEN>
<TOKEN end_char="5838" id="token-28-23" morph="none" pos="punct" start_char="5838">(</TOKEN>
<TOKEN end_char="5845" id="token-28-24" morph="none" pos="word" start_char="5839">English</TOKEN>
<TOKEN end_char="5846" id="token-28-25" morph="none" pos="punct" start_char="5846">)</TOKEN>
<TOKEN end_char="5848" id="token-28-26" morph="none" pos="punct" start_char="5848">(</TOKEN>
<TOKEN end_char="5855" id="token-28-27" morph="none" pos="word" start_char="5849">Spanish</TOKEN>
<TOKEN end_char="5856" id="token-28-28" morph="none" pos="punct" start_char="5856">)</TOKEN>
<TOKEN end_char="5860" id="token-28-29" morph="none" pos="word" start_char="5858">for</TOKEN>
<TOKEN end_char="5873" id="token-28-30" morph="none" pos="word" start_char="5862">bamlanivimab</TOKEN>
<TOKEN end_char="5877" id="token-28-31" morph="none" pos="word" start_char="5875">and</TOKEN>
<TOKEN end_char="5888" id="token-28-32" morph="none" pos="word" start_char="5879">etesevimab</TOKEN>
<TOKEN end_char="5897" id="token-28-33" morph="none" pos="word" start_char="5890">together</TOKEN>
<TOKEN end_char="5898" id="token-28-34" morph="none" pos="punct" start_char="5898">.</TOKEN>
</SEG>
<SEG end_char="6075" id="segment-29" start_char="5900">
<ORIGINAL_TEXT>Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents and Caregivers (English) (Spanish) for bamlanivimab alone.</ORIGINAL_TEXT>
<TOKEN end_char="5905" id="token-29-0" morph="none" pos="word" start_char="5900">Please</TOKEN>
<TOKEN end_char="5909" id="token-29-1" morph="none" pos="word" start_char="5907">see</TOKEN>
<TOKEN end_char="5913" id="token-29-2" morph="none" pos="word" start_char="5911">the</TOKEN>
<TOKEN end_char="5917" id="token-29-3" morph="none" pos="word" start_char="5915">FDA</TOKEN>
<TOKEN end_char="5924" id="token-29-4" morph="none" pos="word" start_char="5919">Letter</TOKEN>
<TOKEN end_char="5927" id="token-29-5" morph="none" pos="word" start_char="5926">of</TOKEN>
<TOKEN end_char="5941" id="token-29-6" morph="none" pos="word" start_char="5929">Authorization</TOKEN>
<TOKEN end_char="5942" id="token-29-7" morph="none" pos="punct" start_char="5942">,</TOKEN>
<TOKEN end_char="5947" id="token-29-8" morph="none" pos="word" start_char="5944">Fact</TOKEN>
<TOKEN end_char="5953" id="token-29-9" morph="none" pos="word" start_char="5949">Sheet</TOKEN>
<TOKEN end_char="5957" id="token-29-10" morph="none" pos="word" start_char="5955">for</TOKEN>
<TOKEN end_char="5968" id="token-29-11" morph="none" pos="word" start_char="5959">Healthcare</TOKEN>
<TOKEN end_char="5978" id="token-29-12" morph="none" pos="word" start_char="5970">Providers</TOKEN>
<TOKEN end_char="5979" id="token-29-13" morph="none" pos="punct" start_char="5979">,</TOKEN>
<TOKEN end_char="5983" id="token-29-14" morph="none" pos="word" start_char="5981">and</TOKEN>
<TOKEN end_char="5988" id="token-29-15" morph="none" pos="word" start_char="5985">Fact</TOKEN>
<TOKEN end_char="5994" id="token-29-16" morph="none" pos="word" start_char="5990">Sheet</TOKEN>
<TOKEN end_char="5998" id="token-29-17" morph="none" pos="word" start_char="5996">for</TOKEN>
<TOKEN end_char="6007" id="token-29-18" morph="none" pos="word" start_char="6000">Patients</TOKEN>
<TOKEN end_char="6008" id="token-29-19" morph="none" pos="punct" start_char="6008">,</TOKEN>
<TOKEN end_char="6016" id="token-29-20" morph="none" pos="word" start_char="6010">Parents</TOKEN>
<TOKEN end_char="6020" id="token-29-21" morph="none" pos="word" start_char="6018">and</TOKEN>
<TOKEN end_char="6031" id="token-29-22" morph="none" pos="word" start_char="6022">Caregivers</TOKEN>
<TOKEN end_char="6033" id="token-29-23" morph="none" pos="punct" start_char="6033">(</TOKEN>
<TOKEN end_char="6040" id="token-29-24" morph="none" pos="word" start_char="6034">English</TOKEN>
<TOKEN end_char="6041" id="token-29-25" morph="none" pos="punct" start_char="6041">)</TOKEN>
<TOKEN end_char="6043" id="token-29-26" morph="none" pos="punct" start_char="6043">(</TOKEN>
<TOKEN end_char="6050" id="token-29-27" morph="none" pos="word" start_char="6044">Spanish</TOKEN>
<TOKEN end_char="6051" id="token-29-28" morph="none" pos="punct" start_char="6051">)</TOKEN>
<TOKEN end_char="6055" id="token-29-29" morph="none" pos="word" start_char="6053">for</TOKEN>
<TOKEN end_char="6068" id="token-29-30" morph="none" pos="word" start_char="6057">bamlanivimab</TOKEN>
<TOKEN end_char="6074" id="token-29-31" morph="none" pos="word" start_char="6070">alone</TOKEN>
<TOKEN end_char="6075" id="token-29-32" morph="none" pos="punct" start_char="6075">.</TOKEN>
</SEG>
<SEG end_char="6124" id="segment-30" start_char="6078">
<ORIGINAL_TEXT>Authorized Use and Important Safety Information</ORIGINAL_TEXT>
<TOKEN end_char="6087" id="token-30-0" morph="none" pos="word" start_char="6078">Authorized</TOKEN>
<TOKEN end_char="6091" id="token-30-1" morph="none" pos="word" start_char="6089">Use</TOKEN>
<TOKEN end_char="6095" id="token-30-2" morph="none" pos="word" start_char="6093">and</TOKEN>
<TOKEN end_char="6105" id="token-30-3" morph="none" pos="word" start_char="6097">Important</TOKEN>
<TOKEN end_char="6112" id="token-30-4" morph="none" pos="word" start_char="6107">Safety</TOKEN>
<TOKEN end_char="6124" id="token-30-5" morph="none" pos="word" start_char="6114">Information</TOKEN>
</SEG>
<SEG end_char="6489" id="segment-31" start_char="6128">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together and bamlanivimab alone are authorized for use under EUA for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.</ORIGINAL_TEXT>
<TOKEN end_char="6139" id="token-31-0" morph="none" pos="word" start_char="6128">Bamlanivimab</TOKEN>
<TOKEN end_char="6143" id="token-31-1" morph="none" pos="word" start_char="6141">and</TOKEN>
<TOKEN end_char="6154" id="token-31-2" morph="none" pos="word" start_char="6145">etesevimab</TOKEN>
<TOKEN end_char="6163" id="token-31-3" morph="none" pos="word" start_char="6156">together</TOKEN>
<TOKEN end_char="6167" id="token-31-4" morph="none" pos="word" start_char="6165">and</TOKEN>
<TOKEN end_char="6180" id="token-31-5" morph="none" pos="word" start_char="6169">bamlanivimab</TOKEN>
<TOKEN end_char="6186" id="token-31-6" morph="none" pos="word" start_char="6182">alone</TOKEN>
<TOKEN end_char="6190" id="token-31-7" morph="none" pos="word" start_char="6188">are</TOKEN>
<TOKEN end_char="6201" id="token-31-8" morph="none" pos="word" start_char="6192">authorized</TOKEN>
<TOKEN end_char="6205" id="token-31-9" morph="none" pos="word" start_char="6203">for</TOKEN>
<TOKEN end_char="6209" id="token-31-10" morph="none" pos="word" start_char="6207">use</TOKEN>
<TOKEN end_char="6215" id="token-31-11" morph="none" pos="word" start_char="6211">under</TOKEN>
<TOKEN end_char="6219" id="token-31-12" morph="none" pos="word" start_char="6217">EUA</TOKEN>
<TOKEN end_char="6223" id="token-31-13" morph="none" pos="word" start_char="6221">for</TOKEN>
<TOKEN end_char="6233" id="token-31-14" morph="none" pos="word" start_char="6225">treatment</TOKEN>
<TOKEN end_char="6236" id="token-31-15" morph="none" pos="word" start_char="6235">of</TOKEN>
<TOKEN end_char="6241" id="token-31-16" morph="none" pos="word" start_char="6238">mild</TOKEN>
<TOKEN end_char="6244" id="token-31-17" morph="none" pos="word" start_char="6243">to</TOKEN>
<TOKEN end_char="6253" id="token-31-18" morph="none" pos="word" start_char="6246">moderate</TOKEN>
<TOKEN end_char="6262" id="token-31-19" morph="none" pos="unknown" start_char="6255">COVID-19</TOKEN>
<TOKEN end_char="6265" id="token-31-20" morph="none" pos="word" start_char="6264">in</TOKEN>
<TOKEN end_char="6272" id="token-31-21" morph="none" pos="word" start_char="6267">adults</TOKEN>
<TOKEN end_char="6276" id="token-31-22" morph="none" pos="word" start_char="6274">and</TOKEN>
<TOKEN end_char="6286" id="token-31-23" morph="none" pos="word" start_char="6278">pediatric</TOKEN>
<TOKEN end_char="6295" id="token-31-24" morph="none" pos="word" start_char="6288">patients</TOKEN>
<TOKEN end_char="6297" id="token-31-25" morph="none" pos="punct" start_char="6297">(</TOKEN>
<TOKEN end_char="6299" id="token-31-26" morph="none" pos="word" start_char="6298">12</TOKEN>
<TOKEN end_char="6305" id="token-31-27" morph="none" pos="word" start_char="6301">years</TOKEN>
<TOKEN end_char="6308" id="token-31-28" morph="none" pos="word" start_char="6307">of</TOKEN>
<TOKEN end_char="6312" id="token-31-29" morph="none" pos="word" start_char="6310">age</TOKEN>
<TOKEN end_char="6316" id="token-31-30" morph="none" pos="word" start_char="6314">and</TOKEN>
<TOKEN end_char="6322" id="token-31-31" morph="none" pos="word" start_char="6318">older</TOKEN>
<TOKEN end_char="6331" id="token-31-32" morph="none" pos="word" start_char="6324">weighing</TOKEN>
<TOKEN end_char="6334" id="token-31-33" morph="none" pos="word" start_char="6333">at</TOKEN>
<TOKEN end_char="6340" id="token-31-34" morph="none" pos="word" start_char="6336">least</TOKEN>
<TOKEN end_char="6343" id="token-31-35" morph="none" pos="word" start_char="6342">40</TOKEN>
<TOKEN end_char="6346" id="token-31-36" morph="none" pos="word" start_char="6345">kg</TOKEN>
<TOKEN end_char="6347" id="token-31-37" morph="none" pos="punct" start_char="6347">)</TOKEN>
<TOKEN end_char="6352" id="token-31-38" morph="none" pos="word" start_char="6349">with</TOKEN>
<TOKEN end_char="6361" id="token-31-39" morph="none" pos="word" start_char="6354">positive</TOKEN>
<TOKEN end_char="6369" id="token-31-40" morph="none" pos="word" start_char="6363">results</TOKEN>
<TOKEN end_char="6372" id="token-31-41" morph="none" pos="word" start_char="6371">of</TOKEN>
<TOKEN end_char="6379" id="token-31-42" morph="none" pos="word" start_char="6374">direct</TOKEN>
<TOKEN end_char="6390" id="token-31-43" morph="none" pos="unknown" start_char="6381">SARS-CoV-2</TOKEN>
<TOKEN end_char="6396" id="token-31-44" morph="none" pos="word" start_char="6392">viral</TOKEN>
<TOKEN end_char="6404" id="token-31-45" morph="none" pos="word" start_char="6398">testing</TOKEN>
<TOKEN end_char="6405" id="token-31-46" morph="none" pos="punct" start_char="6405">,</TOKEN>
<TOKEN end_char="6409" id="token-31-47" morph="none" pos="word" start_char="6407">and</TOKEN>
<TOKEN end_char="6413" id="token-31-48" morph="none" pos="word" start_char="6411">who</TOKEN>
<TOKEN end_char="6417" id="token-31-49" morph="none" pos="word" start_char="6415">are</TOKEN>
<TOKEN end_char="6420" id="token-31-50" morph="none" pos="word" start_char="6419">at</TOKEN>
<TOKEN end_char="6425" id="token-31-51" morph="none" pos="word" start_char="6422">high</TOKEN>
<TOKEN end_char="6430" id="token-31-52" morph="none" pos="word" start_char="6427">risk</TOKEN>
<TOKEN end_char="6434" id="token-31-53" morph="none" pos="word" start_char="6432">for</TOKEN>
<TOKEN end_char="6446" id="token-31-54" morph="none" pos="word" start_char="6436">progressing</TOKEN>
<TOKEN end_char="6449" id="token-31-55" morph="none" pos="word" start_char="6448">to</TOKEN>
<TOKEN end_char="6456" id="token-31-56" morph="none" pos="word" start_char="6451">severe</TOKEN>
<TOKEN end_char="6465" id="token-31-57" morph="none" pos="unknown" start_char="6458">COVID-19</TOKEN>
<TOKEN end_char="6472" id="token-31-58" morph="none" pos="unknown" start_char="6467">and/or</TOKEN>
<TOKEN end_char="6488" id="token-31-59" morph="none" pos="word" start_char="6474">hospitalization</TOKEN>
<TOKEN end_char="6489" id="token-31-60" morph="none" pos="punct" start_char="6489">.</TOKEN>
</SEG>
<SEG end_char="6520" id="segment-32" start_char="6492">
<ORIGINAL_TEXT>Limitations of Authorized Use</ORIGINAL_TEXT>
<TOKEN end_char="6502" id="token-32-0" morph="none" pos="word" start_char="6492">Limitations</TOKEN>
<TOKEN end_char="6505" id="token-32-1" morph="none" pos="word" start_char="6504">of</TOKEN>
<TOKEN end_char="6516" id="token-32-2" morph="none" pos="word" start_char="6507">Authorized</TOKEN>
<TOKEN end_char="6520" id="token-32-3" morph="none" pos="word" start_char="6518">Use</TOKEN>
</SEG>
<SEG end_char="6621" id="segment-33" start_char="6523">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients:</ORIGINAL_TEXT>
<TOKEN end_char="6534" id="token-33-0" morph="none" pos="word" start_char="6523">Bamlanivimab</TOKEN>
<TOKEN end_char="6538" id="token-33-1" morph="none" pos="word" start_char="6536">and</TOKEN>
<TOKEN end_char="6549" id="token-33-2" morph="none" pos="word" start_char="6540">etesevimab</TOKEN>
<TOKEN end_char="6558" id="token-33-3" morph="none" pos="word" start_char="6551">together</TOKEN>
<TOKEN end_char="6562" id="token-33-4" morph="none" pos="word" start_char="6560">and</TOKEN>
<TOKEN end_char="6575" id="token-33-5" morph="none" pos="word" start_char="6564">bamlanivimab</TOKEN>
<TOKEN end_char="6581" id="token-33-6" morph="none" pos="word" start_char="6577">alone</TOKEN>
<TOKEN end_char="6585" id="token-33-7" morph="none" pos="word" start_char="6583">are</TOKEN>
<TOKEN end_char="6589" id="token-33-8" morph="none" pos="word" start_char="6587">not</TOKEN>
<TOKEN end_char="6600" id="token-33-9" morph="none" pos="word" start_char="6591">authorized</TOKEN>
<TOKEN end_char="6604" id="token-33-10" morph="none" pos="word" start_char="6602">for</TOKEN>
<TOKEN end_char="6608" id="token-33-11" morph="none" pos="word" start_char="6606">use</TOKEN>
<TOKEN end_char="6611" id="token-33-12" morph="none" pos="word" start_char="6610">in</TOKEN>
<TOKEN end_char="6620" id="token-33-13" morph="none" pos="word" start_char="6613">patients</TOKEN>
<TOKEN end_char="6621" id="token-33-14" morph="none" pos="punct" start_char="6621">:</TOKEN>
</SEG>
<SEG end_char="6663" id="segment-34" start_char="6624">
<ORIGINAL_TEXT>who are hospitalized due to COVID-19, OR</ORIGINAL_TEXT>
<TOKEN end_char="6626" id="token-34-0" morph="none" pos="word" start_char="6624">who</TOKEN>
<TOKEN end_char="6630" id="token-34-1" morph="none" pos="word" start_char="6628">are</TOKEN>
<TOKEN end_char="6643" id="token-34-2" morph="none" pos="word" start_char="6632">hospitalized</TOKEN>
<TOKEN end_char="6647" id="token-34-3" morph="none" pos="word" start_char="6645">due</TOKEN>
<TOKEN end_char="6650" id="token-34-4" morph="none" pos="word" start_char="6649">to</TOKEN>
<TOKEN end_char="6659" id="token-34-5" morph="none" pos="unknown" start_char="6652">COVID-19</TOKEN>
<TOKEN end_char="6660" id="token-34-6" morph="none" pos="punct" start_char="6660">,</TOKEN>
<TOKEN end_char="6663" id="token-34-7" morph="none" pos="word" start_char="6662">OR</TOKEN>
</SEG>
<SEG end_char="6712" id="segment-35" start_char="6667">
<ORIGINAL_TEXT>who require oxygen therapy due to COVID-19, OR</ORIGINAL_TEXT>
<TOKEN end_char="6669" id="token-35-0" morph="none" pos="word" start_char="6667">who</TOKEN>
<TOKEN end_char="6677" id="token-35-1" morph="none" pos="word" start_char="6671">require</TOKEN>
<TOKEN end_char="6684" id="token-35-2" morph="none" pos="word" start_char="6679">oxygen</TOKEN>
<TOKEN end_char="6692" id="token-35-3" morph="none" pos="word" start_char="6686">therapy</TOKEN>
<TOKEN end_char="6696" id="token-35-4" morph="none" pos="word" start_char="6694">due</TOKEN>
<TOKEN end_char="6699" id="token-35-5" morph="none" pos="word" start_char="6698">to</TOKEN>
<TOKEN end_char="6708" id="token-35-6" morph="none" pos="unknown" start_char="6701">COVID-19</TOKEN>
<TOKEN end_char="6709" id="token-35-7" morph="none" pos="punct" start_char="6709">,</TOKEN>
<TOKEN end_char="6712" id="token-35-8" morph="none" pos="word" start_char="6711">OR</TOKEN>
</SEG>
<SEG end_char="6870" id="segment-36" start_char="6716">
<ORIGINAL_TEXT>who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.</ORIGINAL_TEXT>
<TOKEN end_char="6718" id="token-36-0" morph="none" pos="word" start_char="6716">who</TOKEN>
<TOKEN end_char="6726" id="token-36-1" morph="none" pos="word" start_char="6720">require</TOKEN>
<TOKEN end_char="6729" id="token-36-2" morph="none" pos="word" start_char="6728">an</TOKEN>
<TOKEN end_char="6738" id="token-36-3" morph="none" pos="word" start_char="6731">increase</TOKEN>
<TOKEN end_char="6741" id="token-36-4" morph="none" pos="word" start_char="6740">in</TOKEN>
<TOKEN end_char="6750" id="token-36-5" morph="none" pos="word" start_char="6743">baseline</TOKEN>
<TOKEN end_char="6757" id="token-36-6" morph="none" pos="word" start_char="6752">oxygen</TOKEN>
<TOKEN end_char="6762" id="token-36-7" morph="none" pos="word" start_char="6759">flow</TOKEN>
<TOKEN end_char="6767" id="token-36-8" morph="none" pos="word" start_char="6764">rate</TOKEN>
<TOKEN end_char="6771" id="token-36-9" morph="none" pos="word" start_char="6769">due</TOKEN>
<TOKEN end_char="6774" id="token-36-10" morph="none" pos="word" start_char="6773">to</TOKEN>
<TOKEN end_char="6783" id="token-36-11" morph="none" pos="unknown" start_char="6776">COVID-19</TOKEN>
<TOKEN end_char="6786" id="token-36-12" morph="none" pos="word" start_char="6785">in</TOKEN>
<TOKEN end_char="6792" id="token-36-13" morph="none" pos="word" start_char="6788">those</TOKEN>
<TOKEN end_char="6795" id="token-36-14" morph="none" pos="word" start_char="6794">on</TOKEN>
<TOKEN end_char="6803" id="token-36-15" morph="none" pos="word" start_char="6797">chronic</TOKEN>
<TOKEN end_char="6810" id="token-36-16" morph="none" pos="word" start_char="6805">oxygen</TOKEN>
<TOKEN end_char="6818" id="token-36-17" morph="none" pos="word" start_char="6812">therapy</TOKEN>
<TOKEN end_char="6822" id="token-36-18" morph="none" pos="word" start_char="6820">due</TOKEN>
<TOKEN end_char="6825" id="token-36-19" morph="none" pos="word" start_char="6824">to</TOKEN>
<TOKEN end_char="6836" id="token-36-20" morph="none" pos="word" start_char="6827">underlying</TOKEN>
<TOKEN end_char="6849" id="token-36-21" morph="none" pos="unknown" start_char="6838">non-COVID-19</TOKEN>
<TOKEN end_char="6857" id="token-36-22" morph="none" pos="word" start_char="6851">related</TOKEN>
<TOKEN end_char="6869" id="token-36-23" morph="none" pos="word" start_char="6859">comorbidity</TOKEN>
<TOKEN end_char="6870" id="token-36-24" morph="none" pos="punct" start_char="6870">.</TOKEN>
</SEG>
<SEG end_char="6988" id="segment-37" start_char="6875">
<ORIGINAL_TEXT>Treatment with bamlanivimab and etesevimab together has not been studied in patients hospitalized due to COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="6883" id="token-37-0" morph="none" pos="word" start_char="6875">Treatment</TOKEN>
<TOKEN end_char="6888" id="token-37-1" morph="none" pos="word" start_char="6885">with</TOKEN>
<TOKEN end_char="6901" id="token-37-2" morph="none" pos="word" start_char="6890">bamlanivimab</TOKEN>
<TOKEN end_char="6905" id="token-37-3" morph="none" pos="word" start_char="6903">and</TOKEN>
<TOKEN end_char="6916" id="token-37-4" morph="none" pos="word" start_char="6907">etesevimab</TOKEN>
<TOKEN end_char="6925" id="token-37-5" morph="none" pos="word" start_char="6918">together</TOKEN>
<TOKEN end_char="6929" id="token-37-6" morph="none" pos="word" start_char="6927">has</TOKEN>
<TOKEN end_char="6933" id="token-37-7" morph="none" pos="word" start_char="6931">not</TOKEN>
<TOKEN end_char="6938" id="token-37-8" morph="none" pos="word" start_char="6935">been</TOKEN>
<TOKEN end_char="6946" id="token-37-9" morph="none" pos="word" start_char="6940">studied</TOKEN>
<TOKEN end_char="6949" id="token-37-10" morph="none" pos="word" start_char="6948">in</TOKEN>
<TOKEN end_char="6958" id="token-37-11" morph="none" pos="word" start_char="6951">patients</TOKEN>
<TOKEN end_char="6971" id="token-37-12" morph="none" pos="word" start_char="6960">hospitalized</TOKEN>
<TOKEN end_char="6975" id="token-37-13" morph="none" pos="word" start_char="6973">due</TOKEN>
<TOKEN end_char="6978" id="token-37-14" morph="none" pos="word" start_char="6977">to</TOKEN>
<TOKEN end_char="6987" id="token-37-15" morph="none" pos="unknown" start_char="6980">COVID-19</TOKEN>
<TOKEN end_char="6988" id="token-37-16" morph="none" pos="punct" start_char="6988">.</TOKEN>
</SEG>
<SEG end_char="7097" id="segment-38" start_char="6990">
<ORIGINAL_TEXT>Benefit of treatment with bamlanivimab alone has not been observed in patients hospitalized due to COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="6996" id="token-38-0" morph="none" pos="word" start_char="6990">Benefit</TOKEN>
<TOKEN end_char="6999" id="token-38-1" morph="none" pos="word" start_char="6998">of</TOKEN>
<TOKEN end_char="7009" id="token-38-2" morph="none" pos="word" start_char="7001">treatment</TOKEN>
<TOKEN end_char="7014" id="token-38-3" morph="none" pos="word" start_char="7011">with</TOKEN>
<TOKEN end_char="7027" id="token-38-4" morph="none" pos="word" start_char="7016">bamlanivimab</TOKEN>
<TOKEN end_char="7033" id="token-38-5" morph="none" pos="word" start_char="7029">alone</TOKEN>
<TOKEN end_char="7037" id="token-38-6" morph="none" pos="word" start_char="7035">has</TOKEN>
<TOKEN end_char="7041" id="token-38-7" morph="none" pos="word" start_char="7039">not</TOKEN>
<TOKEN end_char="7046" id="token-38-8" morph="none" pos="word" start_char="7043">been</TOKEN>
<TOKEN end_char="7055" id="token-38-9" morph="none" pos="word" start_char="7048">observed</TOKEN>
<TOKEN end_char="7058" id="token-38-10" morph="none" pos="word" start_char="7057">in</TOKEN>
<TOKEN end_char="7067" id="token-38-11" morph="none" pos="word" start_char="7060">patients</TOKEN>
<TOKEN end_char="7080" id="token-38-12" morph="none" pos="word" start_char="7069">hospitalized</TOKEN>
<TOKEN end_char="7084" id="token-38-13" morph="none" pos="word" start_char="7082">due</TOKEN>
<TOKEN end_char="7087" id="token-38-14" morph="none" pos="word" start_char="7086">to</TOKEN>
<TOKEN end_char="7096" id="token-38-15" morph="none" pos="unknown" start_char="7089">COVID-19</TOKEN>
<TOKEN end_char="7097" id="token-38-16" morph="none" pos="punct" start_char="7097">.</TOKEN>
</SEG>
<SEG end_char="7315" id="segment-39" start_char="7099">
<ORIGINAL_TEXT>Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.</ORIGINAL_TEXT>
<TOKEN end_char="7108" id="token-39-0" morph="none" pos="word" start_char="7099">Monoclonal</TOKEN>
<TOKEN end_char="7119" id="token-39-1" morph="none" pos="word" start_char="7110">antibodies</TOKEN>
<TOKEN end_char="7120" id="token-39-2" morph="none" pos="punct" start_char="7120">,</TOKEN>
<TOKEN end_char="7125" id="token-39-3" morph="none" pos="word" start_char="7122">such</TOKEN>
<TOKEN end_char="7128" id="token-39-4" morph="none" pos="word" start_char="7127">as</TOKEN>
<TOKEN end_char="7141" id="token-39-5" morph="none" pos="word" start_char="7130">bamlanivimab</TOKEN>
<TOKEN end_char="7145" id="token-39-6" morph="none" pos="word" start_char="7143">and</TOKEN>
<TOKEN end_char="7156" id="token-39-7" morph="none" pos="word" start_char="7147">etesevimab</TOKEN>
<TOKEN end_char="7157" id="token-39-8" morph="none" pos="punct" start_char="7157">,</TOKEN>
<TOKEN end_char="7161" id="token-39-9" morph="none" pos="word" start_char="7159">may</TOKEN>
<TOKEN end_char="7164" id="token-39-10" morph="none" pos="word" start_char="7163">be</TOKEN>
<TOKEN end_char="7175" id="token-39-11" morph="none" pos="word" start_char="7166">associated</TOKEN>
<TOKEN end_char="7180" id="token-39-12" morph="none" pos="word" start_char="7177">with</TOKEN>
<TOKEN end_char="7186" id="token-39-13" morph="none" pos="word" start_char="7182">worse</TOKEN>
<TOKEN end_char="7195" id="token-39-14" morph="none" pos="word" start_char="7188">clinical</TOKEN>
<TOKEN end_char="7204" id="token-39-15" morph="none" pos="word" start_char="7197">outcomes</TOKEN>
<TOKEN end_char="7209" id="token-39-16" morph="none" pos="word" start_char="7206">when</TOKEN>
<TOKEN end_char="7222" id="token-39-17" morph="none" pos="word" start_char="7211">administered</TOKEN>
<TOKEN end_char="7225" id="token-39-18" morph="none" pos="word" start_char="7224">to</TOKEN>
<TOKEN end_char="7238" id="token-39-19" morph="none" pos="word" start_char="7227">hospitalized</TOKEN>
<TOKEN end_char="7247" id="token-39-20" morph="none" pos="word" start_char="7240">patients</TOKEN>
<TOKEN end_char="7252" id="token-39-21" morph="none" pos="word" start_char="7249">with</TOKEN>
<TOKEN end_char="7261" id="token-39-22" morph="none" pos="unknown" start_char="7254">COVID-19</TOKEN>
<TOKEN end_char="7271" id="token-39-23" morph="none" pos="word" start_char="7263">requiring</TOKEN>
<TOKEN end_char="7276" id="token-39-24" morph="none" pos="word" start_char="7273">high</TOKEN>
<TOKEN end_char="7281" id="token-39-25" morph="none" pos="word" start_char="7278">flow</TOKEN>
<TOKEN end_char="7288" id="token-39-26" morph="none" pos="word" start_char="7283">oxygen</TOKEN>
<TOKEN end_char="7291" id="token-39-27" morph="none" pos="word" start_char="7290">or</TOKEN>
<TOKEN end_char="7302" id="token-39-28" morph="none" pos="word" start_char="7293">mechanical</TOKEN>
<TOKEN end_char="7314" id="token-39-29" morph="none" pos="word" start_char="7304">ventilation</TOKEN>
<TOKEN end_char="7315" id="token-39-30" morph="none" pos="punct" start_char="7315">.</TOKEN>
</SEG>
<SEG end_char="7454" id="segment-40" start_char="7320">
<ORIGINAL_TEXT>Important Safety Information There are limited clinical data available for bamlanivimab and etesevimab together and bamlanivimab alone.</ORIGINAL_TEXT>
<TOKEN end_char="7328" id="token-40-0" morph="none" pos="word" start_char="7320">Important</TOKEN>
<TOKEN end_char="7335" id="token-40-1" morph="none" pos="word" start_char="7330">Safety</TOKEN>
<TOKEN end_char="7347" id="token-40-2" morph="none" pos="word" start_char="7337">Information</TOKEN>
<TOKEN end_char="7353" id="token-40-3" morph="none" pos="word" start_char="7349">There</TOKEN>
<TOKEN end_char="7357" id="token-40-4" morph="none" pos="word" start_char="7355">are</TOKEN>
<TOKEN end_char="7365" id="token-40-5" morph="none" pos="word" start_char="7359">limited</TOKEN>
<TOKEN end_char="7374" id="token-40-6" morph="none" pos="word" start_char="7367">clinical</TOKEN>
<TOKEN end_char="7379" id="token-40-7" morph="none" pos="word" start_char="7376">data</TOKEN>
<TOKEN end_char="7389" id="token-40-8" morph="none" pos="word" start_char="7381">available</TOKEN>
<TOKEN end_char="7393" id="token-40-9" morph="none" pos="word" start_char="7391">for</TOKEN>
<TOKEN end_char="7406" id="token-40-10" morph="none" pos="word" start_char="7395">bamlanivimab</TOKEN>
<TOKEN end_char="7410" id="token-40-11" morph="none" pos="word" start_char="7408">and</TOKEN>
<TOKEN end_char="7421" id="token-40-12" morph="none" pos="word" start_char="7412">etesevimab</TOKEN>
<TOKEN end_char="7430" id="token-40-13" morph="none" pos="word" start_char="7423">together</TOKEN>
<TOKEN end_char="7434" id="token-40-14" morph="none" pos="word" start_char="7432">and</TOKEN>
<TOKEN end_char="7447" id="token-40-15" morph="none" pos="word" start_char="7436">bamlanivimab</TOKEN>
<TOKEN end_char="7453" id="token-40-16" morph="none" pos="word" start_char="7449">alone</TOKEN>
<TOKEN end_char="7454" id="token-40-17" morph="none" pos="punct" start_char="7454">.</TOKEN>
</SEG>
<SEG end_char="7607" id="segment-41" start_char="7456">
<ORIGINAL_TEXT>Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab and etesevimab together and bamlanivimab alone.</ORIGINAL_TEXT>
<TOKEN end_char="7462" id="token-41-0" morph="none" pos="word" start_char="7456">Serious</TOKEN>
<TOKEN end_char="7466" id="token-41-1" morph="none" pos="word" start_char="7464">and</TOKEN>
<TOKEN end_char="7477" id="token-41-2" morph="none" pos="word" start_char="7468">unexpected</TOKEN>
<TOKEN end_char="7485" id="token-41-3" morph="none" pos="word" start_char="7479">adverse</TOKEN>
<TOKEN end_char="7492" id="token-41-4" morph="none" pos="word" start_char="7487">events</TOKEN>
<TOKEN end_char="7496" id="token-41-5" morph="none" pos="word" start_char="7494">may</TOKEN>
<TOKEN end_char="7502" id="token-41-6" morph="none" pos="word" start_char="7498">occur</TOKEN>
<TOKEN end_char="7507" id="token-41-7" morph="none" pos="word" start_char="7504">that</TOKEN>
<TOKEN end_char="7512" id="token-41-8" morph="none" pos="word" start_char="7509">have</TOKEN>
<TOKEN end_char="7516" id="token-41-9" morph="none" pos="word" start_char="7514">not</TOKEN>
<TOKEN end_char="7521" id="token-41-10" morph="none" pos="word" start_char="7518">been</TOKEN>
<TOKEN end_char="7532" id="token-41-11" morph="none" pos="word" start_char="7523">previously</TOKEN>
<TOKEN end_char="7541" id="token-41-12" morph="none" pos="word" start_char="7534">reported</TOKEN>
<TOKEN end_char="7546" id="token-41-13" morph="none" pos="word" start_char="7543">with</TOKEN>
<TOKEN end_char="7559" id="token-41-14" morph="none" pos="word" start_char="7548">bamlanivimab</TOKEN>
<TOKEN end_char="7563" id="token-41-15" morph="none" pos="word" start_char="7561">and</TOKEN>
<TOKEN end_char="7574" id="token-41-16" morph="none" pos="word" start_char="7565">etesevimab</TOKEN>
<TOKEN end_char="7583" id="token-41-17" morph="none" pos="word" start_char="7576">together</TOKEN>
<TOKEN end_char="7587" id="token-41-18" morph="none" pos="word" start_char="7585">and</TOKEN>
<TOKEN end_char="7600" id="token-41-19" morph="none" pos="word" start_char="7589">bamlanivimab</TOKEN>
<TOKEN end_char="7606" id="token-41-20" morph="none" pos="word" start_char="7602">alone</TOKEN>
<TOKEN end_char="7607" id="token-41-21" morph="none" pos="punct" start_char="7607">.</TOKEN>
</SEG>
<SEG end_char="7678" id="segment-42" start_char="7610">
<ORIGINAL_TEXT>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</ORIGINAL_TEXT>
<TOKEN end_char="7625" id="token-42-0" morph="none" pos="word" start_char="7610">Hypersensitivity</TOKEN>
<TOKEN end_char="7635" id="token-42-1" morph="none" pos="word" start_char="7627">Including</TOKEN>
<TOKEN end_char="7647" id="token-42-2" morph="none" pos="word" start_char="7637">Anaphylaxis</TOKEN>
<TOKEN end_char="7651" id="token-42-3" morph="none" pos="word" start_char="7649">and</TOKEN>
<TOKEN end_char="7668" id="token-42-4" morph="none" pos="unknown" start_char="7653">Infusion-Related</TOKEN>
<TOKEN end_char="7678" id="token-42-5" morph="none" pos="word" start_char="7670">Reactions</TOKEN>
</SEG>
<SEG end_char="7841" id="segment-43" start_char="7681">
<ORIGINAL_TEXT>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab and etesevimab together and bamlanivimab alone.</ORIGINAL_TEXT>
<TOKEN end_char="7687" id="token-43-0" morph="none" pos="word" start_char="7681">Serious</TOKEN>
<TOKEN end_char="7704" id="token-43-1" morph="none" pos="word" start_char="7689">hypersensitivity</TOKEN>
<TOKEN end_char="7714" id="token-43-2" morph="none" pos="word" start_char="7706">reactions</TOKEN>
<TOKEN end_char="7715" id="token-43-3" morph="none" pos="punct" start_char="7715">,</TOKEN>
<TOKEN end_char="7725" id="token-43-4" morph="none" pos="word" start_char="7717">including</TOKEN>
<TOKEN end_char="7737" id="token-43-5" morph="none" pos="word" start_char="7727">anaphylaxis</TOKEN>
<TOKEN end_char="7738" id="token-43-6" morph="none" pos="punct" start_char="7738">,</TOKEN>
<TOKEN end_char="7743" id="token-43-7" morph="none" pos="word" start_char="7740">have</TOKEN>
<TOKEN end_char="7748" id="token-43-8" morph="none" pos="word" start_char="7745">been</TOKEN>
<TOKEN end_char="7757" id="token-43-9" morph="none" pos="word" start_char="7750">observed</TOKEN>
<TOKEN end_char="7762" id="token-43-10" morph="none" pos="word" start_char="7759">with</TOKEN>
<TOKEN end_char="7777" id="token-43-11" morph="none" pos="word" start_char="7764">administration</TOKEN>
<TOKEN end_char="7780" id="token-43-12" morph="none" pos="word" start_char="7779">of</TOKEN>
<TOKEN end_char="7793" id="token-43-13" morph="none" pos="word" start_char="7782">bamlanivimab</TOKEN>
<TOKEN end_char="7797" id="token-43-14" morph="none" pos="word" start_char="7795">and</TOKEN>
<TOKEN end_char="7808" id="token-43-15" morph="none" pos="word" start_char="7799">etesevimab</TOKEN>
<TOKEN end_char="7817" id="token-43-16" morph="none" pos="word" start_char="7810">together</TOKEN>
<TOKEN end_char="7821" id="token-43-17" morph="none" pos="word" start_char="7819">and</TOKEN>
<TOKEN end_char="7834" id="token-43-18" morph="none" pos="word" start_char="7823">bamlanivimab</TOKEN>
<TOKEN end_char="7840" id="token-43-19" morph="none" pos="word" start_char="7836">alone</TOKEN>
<TOKEN end_char="7841" id="token-43-20" morph="none" pos="punct" start_char="7841">.</TOKEN>
</SEG>
<SEG end_char="8039" id="segment-44" start_char="7843">
<ORIGINAL_TEXT>If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</ORIGINAL_TEXT>
<TOKEN end_char="7844" id="token-44-0" morph="none" pos="word" start_char="7843">If</TOKEN>
<TOKEN end_char="7850" id="token-44-1" morph="none" pos="word" start_char="7846">signs</TOKEN>
<TOKEN end_char="7854" id="token-44-2" morph="none" pos="word" start_char="7852">and</TOKEN>
<TOKEN end_char="7863" id="token-44-3" morph="none" pos="word" start_char="7856">symptoms</TOKEN>
<TOKEN end_char="7866" id="token-44-4" morph="none" pos="word" start_char="7865">of</TOKEN>
<TOKEN end_char="7868" id="token-44-5" morph="none" pos="word" start_char="7868">a</TOKEN>
<TOKEN end_char="7879" id="token-44-6" morph="none" pos="word" start_char="7870">clinically</TOKEN>
<TOKEN end_char="7891" id="token-44-7" morph="none" pos="word" start_char="7881">significant</TOKEN>
<TOKEN end_char="7908" id="token-44-8" morph="none" pos="word" start_char="7893">hypersensitivity</TOKEN>
<TOKEN end_char="7917" id="token-44-9" morph="none" pos="word" start_char="7910">reaction</TOKEN>
<TOKEN end_char="7920" id="token-44-10" morph="none" pos="word" start_char="7919">or</TOKEN>
<TOKEN end_char="7932" id="token-44-11" morph="none" pos="word" start_char="7922">anaphylaxis</TOKEN>
<TOKEN end_char="7938" id="token-44-12" morph="none" pos="word" start_char="7934">occur</TOKEN>
<TOKEN end_char="7939" id="token-44-13" morph="none" pos="punct" start_char="7939">,</TOKEN>
<TOKEN end_char="7951" id="token-44-14" morph="none" pos="word" start_char="7941">immediately</TOKEN>
<TOKEN end_char="7963" id="token-44-15" morph="none" pos="word" start_char="7953">discontinue</TOKEN>
<TOKEN end_char="7978" id="token-44-16" morph="none" pos="word" start_char="7965">administration</TOKEN>
<TOKEN end_char="7982" id="token-44-17" morph="none" pos="word" start_char="7980">and</TOKEN>
<TOKEN end_char="7991" id="token-44-18" morph="none" pos="word" start_char="7984">initiate</TOKEN>
<TOKEN end_char="8003" id="token-44-19" morph="none" pos="word" start_char="7993">appropriate</TOKEN>
<TOKEN end_char="8015" id="token-44-20" morph="none" pos="word" start_char="8005">medications</TOKEN>
<TOKEN end_char="8022" id="token-44-21" morph="none" pos="unknown" start_char="8017">and/or</TOKEN>
<TOKEN end_char="8033" id="token-44-22" morph="none" pos="word" start_char="8024">supportive</TOKEN>
<TOKEN end_char="8038" id="token-44-23" morph="none" pos="word" start_char="8035">care</TOKEN>
<TOKEN end_char="8039" id="token-44-24" morph="none" pos="punct" start_char="8039">.</TOKEN>
</SEG>
<SEG end_char="8170" id="segment-45" start_char="8042">
<ORIGINAL_TEXT>Infusion-related reactions have been observed with administration of bamlanivimab and etesevimab together and bamlanivimab alone.</ORIGINAL_TEXT>
<TOKEN end_char="8057" id="token-45-0" morph="none" pos="unknown" start_char="8042">Infusion-related</TOKEN>
<TOKEN end_char="8067" id="token-45-1" morph="none" pos="word" start_char="8059">reactions</TOKEN>
<TOKEN end_char="8072" id="token-45-2" morph="none" pos="word" start_char="8069">have</TOKEN>
<TOKEN end_char="8077" id="token-45-3" morph="none" pos="word" start_char="8074">been</TOKEN>
<TOKEN end_char="8086" id="token-45-4" morph="none" pos="word" start_char="8079">observed</TOKEN>
<TOKEN end_char="8091" id="token-45-5" morph="none" pos="word" start_char="8088">with</TOKEN>
<TOKEN end_char="8106" id="token-45-6" morph="none" pos="word" start_char="8093">administration</TOKEN>
<TOKEN end_char="8109" id="token-45-7" morph="none" pos="word" start_char="8108">of</TOKEN>
<TOKEN end_char="8122" id="token-45-8" morph="none" pos="word" start_char="8111">bamlanivimab</TOKEN>
<TOKEN end_char="8126" id="token-45-9" morph="none" pos="word" start_char="8124">and</TOKEN>
<TOKEN end_char="8137" id="token-45-10" morph="none" pos="word" start_char="8128">etesevimab</TOKEN>
<TOKEN end_char="8146" id="token-45-11" morph="none" pos="word" start_char="8139">together</TOKEN>
<TOKEN end_char="8150" id="token-45-12" morph="none" pos="word" start_char="8148">and</TOKEN>
<TOKEN end_char="8163" id="token-45-13" morph="none" pos="word" start_char="8152">bamlanivimab</TOKEN>
<TOKEN end_char="8169" id="token-45-14" morph="none" pos="word" start_char="8165">alone</TOKEN>
<TOKEN end_char="8170" id="token-45-15" morph="none" pos="punct" start_char="8170">.</TOKEN>
</SEG>
<SEG end_char="8221" id="segment-46" start_char="8172">
<ORIGINAL_TEXT>These reactions may be severe or life threatening.</ORIGINAL_TEXT>
<TOKEN end_char="8176" id="token-46-0" morph="none" pos="word" start_char="8172">These</TOKEN>
<TOKEN end_char="8186" id="token-46-1" morph="none" pos="word" start_char="8178">reactions</TOKEN>
<TOKEN end_char="8190" id="token-46-2" morph="none" pos="word" start_char="8188">may</TOKEN>
<TOKEN end_char="8193" id="token-46-3" morph="none" pos="word" start_char="8192">be</TOKEN>
<TOKEN end_char="8200" id="token-46-4" morph="none" pos="word" start_char="8195">severe</TOKEN>
<TOKEN end_char="8203" id="token-46-5" morph="none" pos="word" start_char="8202">or</TOKEN>
<TOKEN end_char="8208" id="token-46-6" morph="none" pos="word" start_char="8205">life</TOKEN>
<TOKEN end_char="8220" id="token-46-7" morph="none" pos="word" start_char="8210">threatening</TOKEN>
<TOKEN end_char="8221" id="token-46-8" morph="none" pos="punct" start_char="8221">.</TOKEN>
</SEG>
<SEG end_char="8283" id="segment-47" start_char="8223">
<ORIGINAL_TEXT>Signs and symptoms of infusion-related reactions may include:</ORIGINAL_TEXT>
<TOKEN end_char="8227" id="token-47-0" morph="none" pos="word" start_char="8223">Signs</TOKEN>
<TOKEN end_char="8231" id="token-47-1" morph="none" pos="word" start_char="8229">and</TOKEN>
<TOKEN end_char="8240" id="token-47-2" morph="none" pos="word" start_char="8233">symptoms</TOKEN>
<TOKEN end_char="8243" id="token-47-3" morph="none" pos="word" start_char="8242">of</TOKEN>
<TOKEN end_char="8260" id="token-47-4" morph="none" pos="unknown" start_char="8245">infusion-related</TOKEN>
<TOKEN end_char="8270" id="token-47-5" morph="none" pos="word" start_char="8262">reactions</TOKEN>
<TOKEN end_char="8274" id="token-47-6" morph="none" pos="word" start_char="8272">may</TOKEN>
<TOKEN end_char="8282" id="token-47-7" morph="none" pos="word" start_char="8276">include</TOKEN>
<TOKEN end_char="8283" id="token-47-8" morph="none" pos="punct" start_char="8283">:</TOKEN>
</SEG>
<SEG end_char="8650" id="segment-48" start_char="8286">
<ORIGINAL_TEXT>fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g. atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness, and diaphoresis.</ORIGINAL_TEXT>
<TOKEN end_char="8290" id="token-48-0" morph="none" pos="word" start_char="8286">fever</TOKEN>
<TOKEN end_char="8291" id="token-48-1" morph="none" pos="punct" start_char="8291">,</TOKEN>
<TOKEN end_char="8302" id="token-48-2" morph="none" pos="word" start_char="8293">difficulty</TOKEN>
<TOKEN end_char="8312" id="token-48-3" morph="none" pos="word" start_char="8304">breathing</TOKEN>
<TOKEN end_char="8313" id="token-48-4" morph="none" pos="punct" start_char="8313">,</TOKEN>
<TOKEN end_char="8321" id="token-48-5" morph="none" pos="word" start_char="8315">reduced</TOKEN>
<TOKEN end_char="8328" id="token-48-6" morph="none" pos="word" start_char="8323">oxygen</TOKEN>
<TOKEN end_char="8339" id="token-48-7" morph="none" pos="word" start_char="8330">saturation</TOKEN>
<TOKEN end_char="8340" id="token-48-8" morph="none" pos="punct" start_char="8340">,</TOKEN>
<TOKEN end_char="8347" id="token-48-9" morph="none" pos="word" start_char="8342">chills</TOKEN>
<TOKEN end_char="8348" id="token-48-10" morph="none" pos="punct" start_char="8348">,</TOKEN>
<TOKEN end_char="8356" id="token-48-11" morph="none" pos="word" start_char="8350">fatigue</TOKEN>
<TOKEN end_char="8357" id="token-48-12" morph="none" pos="punct" start_char="8357">,</TOKEN>
<TOKEN end_char="8368" id="token-48-13" morph="none" pos="word" start_char="8359">arrhythmia</TOKEN>
<TOKEN end_char="8370" id="token-48-14" morph="none" pos="punct" start_char="8370">(</TOKEN>
<TOKEN end_char="8373" id="token-48-15" morph="none" pos="unknown" start_char="8371">e.g</TOKEN>
<TOKEN end_char="8374" id="token-48-16" morph="none" pos="punct" start_char="8374">.</TOKEN>
<TOKEN end_char="8381" id="token-48-17" morph="none" pos="word" start_char="8376">atrial</TOKEN>
<TOKEN end_char="8394" id="token-48-18" morph="none" pos="word" start_char="8383">fibrillation</TOKEN>
<TOKEN end_char="8395" id="token-48-19" morph="none" pos="punct" start_char="8395">,</TOKEN>
<TOKEN end_char="8401" id="token-48-20" morph="none" pos="word" start_char="8397">sinus</TOKEN>
<TOKEN end_char="8413" id="token-48-21" morph="none" pos="word" start_char="8403">tachycardia</TOKEN>
<TOKEN end_char="8414" id="token-48-22" morph="none" pos="punct" start_char="8414">,</TOKEN>
<TOKEN end_char="8426" id="token-48-23" morph="none" pos="word" start_char="8416">bradycardia</TOKEN>
<TOKEN end_char="8428" id="token-48-24" morph="none" pos="punct" start_char="8427">),</TOKEN>
<TOKEN end_char="8434" id="token-48-25" morph="none" pos="word" start_char="8430">chest</TOKEN>
<TOKEN end_char="8439" id="token-48-26" morph="none" pos="word" start_char="8436">pain</TOKEN>
<TOKEN end_char="8442" id="token-48-27" morph="none" pos="word" start_char="8441">or</TOKEN>
<TOKEN end_char="8453" id="token-48-28" morph="none" pos="word" start_char="8444">discomfort</TOKEN>
<TOKEN end_char="8454" id="token-48-29" morph="none" pos="punct" start_char="8454">,</TOKEN>
<TOKEN end_char="8463" id="token-48-30" morph="none" pos="word" start_char="8456">weakness</TOKEN>
<TOKEN end_char="8464" id="token-48-31" morph="none" pos="punct" start_char="8464">,</TOKEN>
<TOKEN end_char="8472" id="token-48-32" morph="none" pos="word" start_char="8466">altered</TOKEN>
<TOKEN end_char="8479" id="token-48-33" morph="none" pos="word" start_char="8474">mental</TOKEN>
<TOKEN end_char="8486" id="token-48-34" morph="none" pos="word" start_char="8481">status</TOKEN>
<TOKEN end_char="8487" id="token-48-35" morph="none" pos="punct" start_char="8487">,</TOKEN>
<TOKEN end_char="8494" id="token-48-36" morph="none" pos="word" start_char="8489">nausea</TOKEN>
<TOKEN end_char="8495" id="token-48-37" morph="none" pos="punct" start_char="8495">,</TOKEN>
<TOKEN end_char="8504" id="token-48-38" morph="none" pos="word" start_char="8497">headache</TOKEN>
<TOKEN end_char="8505" id="token-48-39" morph="none" pos="punct" start_char="8505">,</TOKEN>
<TOKEN end_char="8518" id="token-48-40" morph="none" pos="word" start_char="8507">bronchospasm</TOKEN>
<TOKEN end_char="8519" id="token-48-41" morph="none" pos="punct" start_char="8519">,</TOKEN>
<TOKEN end_char="8531" id="token-48-42" morph="none" pos="word" start_char="8521">hypotension</TOKEN>
<TOKEN end_char="8532" id="token-48-43" morph="none" pos="punct" start_char="8532">,</TOKEN>
<TOKEN end_char="8545" id="token-48-44" morph="none" pos="word" start_char="8534">hypertension</TOKEN>
<TOKEN end_char="8546" id="token-48-45" morph="none" pos="punct" start_char="8546">,</TOKEN>
<TOKEN end_char="8557" id="token-48-46" morph="none" pos="word" start_char="8548">angioedema</TOKEN>
<TOKEN end_char="8558" id="token-48-47" morph="none" pos="punct" start_char="8558">,</TOKEN>
<TOKEN end_char="8565" id="token-48-48" morph="none" pos="word" start_char="8560">throat</TOKEN>
<TOKEN end_char="8576" id="token-48-49" morph="none" pos="word" start_char="8567">irritation</TOKEN>
<TOKEN end_char="8577" id="token-48-50" morph="none" pos="punct" start_char="8577">,</TOKEN>
<TOKEN end_char="8582" id="token-48-51" morph="none" pos="word" start_char="8579">rash</TOKEN>
<TOKEN end_char="8592" id="token-48-52" morph="none" pos="word" start_char="8584">including</TOKEN>
<TOKEN end_char="8602" id="token-48-53" morph="none" pos="word" start_char="8594">urticaria</TOKEN>
<TOKEN end_char="8603" id="token-48-54" morph="none" pos="punct" start_char="8603">,</TOKEN>
<TOKEN end_char="8612" id="token-48-55" morph="none" pos="word" start_char="8605">pruritus</TOKEN>
<TOKEN end_char="8613" id="token-48-56" morph="none" pos="punct" start_char="8613">,</TOKEN>
<TOKEN end_char="8621" id="token-48-57" morph="none" pos="word" start_char="8615">myalgia</TOKEN>
<TOKEN end_char="8622" id="token-48-58" morph="none" pos="punct" start_char="8622">,</TOKEN>
<TOKEN end_char="8632" id="token-48-59" morph="none" pos="word" start_char="8624">dizziness</TOKEN>
<TOKEN end_char="8633" id="token-48-60" morph="none" pos="punct" start_char="8633">,</TOKEN>
<TOKEN end_char="8637" id="token-48-61" morph="none" pos="word" start_char="8635">and</TOKEN>
<TOKEN end_char="8649" id="token-48-62" morph="none" pos="word" start_char="8639">diaphoresis</TOKEN>
<TOKEN end_char="8650" id="token-48-63" morph="none" pos="punct" start_char="8650">.</TOKEN>
</SEG>
<SEG end_char="8798" id="segment-49" start_char="8655">
<ORIGINAL_TEXT>If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.</ORIGINAL_TEXT>
<TOKEN end_char="8656" id="token-49-0" morph="none" pos="word" start_char="8655">If</TOKEN>
<TOKEN end_char="8659" id="token-49-1" morph="none" pos="word" start_char="8658">an</TOKEN>
<TOKEN end_char="8676" id="token-49-2" morph="none" pos="unknown" start_char="8661">infusion-related</TOKEN>
<TOKEN end_char="8685" id="token-49-3" morph="none" pos="word" start_char="8678">reaction</TOKEN>
<TOKEN end_char="8692" id="token-49-4" morph="none" pos="word" start_char="8687">occurs</TOKEN>
<TOKEN end_char="8693" id="token-49-5" morph="none" pos="punct" start_char="8693">,</TOKEN>
<TOKEN end_char="8702" id="token-49-6" morph="none" pos="word" start_char="8695">consider</TOKEN>
<TOKEN end_char="8710" id="token-49-7" morph="none" pos="word" start_char="8704">slowing</TOKEN>
<TOKEN end_char="8713" id="token-49-8" morph="none" pos="word" start_char="8712">or</TOKEN>
<TOKEN end_char="8722" id="token-49-9" morph="none" pos="word" start_char="8715">stopping</TOKEN>
<TOKEN end_char="8726" id="token-49-10" morph="none" pos="word" start_char="8724">the</TOKEN>
<TOKEN end_char="8735" id="token-49-11" morph="none" pos="word" start_char="8728">infusion</TOKEN>
<TOKEN end_char="8739" id="token-49-12" morph="none" pos="word" start_char="8737">and</TOKEN>
<TOKEN end_char="8750" id="token-49-13" morph="none" pos="word" start_char="8741">administer</TOKEN>
<TOKEN end_char="8762" id="token-49-14" morph="none" pos="word" start_char="8752">appropriate</TOKEN>
<TOKEN end_char="8774" id="token-49-15" morph="none" pos="word" start_char="8764">medications</TOKEN>
<TOKEN end_char="8781" id="token-49-16" morph="none" pos="unknown" start_char="8776">and/or</TOKEN>
<TOKEN end_char="8792" id="token-49-17" morph="none" pos="word" start_char="8783">supportive</TOKEN>
<TOKEN end_char="8797" id="token-49-18" morph="none" pos="word" start_char="8794">care</TOKEN>
<TOKEN end_char="8798" id="token-49-19" morph="none" pos="punct" start_char="8798">.</TOKEN>
</SEG>
<SEG end_char="8852" id="segment-50" start_char="8801">
<ORIGINAL_TEXT>Clinical Worsening After Bamlanivimab Administration</ORIGINAL_TEXT>
<TOKEN end_char="8808" id="token-50-0" morph="none" pos="word" start_char="8801">Clinical</TOKEN>
<TOKEN end_char="8818" id="token-50-1" morph="none" pos="word" start_char="8810">Worsening</TOKEN>
<TOKEN end_char="8824" id="token-50-2" morph="none" pos="word" start_char="8820">After</TOKEN>
<TOKEN end_char="8837" id="token-50-3" morph="none" pos="word" start_char="8826">Bamlanivimab</TOKEN>
<TOKEN end_char="8852" id="token-50-4" morph="none" pos="word" start_char="8839">Administration</TOKEN>
</SEG>
<SEG end_char="9136" id="segment-51" start_char="8855">
<ORIGINAL_TEXT>Clinical worsening of COVID-19 after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status.</ORIGINAL_TEXT>
<TOKEN end_char="8862" id="token-51-0" morph="none" pos="word" start_char="8855">Clinical</TOKEN>
<TOKEN end_char="8872" id="token-51-1" morph="none" pos="word" start_char="8864">worsening</TOKEN>
<TOKEN end_char="8875" id="token-51-2" morph="none" pos="word" start_char="8874">of</TOKEN>
<TOKEN end_char="8884" id="token-51-3" morph="none" pos="unknown" start_char="8877">COVID-19</TOKEN>
<TOKEN end_char="8890" id="token-51-4" morph="none" pos="word" start_char="8886">after</TOKEN>
<TOKEN end_char="8905" id="token-51-5" morph="none" pos="word" start_char="8892">administration</TOKEN>
<TOKEN end_char="8908" id="token-51-6" morph="none" pos="word" start_char="8907">of</TOKEN>
<TOKEN end_char="8921" id="token-51-7" morph="none" pos="word" start_char="8910">bamlanivimab</TOKEN>
<TOKEN end_char="8925" id="token-51-8" morph="none" pos="word" start_char="8923">has</TOKEN>
<TOKEN end_char="8930" id="token-51-9" morph="none" pos="word" start_char="8927">been</TOKEN>
<TOKEN end_char="8939" id="token-51-10" morph="none" pos="word" start_char="8932">reported</TOKEN>
<TOKEN end_char="8943" id="token-51-11" morph="none" pos="word" start_char="8941">and</TOKEN>
<TOKEN end_char="8947" id="token-51-12" morph="none" pos="word" start_char="8945">may</TOKEN>
<TOKEN end_char="8955" id="token-51-13" morph="none" pos="word" start_char="8949">include</TOKEN>
<TOKEN end_char="8961" id="token-51-14" morph="none" pos="word" start_char="8957">signs</TOKEN>
<TOKEN end_char="8964" id="token-51-15" morph="none" pos="word" start_char="8963">or</TOKEN>
<TOKEN end_char="8973" id="token-51-16" morph="none" pos="word" start_char="8966">symptoms</TOKEN>
<TOKEN end_char="8976" id="token-51-17" morph="none" pos="word" start_char="8975">of</TOKEN>
<TOKEN end_char="8982" id="token-51-18" morph="none" pos="word" start_char="8978">fever</TOKEN>
<TOKEN end_char="8983" id="token-51-19" morph="none" pos="punct" start_char="8983">,</TOKEN>
<TOKEN end_char="8991" id="token-51-20" morph="none" pos="word" start_char="8985">hypoxia</TOKEN>
<TOKEN end_char="8994" id="token-51-21" morph="none" pos="word" start_char="8993">or</TOKEN>
<TOKEN end_char="9004" id="token-51-22" morph="none" pos="word" start_char="8996">increased</TOKEN>
<TOKEN end_char="9016" id="token-51-23" morph="none" pos="word" start_char="9006">respiratory</TOKEN>
<TOKEN end_char="9027" id="token-51-24" morph="none" pos="word" start_char="9018">difficulty</TOKEN>
<TOKEN end_char="9028" id="token-51-25" morph="none" pos="punct" start_char="9028">,</TOKEN>
<TOKEN end_char="9039" id="token-51-26" morph="none" pos="word" start_char="9030">arrhythmia</TOKEN>
<TOKEN end_char="9041" id="token-51-27" morph="none" pos="punct" start_char="9041">(</TOKEN>
<TOKEN end_char="9044" id="token-51-28" morph="none" pos="unknown" start_char="9042">e.g</TOKEN>
<TOKEN end_char="9046" id="token-51-29" morph="none" pos="punct" start_char="9045">.,</TOKEN>
<TOKEN end_char="9053" id="token-51-30" morph="none" pos="word" start_char="9048">atrial</TOKEN>
<TOKEN end_char="9066" id="token-51-31" morph="none" pos="word" start_char="9055">fibrillation</TOKEN>
<TOKEN end_char="9067" id="token-51-32" morph="none" pos="punct" start_char="9067">,</TOKEN>
<TOKEN end_char="9073" id="token-51-33" morph="none" pos="word" start_char="9069">sinus</TOKEN>
<TOKEN end_char="9085" id="token-51-34" morph="none" pos="word" start_char="9075">tachycardia</TOKEN>
<TOKEN end_char="9086" id="token-51-35" morph="none" pos="punct" start_char="9086">,</TOKEN>
<TOKEN end_char="9098" id="token-51-36" morph="none" pos="word" start_char="9088">bradycardia</TOKEN>
<TOKEN end_char="9100" id="token-51-37" morph="none" pos="punct" start_char="9099">),</TOKEN>
<TOKEN end_char="9108" id="token-51-38" morph="none" pos="word" start_char="9102">fatigue</TOKEN>
<TOKEN end_char="9109" id="token-51-39" morph="none" pos="punct" start_char="9109">,</TOKEN>
<TOKEN end_char="9113" id="token-51-40" morph="none" pos="word" start_char="9111">and</TOKEN>
<TOKEN end_char="9121" id="token-51-41" morph="none" pos="word" start_char="9115">altered</TOKEN>
<TOKEN end_char="9128" id="token-51-42" morph="none" pos="word" start_char="9123">mental</TOKEN>
<TOKEN end_char="9135" id="token-51-43" morph="none" pos="word" start_char="9130">status</TOKEN>
<TOKEN end_char="9136" id="token-51-44" morph="none" pos="punct" start_char="9136">.</TOKEN>
</SEG>
<SEG end_char="9183" id="segment-52" start_char="9138">
<ORIGINAL_TEXT>Some of these events required hospitalization.</ORIGINAL_TEXT>
<TOKEN end_char="9141" id="token-52-0" morph="none" pos="word" start_char="9138">Some</TOKEN>
<TOKEN end_char="9144" id="token-52-1" morph="none" pos="word" start_char="9143">of</TOKEN>
<TOKEN end_char="9150" id="token-52-2" morph="none" pos="word" start_char="9146">these</TOKEN>
<TOKEN end_char="9157" id="token-52-3" morph="none" pos="word" start_char="9152">events</TOKEN>
<TOKEN end_char="9166" id="token-52-4" morph="none" pos="word" start_char="9159">required</TOKEN>
<TOKEN end_char="9182" id="token-52-5" morph="none" pos="word" start_char="9168">hospitalization</TOKEN>
<TOKEN end_char="9183" id="token-52-6" morph="none" pos="punct" start_char="9183">.</TOKEN>
</SEG>
<SEG end_char="9288" id="segment-53" start_char="9185">
<ORIGINAL_TEXT>It is not known if these events were related to bamlanivimab use or were due to progression of COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="9186" id="token-53-0" morph="none" pos="word" start_char="9185">It</TOKEN>
<TOKEN end_char="9189" id="token-53-1" morph="none" pos="word" start_char="9188">is</TOKEN>
<TOKEN end_char="9193" id="token-53-2" morph="none" pos="word" start_char="9191">not</TOKEN>
<TOKEN end_char="9199" id="token-53-3" morph="none" pos="word" start_char="9195">known</TOKEN>
<TOKEN end_char="9202" id="token-53-4" morph="none" pos="word" start_char="9201">if</TOKEN>
<TOKEN end_char="9208" id="token-53-5" morph="none" pos="word" start_char="9204">these</TOKEN>
<TOKEN end_char="9215" id="token-53-6" morph="none" pos="word" start_char="9210">events</TOKEN>
<TOKEN end_char="9220" id="token-53-7" morph="none" pos="word" start_char="9217">were</TOKEN>
<TOKEN end_char="9228" id="token-53-8" morph="none" pos="word" start_char="9222">related</TOKEN>
<TOKEN end_char="9231" id="token-53-9" morph="none" pos="word" start_char="9230">to</TOKEN>
<TOKEN end_char="9244" id="token-53-10" morph="none" pos="word" start_char="9233">bamlanivimab</TOKEN>
<TOKEN end_char="9248" id="token-53-11" morph="none" pos="word" start_char="9246">use</TOKEN>
<TOKEN end_char="9251" id="token-53-12" morph="none" pos="word" start_char="9250">or</TOKEN>
<TOKEN end_char="9256" id="token-53-13" morph="none" pos="word" start_char="9253">were</TOKEN>
<TOKEN end_char="9260" id="token-53-14" morph="none" pos="word" start_char="9258">due</TOKEN>
<TOKEN end_char="9263" id="token-53-15" morph="none" pos="word" start_char="9262">to</TOKEN>
<TOKEN end_char="9275" id="token-53-16" morph="none" pos="word" start_char="9265">progression</TOKEN>
<TOKEN end_char="9278" id="token-53-17" morph="none" pos="word" start_char="9277">of</TOKEN>
<TOKEN end_char="9287" id="token-53-18" morph="none" pos="unknown" start_char="9280">COVID-19</TOKEN>
<TOKEN end_char="9288" id="token-53-19" morph="none" pos="punct" start_char="9288">.</TOKEN>
</SEG>
<SEG end_char="9364" id="segment-54" start_char="9291">
<ORIGINAL_TEXT>Limitations of Benefit and Potential Risk in Patients with Severe COVID-19</ORIGINAL_TEXT>
<TOKEN end_char="9301" id="token-54-0" morph="none" pos="word" start_char="9291">Limitations</TOKEN>
<TOKEN end_char="9304" id="token-54-1" morph="none" pos="word" start_char="9303">of</TOKEN>
<TOKEN end_char="9312" id="token-54-2" morph="none" pos="word" start_char="9306">Benefit</TOKEN>
<TOKEN end_char="9316" id="token-54-3" morph="none" pos="word" start_char="9314">and</TOKEN>
<TOKEN end_char="9326" id="token-54-4" morph="none" pos="word" start_char="9318">Potential</TOKEN>
<TOKEN end_char="9331" id="token-54-5" morph="none" pos="word" start_char="9328">Risk</TOKEN>
<TOKEN end_char="9334" id="token-54-6" morph="none" pos="word" start_char="9333">in</TOKEN>
<TOKEN end_char="9343" id="token-54-7" morph="none" pos="word" start_char="9336">Patients</TOKEN>
<TOKEN end_char="9348" id="token-54-8" morph="none" pos="word" start_char="9345">with</TOKEN>
<TOKEN end_char="9355" id="token-54-9" morph="none" pos="word" start_char="9350">Severe</TOKEN>
<TOKEN end_char="9364" id="token-54-10" morph="none" pos="unknown" start_char="9357">COVID-19</TOKEN>
</SEG>
<SEG end_char="9480" id="segment-55" start_char="9367">
<ORIGINAL_TEXT>Treatment with bamlanivimab and etesevimab together has not been studied in patients hospitalized due to COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="9375" id="token-55-0" morph="none" pos="word" start_char="9367">Treatment</TOKEN>
<TOKEN end_char="9380" id="token-55-1" morph="none" pos="word" start_char="9377">with</TOKEN>
<TOKEN end_char="9393" id="token-55-2" morph="none" pos="word" start_char="9382">bamlanivimab</TOKEN>
<TOKEN end_char="9397" id="token-55-3" morph="none" pos="word" start_char="9395">and</TOKEN>
<TOKEN end_char="9408" id="token-55-4" morph="none" pos="word" start_char="9399">etesevimab</TOKEN>
<TOKEN end_char="9417" id="token-55-5" morph="none" pos="word" start_char="9410">together</TOKEN>
<TOKEN end_char="9421" id="token-55-6" morph="none" pos="word" start_char="9419">has</TOKEN>
<TOKEN end_char="9425" id="token-55-7" morph="none" pos="word" start_char="9423">not</TOKEN>
<TOKEN end_char="9430" id="token-55-8" morph="none" pos="word" start_char="9427">been</TOKEN>
<TOKEN end_char="9438" id="token-55-9" morph="none" pos="word" start_char="9432">studied</TOKEN>
<TOKEN end_char="9441" id="token-55-10" morph="none" pos="word" start_char="9440">in</TOKEN>
<TOKEN end_char="9450" id="token-55-11" morph="none" pos="word" start_char="9443">patients</TOKEN>
<TOKEN end_char="9463" id="token-55-12" morph="none" pos="word" start_char="9452">hospitalized</TOKEN>
<TOKEN end_char="9467" id="token-55-13" morph="none" pos="word" start_char="9465">due</TOKEN>
<TOKEN end_char="9470" id="token-55-14" morph="none" pos="word" start_char="9469">to</TOKEN>
<TOKEN end_char="9479" id="token-55-15" morph="none" pos="unknown" start_char="9472">COVID-19</TOKEN>
<TOKEN end_char="9480" id="token-55-16" morph="none" pos="punct" start_char="9480">.</TOKEN>
</SEG>
<SEG end_char="9588" id="segment-56" start_char="9482">
<ORIGINAL_TEXT>Benefit of treatment with bamlanivimab alone has not been observed in patient hospitalized due to COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="9488" id="token-56-0" morph="none" pos="word" start_char="9482">Benefit</TOKEN>
<TOKEN end_char="9491" id="token-56-1" morph="none" pos="word" start_char="9490">of</TOKEN>
<TOKEN end_char="9501" id="token-56-2" morph="none" pos="word" start_char="9493">treatment</TOKEN>
<TOKEN end_char="9506" id="token-56-3" morph="none" pos="word" start_char="9503">with</TOKEN>
<TOKEN end_char="9519" id="token-56-4" morph="none" pos="word" start_char="9508">bamlanivimab</TOKEN>
<TOKEN end_char="9525" id="token-56-5" morph="none" pos="word" start_char="9521">alone</TOKEN>
<TOKEN end_char="9529" id="token-56-6" morph="none" pos="word" start_char="9527">has</TOKEN>
<TOKEN end_char="9533" id="token-56-7" morph="none" pos="word" start_char="9531">not</TOKEN>
<TOKEN end_char="9538" id="token-56-8" morph="none" pos="word" start_char="9535">been</TOKEN>
<TOKEN end_char="9547" id="token-56-9" morph="none" pos="word" start_char="9540">observed</TOKEN>
<TOKEN end_char="9550" id="token-56-10" morph="none" pos="word" start_char="9549">in</TOKEN>
<TOKEN end_char="9558" id="token-56-11" morph="none" pos="word" start_char="9552">patient</TOKEN>
<TOKEN end_char="9571" id="token-56-12" morph="none" pos="word" start_char="9560">hospitalized</TOKEN>
<TOKEN end_char="9575" id="token-56-13" morph="none" pos="word" start_char="9573">due</TOKEN>
<TOKEN end_char="9578" id="token-56-14" morph="none" pos="word" start_char="9577">to</TOKEN>
<TOKEN end_char="9587" id="token-56-15" morph="none" pos="unknown" start_char="9580">COVID-19</TOKEN>
<TOKEN end_char="9588" id="token-56-16" morph="none" pos="punct" start_char="9588">.</TOKEN>
</SEG>
<SEG end_char="9806" id="segment-57" start_char="9590">
<ORIGINAL_TEXT>Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.</ORIGINAL_TEXT>
<TOKEN end_char="9599" id="token-57-0" morph="none" pos="word" start_char="9590">Monoclonal</TOKEN>
<TOKEN end_char="9610" id="token-57-1" morph="none" pos="word" start_char="9601">antibodies</TOKEN>
<TOKEN end_char="9611" id="token-57-2" morph="none" pos="punct" start_char="9611">,</TOKEN>
<TOKEN end_char="9616" id="token-57-3" morph="none" pos="word" start_char="9613">such</TOKEN>
<TOKEN end_char="9619" id="token-57-4" morph="none" pos="word" start_char="9618">as</TOKEN>
<TOKEN end_char="9632" id="token-57-5" morph="none" pos="word" start_char="9621">bamlanivimab</TOKEN>
<TOKEN end_char="9636" id="token-57-6" morph="none" pos="word" start_char="9634">and</TOKEN>
<TOKEN end_char="9647" id="token-57-7" morph="none" pos="word" start_char="9638">etesevimab</TOKEN>
<TOKEN end_char="9648" id="token-57-8" morph="none" pos="punct" start_char="9648">,</TOKEN>
<TOKEN end_char="9652" id="token-57-9" morph="none" pos="word" start_char="9650">may</TOKEN>
<TOKEN end_char="9655" id="token-57-10" morph="none" pos="word" start_char="9654">be</TOKEN>
<TOKEN end_char="9666" id="token-57-11" morph="none" pos="word" start_char="9657">associated</TOKEN>
<TOKEN end_char="9671" id="token-57-12" morph="none" pos="word" start_char="9668">with</TOKEN>
<TOKEN end_char="9677" id="token-57-13" morph="none" pos="word" start_char="9673">worse</TOKEN>
<TOKEN end_char="9686" id="token-57-14" morph="none" pos="word" start_char="9679">clinical</TOKEN>
<TOKEN end_char="9695" id="token-57-15" morph="none" pos="word" start_char="9688">outcomes</TOKEN>
<TOKEN end_char="9700" id="token-57-16" morph="none" pos="word" start_char="9697">when</TOKEN>
<TOKEN end_char="9713" id="token-57-17" morph="none" pos="word" start_char="9702">administered</TOKEN>
<TOKEN end_char="9716" id="token-57-18" morph="none" pos="word" start_char="9715">to</TOKEN>
<TOKEN end_char="9729" id="token-57-19" morph="none" pos="word" start_char="9718">hospitalized</TOKEN>
<TOKEN end_char="9738" id="token-57-20" morph="none" pos="word" start_char="9731">patients</TOKEN>
<TOKEN end_char="9743" id="token-57-21" morph="none" pos="word" start_char="9740">with</TOKEN>
<TOKEN end_char="9752" id="token-57-22" morph="none" pos="unknown" start_char="9745">COVID-19</TOKEN>
<TOKEN end_char="9762" id="token-57-23" morph="none" pos="word" start_char="9754">requiring</TOKEN>
<TOKEN end_char="9767" id="token-57-24" morph="none" pos="word" start_char="9764">high</TOKEN>
<TOKEN end_char="9772" id="token-57-25" morph="none" pos="word" start_char="9769">flow</TOKEN>
<TOKEN end_char="9779" id="token-57-26" morph="none" pos="word" start_char="9774">oxygen</TOKEN>
<TOKEN end_char="9782" id="token-57-27" morph="none" pos="word" start_char="9781">or</TOKEN>
<TOKEN end_char="9793" id="token-57-28" morph="none" pos="word" start_char="9784">mechanical</TOKEN>
<TOKEN end_char="9805" id="token-57-29" morph="none" pos="word" start_char="9795">ventilation</TOKEN>
<TOKEN end_char="9806" id="token-57-30" morph="none" pos="punct" start_char="9806">.</TOKEN>
</SEG>
<SEG end_char="9841" id="segment-58" start_char="9808">
<ORIGINAL_TEXT>See Limitations of Authorized Use.</ORIGINAL_TEXT>
<TOKEN end_char="9810" id="token-58-0" morph="none" pos="word" start_char="9808">See</TOKEN>
<TOKEN end_char="9822" id="token-58-1" morph="none" pos="word" start_char="9812">Limitations</TOKEN>
<TOKEN end_char="9825" id="token-58-2" morph="none" pos="word" start_char="9824">of</TOKEN>
<TOKEN end_char="9836" id="token-58-3" morph="none" pos="word" start_char="9827">Authorized</TOKEN>
<TOKEN end_char="9840" id="token-58-4" morph="none" pos="word" start_char="9838">Use</TOKEN>
<TOKEN end_char="9841" id="token-58-5" morph="none" pos="punct" start_char="9841">.</TOKEN>
</SEG>
<SEG end_char="9857" id="segment-59" start_char="9844">
<ORIGINAL_TEXT>Adverse Events</ORIGINAL_TEXT>
<TOKEN end_char="9850" id="token-59-0" morph="none" pos="word" start_char="9844">Adverse</TOKEN>
<TOKEN end_char="9857" id="token-59-1" morph="none" pos="word" start_char="9852">Events</TOKEN>
<TRANSLATED_TEXT>Bivirkninger</TRANSLATED_TEXT><DETECTED_LANGUAGE>nl</DETECTED_LANGUAGE></SEG>
<SEG end_char="10076" id="segment-60" start_char="9860">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together Based on Phase 2 data from BLAZE-1, nausea was the most commonly reported adverse event, reported by 4% of subjects in both bamlanivimab and etesevimab together and placebo groups.</ORIGINAL_TEXT>
<TOKEN end_char="9871" id="token-60-0" morph="none" pos="word" start_char="9860">Bamlanivimab</TOKEN>
<TOKEN end_char="9875" id="token-60-1" morph="none" pos="word" start_char="9873">and</TOKEN>
<TOKEN end_char="9886" id="token-60-2" morph="none" pos="word" start_char="9877">etesevimab</TOKEN>
<TOKEN end_char="9895" id="token-60-3" morph="none" pos="word" start_char="9888">together</TOKEN>
<TOKEN end_char="9901" id="token-60-4" morph="none" pos="word" start_char="9897">Based</TOKEN>
<TOKEN end_char="9904" id="token-60-5" morph="none" pos="word" start_char="9903">on</TOKEN>
<TOKEN end_char="9910" id="token-60-6" morph="none" pos="word" start_char="9906">Phase</TOKEN>
<TOKEN end_char="9912" id="token-60-7" morph="none" pos="word" start_char="9912">2</TOKEN>
<TOKEN end_char="9917" id="token-60-8" morph="none" pos="word" start_char="9914">data</TOKEN>
<TOKEN end_char="9922" id="token-60-9" morph="none" pos="word" start_char="9919">from</TOKEN>
<TOKEN end_char="9930" id="token-60-10" morph="none" pos="unknown" start_char="9924">BLAZE-1</TOKEN>
<TOKEN end_char="9931" id="token-60-11" morph="none" pos="punct" start_char="9931">,</TOKEN>
<TOKEN end_char="9938" id="token-60-12" morph="none" pos="word" start_char="9933">nausea</TOKEN>
<TOKEN end_char="9942" id="token-60-13" morph="none" pos="word" start_char="9940">was</TOKEN>
<TOKEN end_char="9946" id="token-60-14" morph="none" pos="word" start_char="9944">the</TOKEN>
<TOKEN end_char="9951" id="token-60-15" morph="none" pos="word" start_char="9948">most</TOKEN>
<TOKEN end_char="9960" id="token-60-16" morph="none" pos="word" start_char="9953">commonly</TOKEN>
<TOKEN end_char="9969" id="token-60-17" morph="none" pos="word" start_char="9962">reported</TOKEN>
<TOKEN end_char="9977" id="token-60-18" morph="none" pos="word" start_char="9971">adverse</TOKEN>
<TOKEN end_char="9983" id="token-60-19" morph="none" pos="word" start_char="9979">event</TOKEN>
<TOKEN end_char="9984" id="token-60-20" morph="none" pos="punct" start_char="9984">,</TOKEN>
<TOKEN end_char="9993" id="token-60-21" morph="none" pos="word" start_char="9986">reported</TOKEN>
<TOKEN end_char="9996" id="token-60-22" morph="none" pos="word" start_char="9995">by</TOKEN>
<TOKEN end_char="9998" id="token-60-23" morph="none" pos="word" start_char="9998">4</TOKEN>
<TOKEN end_char="9999" id="token-60-24" morph="none" pos="punct" start_char="9999">%</TOKEN>
<TOKEN end_char="10002" id="token-60-25" morph="none" pos="word" start_char="10001">of</TOKEN>
<TOKEN end_char="10011" id="token-60-26" morph="none" pos="word" start_char="10004">subjects</TOKEN>
<TOKEN end_char="10014" id="token-60-27" morph="none" pos="word" start_char="10013">in</TOKEN>
<TOKEN end_char="10019" id="token-60-28" morph="none" pos="word" start_char="10016">both</TOKEN>
<TOKEN end_char="10032" id="token-60-29" morph="none" pos="word" start_char="10021">bamlanivimab</TOKEN>
<TOKEN end_char="10036" id="token-60-30" morph="none" pos="word" start_char="10034">and</TOKEN>
<TOKEN end_char="10047" id="token-60-31" morph="none" pos="word" start_char="10038">etesevimab</TOKEN>
<TOKEN end_char="10056" id="token-60-32" morph="none" pos="word" start_char="10049">together</TOKEN>
<TOKEN end_char="10060" id="token-60-33" morph="none" pos="word" start_char="10058">and</TOKEN>
<TOKEN end_char="10068" id="token-60-34" morph="none" pos="word" start_char="10062">placebo</TOKEN>
<TOKEN end_char="10075" id="token-60-35" morph="none" pos="word" start_char="10070">groups</TOKEN>
<TOKEN end_char="10076" id="token-60-36" morph="none" pos="punct" start_char="10076">.</TOKEN>
</SEG>
<SEG end_char="10246" id="segment-61" start_char="10078">
<ORIGINAL_TEXT>Pruritus and pyrexia were more frequently reported from subjects treated with both bamlanivimab and etesevimab (2% and 1%) compared to placebo (1% and 0%, respectively).</ORIGINAL_TEXT>
<TOKEN end_char="10085" id="token-61-0" morph="none" pos="word" start_char="10078">Pruritus</TOKEN>
<TOKEN end_char="10089" id="token-61-1" morph="none" pos="word" start_char="10087">and</TOKEN>
<TOKEN end_char="10097" id="token-61-2" morph="none" pos="word" start_char="10091">pyrexia</TOKEN>
<TOKEN end_char="10102" id="token-61-3" morph="none" pos="word" start_char="10099">were</TOKEN>
<TOKEN end_char="10107" id="token-61-4" morph="none" pos="word" start_char="10104">more</TOKEN>
<TOKEN end_char="10118" id="token-61-5" morph="none" pos="word" start_char="10109">frequently</TOKEN>
<TOKEN end_char="10127" id="token-61-6" morph="none" pos="word" start_char="10120">reported</TOKEN>
<TOKEN end_char="10132" id="token-61-7" morph="none" pos="word" start_char="10129">from</TOKEN>
<TOKEN end_char="10141" id="token-61-8" morph="none" pos="word" start_char="10134">subjects</TOKEN>
<TOKEN end_char="10149" id="token-61-9" morph="none" pos="word" start_char="10143">treated</TOKEN>
<TOKEN end_char="10154" id="token-61-10" morph="none" pos="word" start_char="10151">with</TOKEN>
<TOKEN end_char="10159" id="token-61-11" morph="none" pos="word" start_char="10156">both</TOKEN>
<TOKEN end_char="10172" id="token-61-12" morph="none" pos="word" start_char="10161">bamlanivimab</TOKEN>
<TOKEN end_char="10176" id="token-61-13" morph="none" pos="word" start_char="10174">and</TOKEN>
<TOKEN end_char="10187" id="token-61-14" morph="none" pos="word" start_char="10178">etesevimab</TOKEN>
<TOKEN end_char="10189" id="token-61-15" morph="none" pos="punct" start_char="10189">(</TOKEN>
<TOKEN end_char="10190" id="token-61-16" morph="none" pos="word" start_char="10190">2</TOKEN>
<TOKEN end_char="10191" id="token-61-17" morph="none" pos="punct" start_char="10191">%</TOKEN>
<TOKEN end_char="10195" id="token-61-18" morph="none" pos="word" start_char="10193">and</TOKEN>
<TOKEN end_char="10197" id="token-61-19" morph="none" pos="word" start_char="10197">1</TOKEN>
<TOKEN end_char="10199" id="token-61-20" morph="none" pos="punct" start_char="10198">%)</TOKEN>
<TOKEN end_char="10208" id="token-61-21" morph="none" pos="word" start_char="10201">compared</TOKEN>
<TOKEN end_char="10211" id="token-61-22" morph="none" pos="word" start_char="10210">to</TOKEN>
<TOKEN end_char="10219" id="token-61-23" morph="none" pos="word" start_char="10213">placebo</TOKEN>
<TOKEN end_char="10221" id="token-61-24" morph="none" pos="punct" start_char="10221">(</TOKEN>
<TOKEN end_char="10222" id="token-61-25" morph="none" pos="word" start_char="10222">1</TOKEN>
<TOKEN end_char="10223" id="token-61-26" morph="none" pos="punct" start_char="10223">%</TOKEN>
<TOKEN end_char="10227" id="token-61-27" morph="none" pos="word" start_char="10225">and</TOKEN>
<TOKEN end_char="10229" id="token-61-28" morph="none" pos="word" start_char="10229">0</TOKEN>
<TOKEN end_char="10231" id="token-61-29" morph="none" pos="punct" start_char="10230">%,</TOKEN>
<TOKEN end_char="10244" id="token-61-30" morph="none" pos="word" start_char="10233">respectively</TOKEN>
<TOKEN end_char="10246" id="token-61-31" morph="none" pos="punct" start_char="10245">).</TOKEN>
</SEG>
<SEG end_char="10348" id="segment-62" start_char="10249">
<ORIGINAL_TEXT>Based on Phase 3 data from BLAZE-1, the most common adverse events were nausea, dizziness, and rash.</ORIGINAL_TEXT>
<TOKEN end_char="10253" id="token-62-0" morph="none" pos="word" start_char="10249">Based</TOKEN>
<TOKEN end_char="10256" id="token-62-1" morph="none" pos="word" start_char="10255">on</TOKEN>
<TOKEN end_char="10262" id="token-62-2" morph="none" pos="word" start_char="10258">Phase</TOKEN>
<TOKEN end_char="10264" id="token-62-3" morph="none" pos="word" start_char="10264">3</TOKEN>
<TOKEN end_char="10269" id="token-62-4" morph="none" pos="word" start_char="10266">data</TOKEN>
<TOKEN end_char="10274" id="token-62-5" morph="none" pos="word" start_char="10271">from</TOKEN>
<TOKEN end_char="10282" id="token-62-6" morph="none" pos="unknown" start_char="10276">BLAZE-1</TOKEN>
<TOKEN end_char="10283" id="token-62-7" morph="none" pos="punct" start_char="10283">,</TOKEN>
<TOKEN end_char="10287" id="token-62-8" morph="none" pos="word" start_char="10285">the</TOKEN>
<TOKEN end_char="10292" id="token-62-9" morph="none" pos="word" start_char="10289">most</TOKEN>
<TOKEN end_char="10299" id="token-62-10" morph="none" pos="word" start_char="10294">common</TOKEN>
<TOKEN end_char="10307" id="token-62-11" morph="none" pos="word" start_char="10301">adverse</TOKEN>
<TOKEN end_char="10314" id="token-62-12" morph="none" pos="word" start_char="10309">events</TOKEN>
<TOKEN end_char="10319" id="token-62-13" morph="none" pos="word" start_char="10316">were</TOKEN>
<TOKEN end_char="10326" id="token-62-14" morph="none" pos="word" start_char="10321">nausea</TOKEN>
<TOKEN end_char="10327" id="token-62-15" morph="none" pos="punct" start_char="10327">,</TOKEN>
<TOKEN end_char="10337" id="token-62-16" morph="none" pos="word" start_char="10329">dizziness</TOKEN>
<TOKEN end_char="10338" id="token-62-17" morph="none" pos="punct" start_char="10338">,</TOKEN>
<TOKEN end_char="10342" id="token-62-18" morph="none" pos="word" start_char="10340">and</TOKEN>
<TOKEN end_char="10347" id="token-62-19" morph="none" pos="word" start_char="10344">rash</TOKEN>
<TOKEN end_char="10348" id="token-62-20" morph="none" pos="punct" start_char="10348">.</TOKEN>
</SEG>
<SEG end_char="10474" id="segment-63" start_char="10350">
<ORIGINAL_TEXT>These events each occurred in 1% of subjects treated with bamlanivimab and etesevimab together and in 1% of placebo subjects.</ORIGINAL_TEXT>
<TOKEN end_char="10354" id="token-63-0" morph="none" pos="word" start_char="10350">These</TOKEN>
<TOKEN end_char="10361" id="token-63-1" morph="none" pos="word" start_char="10356">events</TOKEN>
<TOKEN end_char="10366" id="token-63-2" morph="none" pos="word" start_char="10363">each</TOKEN>
<TOKEN end_char="10375" id="token-63-3" morph="none" pos="word" start_char="10368">occurred</TOKEN>
<TOKEN end_char="10378" id="token-63-4" morph="none" pos="word" start_char="10377">in</TOKEN>
<TOKEN end_char="10380" id="token-63-5" morph="none" pos="word" start_char="10380">1</TOKEN>
<TOKEN end_char="10381" id="token-63-6" morph="none" pos="punct" start_char="10381">%</TOKEN>
<TOKEN end_char="10384" id="token-63-7" morph="none" pos="word" start_char="10383">of</TOKEN>
<TOKEN end_char="10393" id="token-63-8" morph="none" pos="word" start_char="10386">subjects</TOKEN>
<TOKEN end_char="10401" id="token-63-9" morph="none" pos="word" start_char="10395">treated</TOKEN>
<TOKEN end_char="10406" id="token-63-10" morph="none" pos="word" start_char="10403">with</TOKEN>
<TOKEN end_char="10419" id="token-63-11" morph="none" pos="word" start_char="10408">bamlanivimab</TOKEN>
<TOKEN end_char="10423" id="token-63-12" morph="none" pos="word" start_char="10421">and</TOKEN>
<TOKEN end_char="10434" id="token-63-13" morph="none" pos="word" start_char="10425">etesevimab</TOKEN>
<TOKEN end_char="10443" id="token-63-14" morph="none" pos="word" start_char="10436">together</TOKEN>
<TOKEN end_char="10447" id="token-63-15" morph="none" pos="word" start_char="10445">and</TOKEN>
<TOKEN end_char="10450" id="token-63-16" morph="none" pos="word" start_char="10449">in</TOKEN>
<TOKEN end_char="10452" id="token-63-17" morph="none" pos="word" start_char="10452">1</TOKEN>
<TOKEN end_char="10453" id="token-63-18" morph="none" pos="punct" start_char="10453">%</TOKEN>
<TOKEN end_char="10456" id="token-63-19" morph="none" pos="word" start_char="10455">of</TOKEN>
<TOKEN end_char="10464" id="token-63-20" morph="none" pos="word" start_char="10458">placebo</TOKEN>
<TOKEN end_char="10473" id="token-63-21" morph="none" pos="word" start_char="10466">subjects</TOKEN>
<TOKEN end_char="10474" id="token-63-22" morph="none" pos="punct" start_char="10474">.</TOKEN>
</SEG>
<SEG end_char="10745" id="segment-64" start_char="10477">
<ORIGINAL_TEXT>Bamlanivimab alone Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg alone or placebo were nausea (3% vs 4%), diarrhea (1% vs 5%), dizziness (3% vs 2%), headache (3% vs 2%), pruritus (2% vs 1%) and vomiting (1% vs 3%).</ORIGINAL_TEXT>
<TOKEN end_char="10488" id="token-64-0" morph="none" pos="word" start_char="10477">Bamlanivimab</TOKEN>
<TOKEN end_char="10494" id="token-64-1" morph="none" pos="word" start_char="10490">alone</TOKEN>
<TOKEN end_char="10502" id="token-64-2" morph="none" pos="word" start_char="10496">Adverse</TOKEN>
<TOKEN end_char="10509" id="token-64-3" morph="none" pos="word" start_char="10504">events</TOKEN>
<TOKEN end_char="10518" id="token-64-4" morph="none" pos="word" start_char="10511">reported</TOKEN>
<TOKEN end_char="10521" id="token-64-5" morph="none" pos="word" start_char="10520">in</TOKEN>
<TOKEN end_char="10524" id="token-64-6" morph="none" pos="word" start_char="10523">at</TOKEN>
<TOKEN end_char="10530" id="token-64-7" morph="none" pos="word" start_char="10526">least</TOKEN>
<TOKEN end_char="10532" id="token-64-8" morph="none" pos="word" start_char="10532">1</TOKEN>
<TOKEN end_char="10533" id="token-64-9" morph="none" pos="punct" start_char="10533">%</TOKEN>
<TOKEN end_char="10536" id="token-64-10" morph="none" pos="word" start_char="10535">of</TOKEN>
<TOKEN end_char="10544" id="token-64-11" morph="none" pos="unknown" start_char="10538">BLAZE-1</TOKEN>
<TOKEN end_char="10553" id="token-64-12" morph="none" pos="word" start_char="10546">clinical</TOKEN>
<TOKEN end_char="10559" id="token-64-13" morph="none" pos="word" start_char="10555">trial</TOKEN>
<TOKEN end_char="10572" id="token-64-14" morph="none" pos="word" start_char="10561">participants</TOKEN>
<TOKEN end_char="10575" id="token-64-15" morph="none" pos="word" start_char="10574">on</TOKEN>
<TOKEN end_char="10588" id="token-64-16" morph="none" pos="word" start_char="10577">bamlanivimab</TOKEN>
<TOKEN end_char="10592" id="token-64-17" morph="none" pos="word" start_char="10590">700</TOKEN>
<TOKEN end_char="10595" id="token-64-18" morph="none" pos="word" start_char="10594">mg</TOKEN>
<TOKEN end_char="10601" id="token-64-19" morph="none" pos="word" start_char="10597">alone</TOKEN>
<TOKEN end_char="10604" id="token-64-20" morph="none" pos="word" start_char="10603">or</TOKEN>
<TOKEN end_char="10612" id="token-64-21" morph="none" pos="word" start_char="10606">placebo</TOKEN>
<TOKEN end_char="10617" id="token-64-22" morph="none" pos="word" start_char="10614">were</TOKEN>
<TOKEN end_char="10624" id="token-64-23" morph="none" pos="word" start_char="10619">nausea</TOKEN>
<TOKEN end_char="10626" id="token-64-24" morph="none" pos="punct" start_char="10626">(</TOKEN>
<TOKEN end_char="10627" id="token-64-25" morph="none" pos="word" start_char="10627">3</TOKEN>
<TOKEN end_char="10628" id="token-64-26" morph="none" pos="punct" start_char="10628">%</TOKEN>
<TOKEN end_char="10631" id="token-64-27" morph="none" pos="word" start_char="10630">vs</TOKEN>
<TOKEN end_char="10633" id="token-64-28" morph="none" pos="word" start_char="10633">4</TOKEN>
<TOKEN end_char="10636" id="token-64-29" morph="none" pos="punct" start_char="10634">%),</TOKEN>
<TOKEN end_char="10645" id="token-64-30" morph="none" pos="word" start_char="10638">diarrhea</TOKEN>
<TOKEN end_char="10647" id="token-64-31" morph="none" pos="punct" start_char="10647">(</TOKEN>
<TOKEN end_char="10648" id="token-64-32" morph="none" pos="word" start_char="10648">1</TOKEN>
<TOKEN end_char="10649" id="token-64-33" morph="none" pos="punct" start_char="10649">%</TOKEN>
<TOKEN end_char="10652" id="token-64-34" morph="none" pos="word" start_char="10651">vs</TOKEN>
<TOKEN end_char="10654" id="token-64-35" morph="none" pos="word" start_char="10654">5</TOKEN>
<TOKEN end_char="10657" id="token-64-36" morph="none" pos="punct" start_char="10655">%),</TOKEN>
<TOKEN end_char="10667" id="token-64-37" morph="none" pos="word" start_char="10659">dizziness</TOKEN>
<TOKEN end_char="10669" id="token-64-38" morph="none" pos="punct" start_char="10669">(</TOKEN>
<TOKEN end_char="10670" id="token-64-39" morph="none" pos="word" start_char="10670">3</TOKEN>
<TOKEN end_char="10671" id="token-64-40" morph="none" pos="punct" start_char="10671">%</TOKEN>
<TOKEN end_char="10674" id="token-64-41" morph="none" pos="word" start_char="10673">vs</TOKEN>
<TOKEN end_char="10676" id="token-64-42" morph="none" pos="word" start_char="10676">2</TOKEN>
<TOKEN end_char="10679" id="token-64-43" morph="none" pos="punct" start_char="10677">%),</TOKEN>
<TOKEN end_char="10688" id="token-64-44" morph="none" pos="word" start_char="10681">headache</TOKEN>
<TOKEN end_char="10690" id="token-64-45" morph="none" pos="punct" start_char="10690">(</TOKEN>
<TOKEN end_char="10691" id="token-64-46" morph="none" pos="word" start_char="10691">3</TOKEN>
<TOKEN end_char="10692" id="token-64-47" morph="none" pos="punct" start_char="10692">%</TOKEN>
<TOKEN end_char="10695" id="token-64-48" morph="none" pos="word" start_char="10694">vs</TOKEN>
<TOKEN end_char="10697" id="token-64-49" morph="none" pos="word" start_char="10697">2</TOKEN>
<TOKEN end_char="10700" id="token-64-50" morph="none" pos="punct" start_char="10698">%),</TOKEN>
<TOKEN end_char="10709" id="token-64-51" morph="none" pos="word" start_char="10702">pruritus</TOKEN>
<TOKEN end_char="10711" id="token-64-52" morph="none" pos="punct" start_char="10711">(</TOKEN>
<TOKEN end_char="10712" id="token-64-53" morph="none" pos="word" start_char="10712">2</TOKEN>
<TOKEN end_char="10713" id="token-64-54" morph="none" pos="punct" start_char="10713">%</TOKEN>
<TOKEN end_char="10716" id="token-64-55" morph="none" pos="word" start_char="10715">vs</TOKEN>
<TOKEN end_char="10718" id="token-64-56" morph="none" pos="word" start_char="10718">1</TOKEN>
<TOKEN end_char="10720" id="token-64-57" morph="none" pos="punct" start_char="10719">%)</TOKEN>
<TOKEN end_char="10724" id="token-64-58" morph="none" pos="word" start_char="10722">and</TOKEN>
<TOKEN end_char="10733" id="token-64-59" morph="none" pos="word" start_char="10726">vomiting</TOKEN>
<TOKEN end_char="10735" id="token-64-60" morph="none" pos="punct" start_char="10735">(</TOKEN>
<TOKEN end_char="10736" id="token-64-61" morph="none" pos="word" start_char="10736">1</TOKEN>
<TOKEN end_char="10737" id="token-64-62" morph="none" pos="punct" start_char="10737">%</TOKEN>
<TOKEN end_char="10740" id="token-64-63" morph="none" pos="word" start_char="10739">vs</TOKEN>
<TOKEN end_char="10742" id="token-64-64" morph="none" pos="word" start_char="10742">3</TOKEN>
<TOKEN end_char="10745" id="token-64-65" morph="none" pos="punct" start_char="10743">%).</TOKEN>
</SEG>
<SEG end_char="10774" id="segment-65" start_char="10748">
<ORIGINAL_TEXT>Use in Specific Populations</ORIGINAL_TEXT>
<TOKEN end_char="10750" id="token-65-0" morph="none" pos="word" start_char="10748">Use</TOKEN>
<TOKEN end_char="10753" id="token-65-1" morph="none" pos="word" start_char="10752">in</TOKEN>
<TOKEN end_char="10762" id="token-65-2" morph="none" pos="word" start_char="10755">Specific</TOKEN>
<TOKEN end_char="10774" id="token-65-3" morph="none" pos="word" start_char="10764">Populations</TOKEN>
</SEG>
<SEG end_char="10786" id="segment-66" start_char="10778">
<ORIGINAL_TEXT>Pregnancy</ORIGINAL_TEXT>
<TOKEN end_char="10786" id="token-66-0" morph="none" pos="word" start_char="10778">Pregnancy</TOKEN>
<TRANSLATED_TEXT>Graviditet</TRANSLATED_TEXT><DETECTED_LANGUAGE>it</DETECTED_LANGUAGE></SEG>
<SEG end_char="10907" id="segment-67" start_char="10789">
<ORIGINAL_TEXT>There are insufficient data on the use of bamlanivimab and etesevimab together and bamlanivimab alone during pregnancy.</ORIGINAL_TEXT>
<TOKEN end_char="10793" id="token-67-0" morph="none" pos="word" start_char="10789">There</TOKEN>
<TOKEN end_char="10797" id="token-67-1" morph="none" pos="word" start_char="10795">are</TOKEN>
<TOKEN end_char="10810" id="token-67-2" morph="none" pos="word" start_char="10799">insufficient</TOKEN>
<TOKEN end_char="10815" id="token-67-3" morph="none" pos="word" start_char="10812">data</TOKEN>
<TOKEN end_char="10818" id="token-67-4" morph="none" pos="word" start_char="10817">on</TOKEN>
<TOKEN end_char="10822" id="token-67-5" morph="none" pos="word" start_char="10820">the</TOKEN>
<TOKEN end_char="10826" id="token-67-6" morph="none" pos="word" start_char="10824">use</TOKEN>
<TOKEN end_char="10829" id="token-67-7" morph="none" pos="word" start_char="10828">of</TOKEN>
<TOKEN end_char="10842" id="token-67-8" morph="none" pos="word" start_char="10831">bamlanivimab</TOKEN>
<TOKEN end_char="10846" id="token-67-9" morph="none" pos="word" start_char="10844">and</TOKEN>
<TOKEN end_char="10857" id="token-67-10" morph="none" pos="word" start_char="10848">etesevimab</TOKEN>
<TOKEN end_char="10866" id="token-67-11" morph="none" pos="word" start_char="10859">together</TOKEN>
<TOKEN end_char="10870" id="token-67-12" morph="none" pos="word" start_char="10868">and</TOKEN>
<TOKEN end_char="10883" id="token-67-13" morph="none" pos="word" start_char="10872">bamlanivimab</TOKEN>
<TOKEN end_char="10889" id="token-67-14" morph="none" pos="word" start_char="10885">alone</TOKEN>
<TOKEN end_char="10896" id="token-67-15" morph="none" pos="word" start_char="10891">during</TOKEN>
<TOKEN end_char="10906" id="token-67-16" morph="none" pos="word" start_char="10898">pregnancy</TOKEN>
<TOKEN end_char="10907" id="token-67-17" morph="none" pos="punct" start_char="10907">.</TOKEN>
</SEG>
<SEG end_char="11088" id="segment-68" start_char="10909">
<ORIGINAL_TEXT>Bamlanivimab and etesevimab together and bamlanivimab alone should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.</ORIGINAL_TEXT>
<TOKEN end_char="10920" id="token-68-0" morph="none" pos="word" start_char="10909">Bamlanivimab</TOKEN>
<TOKEN end_char="10924" id="token-68-1" morph="none" pos="word" start_char="10922">and</TOKEN>
<TOKEN end_char="10935" id="token-68-2" morph="none" pos="word" start_char="10926">etesevimab</TOKEN>
<TOKEN end_char="10944" id="token-68-3" morph="none" pos="word" start_char="10937">together</TOKEN>
<TOKEN end_char="10948" id="token-68-4" morph="none" pos="word" start_char="10946">and</TOKEN>
<TOKEN end_char="10961" id="token-68-5" morph="none" pos="word" start_char="10950">bamlanivimab</TOKEN>
<TOKEN end_char="10967" id="token-68-6" morph="none" pos="word" start_char="10963">alone</TOKEN>
<TOKEN end_char="10974" id="token-68-7" morph="none" pos="word" start_char="10969">should</TOKEN>
<TOKEN end_char="10979" id="token-68-8" morph="none" pos="word" start_char="10976">only</TOKEN>
<TOKEN end_char="10982" id="token-68-9" morph="none" pos="word" start_char="10981">be</TOKEN>
<TOKEN end_char="10987" id="token-68-10" morph="none" pos="word" start_char="10984">used</TOKEN>
<TOKEN end_char="10994" id="token-68-11" morph="none" pos="word" start_char="10989">during</TOKEN>
<TOKEN end_char="11004" id="token-68-12" morph="none" pos="word" start_char="10996">pregnancy</TOKEN>
<TOKEN end_char="11007" id="token-68-13" morph="none" pos="word" start_char="11006">if</TOKEN>
<TOKEN end_char="11011" id="token-68-14" morph="none" pos="word" start_char="11009">the</TOKEN>
<TOKEN end_char="11021" id="token-68-15" morph="none" pos="word" start_char="11013">potential</TOKEN>
<TOKEN end_char="11029" id="token-68-16" morph="none" pos="word" start_char="11023">benefit</TOKEN>
<TOKEN end_char="11039" id="token-68-17" morph="none" pos="word" start_char="11031">outweighs</TOKEN>
<TOKEN end_char="11043" id="token-68-18" morph="none" pos="word" start_char="11041">the</TOKEN>
<TOKEN end_char="11053" id="token-68-19" morph="none" pos="word" start_char="11045">potential</TOKEN>
<TOKEN end_char="11058" id="token-68-20" morph="none" pos="word" start_char="11055">risk</TOKEN>
<TOKEN end_char="11062" id="token-68-21" morph="none" pos="word" start_char="11060">for</TOKEN>
<TOKEN end_char="11066" id="token-68-22" morph="none" pos="word" start_char="11064">the</TOKEN>
<TOKEN end_char="11073" id="token-68-23" morph="none" pos="word" start_char="11068">mother</TOKEN>
<TOKEN end_char="11077" id="token-68-24" morph="none" pos="word" start_char="11075">and</TOKEN>
<TOKEN end_char="11081" id="token-68-25" morph="none" pos="word" start_char="11079">the</TOKEN>
<TOKEN end_char="11087" id="token-68-26" morph="none" pos="word" start_char="11083">fetus</TOKEN>
<TOKEN end_char="11088" id="token-68-27" morph="none" pos="punct" start_char="11088">.</TOKEN>
</SEG>
<SEG end_char="11103" id="segment-69" start_char="11091">
<ORIGINAL_TEXT>Breastfeeding</ORIGINAL_TEXT>
<TOKEN end_char="11103" id="token-69-0" morph="none" pos="word" start_char="11091">Breastfeeding</TOKEN>
</SEG>
<SEG end_char="11275" id="segment-70" start_char="11106">
<ORIGINAL_TEXT>There are no available data on the presence of bamlanivimab or etesevimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production.</ORIGINAL_TEXT>
<TOKEN end_char="11110" id="token-70-0" morph="none" pos="word" start_char="11106">There</TOKEN>
<TOKEN end_char="11114" id="token-70-1" morph="none" pos="word" start_char="11112">are</TOKEN>
<TOKEN end_char="11117" id="token-70-2" morph="none" pos="word" start_char="11116">no</TOKEN>
<TOKEN end_char="11127" id="token-70-3" morph="none" pos="word" start_char="11119">available</TOKEN>
<TOKEN end_char="11132" id="token-70-4" morph="none" pos="word" start_char="11129">data</TOKEN>
<TOKEN end_char="11135" id="token-70-5" morph="none" pos="word" start_char="11134">on</TOKEN>
<TOKEN end_char="11139" id="token-70-6" morph="none" pos="word" start_char="11137">the</TOKEN>
<TOKEN end_char="11148" id="token-70-7" morph="none" pos="word" start_char="11141">presence</TOKEN>
<TOKEN end_char="11151" id="token-70-8" morph="none" pos="word" start_char="11150">of</TOKEN>
<TOKEN end_char="11164" id="token-70-9" morph="none" pos="word" start_char="11153">bamlanivimab</TOKEN>
<TOKEN end_char="11167" id="token-70-10" morph="none" pos="word" start_char="11166">or</TOKEN>
<TOKEN end_char="11178" id="token-70-11" morph="none" pos="word" start_char="11169">etesevimab</TOKEN>
<TOKEN end_char="11181" id="token-70-12" morph="none" pos="word" start_char="11180">in</TOKEN>
<TOKEN end_char="11187" id="token-70-13" morph="none" pos="word" start_char="11183">human</TOKEN>
<TOKEN end_char="11190" id="token-70-14" morph="none" pos="word" start_char="11189">or</TOKEN>
<TOKEN end_char="11197" id="token-70-15" morph="none" pos="word" start_char="11192">animal</TOKEN>
<TOKEN end_char="11202" id="token-70-16" morph="none" pos="word" start_char="11199">milk</TOKEN>
<TOKEN end_char="11203" id="token-70-17" morph="none" pos="punct" start_char="11203">,</TOKEN>
<TOKEN end_char="11207" id="token-70-18" morph="none" pos="word" start_char="11205">the</TOKEN>
<TOKEN end_char="11215" id="token-70-19" morph="none" pos="word" start_char="11209">effects</TOKEN>
<TOKEN end_char="11218" id="token-70-20" morph="none" pos="word" start_char="11217">on</TOKEN>
<TOKEN end_char="11222" id="token-70-21" morph="none" pos="word" start_char="11220">the</TOKEN>
<TOKEN end_char="11232" id="token-70-22" morph="none" pos="word" start_char="11224">breastfed</TOKEN>
<TOKEN end_char="11239" id="token-70-23" morph="none" pos="word" start_char="11234">infant</TOKEN>
<TOKEN end_char="11240" id="token-70-24" morph="none" pos="punct" start_char="11240">,</TOKEN>
<TOKEN end_char="11243" id="token-70-25" morph="none" pos="word" start_char="11242">or</TOKEN>
<TOKEN end_char="11247" id="token-70-26" morph="none" pos="word" start_char="11245">the</TOKEN>
<TOKEN end_char="11255" id="token-70-27" morph="none" pos="word" start_char="11249">effects</TOKEN>
<TOKEN end_char="11258" id="token-70-28" morph="none" pos="word" start_char="11257">on</TOKEN>
<TOKEN end_char="11263" id="token-70-29" morph="none" pos="word" start_char="11260">milk</TOKEN>
<TOKEN end_char="11274" id="token-70-30" morph="none" pos="word" start_char="11265">production</TOKEN>
<TOKEN end_char="11275" id="token-70-31" morph="none" pos="punct" start_char="11275">.</TOKEN>
</SEG>
<SEG end_char="11414" id="segment-71" start_char="11277">
<ORIGINAL_TEXT>Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="11289" id="token-71-0" morph="none" pos="word" start_char="11277">Breastfeeding</TOKEN>
<TOKEN end_char="11301" id="token-71-1" morph="none" pos="word" start_char="11291">individuals</TOKEN>
<TOKEN end_char="11306" id="token-71-2" morph="none" pos="word" start_char="11303">with</TOKEN>
<TOKEN end_char="11315" id="token-71-3" morph="none" pos="unknown" start_char="11308">COVID-19</TOKEN>
<TOKEN end_char="11322" id="token-71-4" morph="none" pos="word" start_char="11317">should</TOKEN>
<TOKEN end_char="11329" id="token-71-5" morph="none" pos="word" start_char="11324">follow</TOKEN>
<TOKEN end_char="11339" id="token-71-6" morph="none" pos="word" start_char="11331">practices</TOKEN>
<TOKEN end_char="11349" id="token-71-7" morph="none" pos="word" start_char="11341">according</TOKEN>
<TOKEN end_char="11352" id="token-71-8" morph="none" pos="word" start_char="11351">to</TOKEN>
<TOKEN end_char="11361" id="token-71-9" morph="none" pos="word" start_char="11354">clinical</TOKEN>
<TOKEN end_char="11372" id="token-71-10" morph="none" pos="word" start_char="11363">guidelines</TOKEN>
<TOKEN end_char="11375" id="token-71-11" morph="none" pos="word" start_char="11374">to</TOKEN>
<TOKEN end_char="11381" id="token-71-12" morph="none" pos="word" start_char="11377">avoid</TOKEN>
<TOKEN end_char="11390" id="token-71-13" morph="none" pos="word" start_char="11383">exposing</TOKEN>
<TOKEN end_char="11394" id="token-71-14" morph="none" pos="word" start_char="11392">the</TOKEN>
<TOKEN end_char="11401" id="token-71-15" morph="none" pos="word" start_char="11396">infant</TOKEN>
<TOKEN end_char="11404" id="token-71-16" morph="none" pos="word" start_char="11403">to</TOKEN>
<TOKEN end_char="11413" id="token-71-17" morph="none" pos="unknown" start_char="11406">COVID-19</TOKEN>
<TOKEN end_char="11414" id="token-71-18" morph="none" pos="punct" start_char="11414">.</TOKEN>
</SEG>
<SEG end_char="11565" id="segment-72" start_char="11417">
<ORIGINAL_TEXT>About bamlanivimab Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.</ORIGINAL_TEXT>
<TOKEN end_char="11421" id="token-72-0" morph="none" pos="word" start_char="11417">About</TOKEN>
<TOKEN end_char="11434" id="token-72-1" morph="none" pos="word" start_char="11423">bamlanivimab</TOKEN>
<TOKEN end_char="11447" id="token-72-2" morph="none" pos="word" start_char="11436">Bamlanivimab</TOKEN>
<TOKEN end_char="11450" id="token-72-3" morph="none" pos="word" start_char="11449">is</TOKEN>
<TOKEN end_char="11452" id="token-72-4" morph="none" pos="word" start_char="11452">a</TOKEN>
<TOKEN end_char="11464" id="token-72-5" morph="none" pos="word" start_char="11454">recombinant</TOKEN>
<TOKEN end_char="11465" id="token-72-6" morph="none" pos="punct" start_char="11465">,</TOKEN>
<TOKEN end_char="11478" id="token-72-7" morph="none" pos="word" start_char="11467">neutralizing</TOKEN>
<TOKEN end_char="11484" id="token-72-8" morph="none" pos="word" start_char="11480">human</TOKEN>
<TOKEN end_char="11489" id="token-72-9" morph="none" pos="word" start_char="11486">IgG1</TOKEN>
<TOKEN end_char="11500" id="token-72-10" morph="none" pos="word" start_char="11491">monoclonal</TOKEN>
<TOKEN end_char="11509" id="token-72-11" morph="none" pos="word" start_char="11502">antibody</TOKEN>
<TOKEN end_char="11511" id="token-72-12" morph="none" pos="punct" start_char="11511">(</TOKEN>
<TOKEN end_char="11514" id="token-72-13" morph="none" pos="word" start_char="11512">mAb</TOKEN>
<TOKEN end_char="11515" id="token-72-14" morph="none" pos="punct" start_char="11515">)</TOKEN>
<TOKEN end_char="11524" id="token-72-15" morph="none" pos="word" start_char="11517">directed</TOKEN>
<TOKEN end_char="11532" id="token-72-16" morph="none" pos="word" start_char="11526">against</TOKEN>
<TOKEN end_char="11536" id="token-72-17" morph="none" pos="word" start_char="11534">the</TOKEN>
<TOKEN end_char="11542" id="token-72-18" morph="none" pos="word" start_char="11538">spike</TOKEN>
<TOKEN end_char="11550" id="token-72-19" morph="none" pos="word" start_char="11544">protein</TOKEN>
<TOKEN end_char="11553" id="token-72-20" morph="none" pos="word" start_char="11552">of</TOKEN>
<TOKEN end_char="11564" id="token-72-21" morph="none" pos="unknown" start_char="11555">SARS-CoV-2</TOKEN>
<TOKEN end_char="11565" id="token-72-22" morph="none" pos="punct" start_char="11565">.</TOKEN>
</SEG>
<SEG end_char="11694" id="segment-73" start_char="11567">
<ORIGINAL_TEXT>It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="11568" id="token-73-0" morph="none" pos="word" start_char="11567">It</TOKEN>
<TOKEN end_char="11571" id="token-73-1" morph="none" pos="word" start_char="11570">is</TOKEN>
<TOKEN end_char="11580" id="token-73-2" morph="none" pos="word" start_char="11573">designed</TOKEN>
<TOKEN end_char="11583" id="token-73-3" morph="none" pos="word" start_char="11582">to</TOKEN>
<TOKEN end_char="11589" id="token-73-4" morph="none" pos="word" start_char="11585">block</TOKEN>
<TOKEN end_char="11595" id="token-73-5" morph="none" pos="word" start_char="11591">viral</TOKEN>
<TOKEN end_char="11606" id="token-73-6" morph="none" pos="word" start_char="11597">attachment</TOKEN>
<TOKEN end_char="11610" id="token-73-7" morph="none" pos="word" start_char="11608">and</TOKEN>
<TOKEN end_char="11616" id="token-73-8" morph="none" pos="word" start_char="11612">entry</TOKEN>
<TOKEN end_char="11621" id="token-73-9" morph="none" pos="word" start_char="11618">into</TOKEN>
<TOKEN end_char="11627" id="token-73-10" morph="none" pos="word" start_char="11623">human</TOKEN>
<TOKEN end_char="11633" id="token-73-11" morph="none" pos="word" start_char="11629">cells</TOKEN>
<TOKEN end_char="11634" id="token-73-12" morph="none" pos="punct" start_char="11634">,</TOKEN>
<TOKEN end_char="11639" id="token-73-13" morph="none" pos="word" start_char="11636">thus</TOKEN>
<TOKEN end_char="11652" id="token-73-14" morph="none" pos="word" start_char="11641">neutralizing</TOKEN>
<TOKEN end_char="11656" id="token-73-15" morph="none" pos="word" start_char="11654">the</TOKEN>
<TOKEN end_char="11662" id="token-73-16" morph="none" pos="word" start_char="11658">virus</TOKEN>
<TOKEN end_char="11663" id="token-73-17" morph="none" pos="punct" start_char="11663">,</TOKEN>
<TOKEN end_char="11675" id="token-73-18" morph="none" pos="word" start_char="11665">potentially</TOKEN>
<TOKEN end_char="11684" id="token-73-19" morph="none" pos="word" start_char="11677">treating</TOKEN>
<TOKEN end_char="11693" id="token-73-20" morph="none" pos="unknown" start_char="11686">COVID-19</TOKEN>
<TOKEN end_char="11694" id="token-73-21" morph="none" pos="punct" start_char="11694">.</TOKEN>
</SEG>
<SEG end_char="11841" id="segment-74" start_char="11696">
<ORIGINAL_TEXT>Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="11707" id="token-74-0" morph="none" pos="word" start_char="11696">Bamlanivimab</TOKEN>
<TOKEN end_char="11715" id="token-74-1" morph="none" pos="word" start_char="11709">emerged</TOKEN>
<TOKEN end_char="11720" id="token-74-2" morph="none" pos="word" start_char="11717">from</TOKEN>
<TOKEN end_char="11724" id="token-74-3" morph="none" pos="word" start_char="11722">the</TOKEN>
<TOKEN end_char="11738" id="token-74-4" morph="none" pos="word" start_char="11726">collaboration</TOKEN>
<TOKEN end_char="11746" id="token-74-5" morph="none" pos="word" start_char="11740">between</TOKEN>
<TOKEN end_char="11752" id="token-74-6" morph="none" pos="word" start_char="11748">Lilly</TOKEN>
<TOKEN end_char="11756" id="token-74-7" morph="none" pos="word" start_char="11754">and</TOKEN>
<TOKEN end_char="11766" id="token-74-8" morph="none" pos="word" start_char="11758">AbCellera</TOKEN>
<TOKEN end_char="11769" id="token-74-9" morph="none" pos="word" start_char="11768">to</TOKEN>
<TOKEN end_char="11776" id="token-74-10" morph="none" pos="word" start_char="11771">create</TOKEN>
<TOKEN end_char="11785" id="token-74-11" morph="none" pos="word" start_char="11778">antibody</TOKEN>
<TOKEN end_char="11795" id="token-74-12" morph="none" pos="word" start_char="11787">therapies</TOKEN>
<TOKEN end_char="11799" id="token-74-13" morph="none" pos="word" start_char="11797">for</TOKEN>
<TOKEN end_char="11803" id="token-74-14" morph="none" pos="word" start_char="11801">the</TOKEN>
<TOKEN end_char="11814" id="token-74-15" morph="none" pos="word" start_char="11805">prevention</TOKEN>
<TOKEN end_char="11818" id="token-74-16" morph="none" pos="word" start_char="11816">and</TOKEN>
<TOKEN end_char="11828" id="token-74-17" morph="none" pos="word" start_char="11820">treatment</TOKEN>
<TOKEN end_char="11831" id="token-74-18" morph="none" pos="word" start_char="11830">of</TOKEN>
<TOKEN end_char="11840" id="token-74-19" morph="none" pos="unknown" start_char="11833">COVID-19</TOKEN>
<TOKEN end_char="11841" id="token-74-20" morph="none" pos="punct" start_char="11841">.</TOKEN>
</SEG>
<SEG end_char="12065" id="segment-75" start_char="11843">
<ORIGINAL_TEXT>Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.</ORIGINAL_TEXT>
<TOKEN end_char="11847" id="token-75-0" morph="none" pos="word" start_char="11843">Lilly</TOKEN>
<TOKEN end_char="11858" id="token-75-1" morph="none" pos="word" start_char="11849">scientists</TOKEN>
<TOKEN end_char="11866" id="token-75-2" morph="none" pos="word" start_char="11860">rapidly</TOKEN>
<TOKEN end_char="11876" id="token-75-3" morph="none" pos="word" start_char="11868">developed</TOKEN>
<TOKEN end_char="11880" id="token-75-4" morph="none" pos="word" start_char="11878">the</TOKEN>
<TOKEN end_char="11889" id="token-75-5" morph="none" pos="word" start_char="11882">antibody</TOKEN>
<TOKEN end_char="11892" id="token-75-6" morph="none" pos="word" start_char="11891">in</TOKEN>
<TOKEN end_char="11897" id="token-75-7" morph="none" pos="word" start_char="11894">less</TOKEN>
<TOKEN end_char="11902" id="token-75-8" morph="none" pos="word" start_char="11899">than</TOKEN>
<TOKEN end_char="11908" id="token-75-9" morph="none" pos="word" start_char="11904">three</TOKEN>
<TOKEN end_char="11915" id="token-75-10" morph="none" pos="word" start_char="11910">months</TOKEN>
<TOKEN end_char="11921" id="token-75-11" morph="none" pos="word" start_char="11917">after</TOKEN>
<TOKEN end_char="11924" id="token-75-12" morph="none" pos="word" start_char="11923">it</TOKEN>
<TOKEN end_char="11928" id="token-75-13" morph="none" pos="word" start_char="11926">was</TOKEN>
<TOKEN end_char="11939" id="token-75-14" morph="none" pos="word" start_char="11930">discovered</TOKEN>
<TOKEN end_char="11942" id="token-75-15" morph="none" pos="word" start_char="11941">by</TOKEN>
<TOKEN end_char="11952" id="token-75-16" morph="none" pos="word" start_char="11944">AbCellera</TOKEN>
<TOKEN end_char="11956" id="token-75-17" morph="none" pos="word" start_char="11954">and</TOKEN>
<TOKEN end_char="11960" id="token-75-18" morph="none" pos="word" start_char="11958">the</TOKEN>
<TOKEN end_char="11971" id="token-75-19" morph="none" pos="word" start_char="11962">scientists</TOKEN>
<TOKEN end_char="11974" id="token-75-20" morph="none" pos="word" start_char="11973">at</TOKEN>
<TOKEN end_char="11978" id="token-75-21" morph="none" pos="word" start_char="11976">the</TOKEN>
<TOKEN end_char="11987" id="token-75-22" morph="none" pos="word" start_char="11980">National</TOKEN>
<TOKEN end_char="11997" id="token-75-23" morph="none" pos="word" start_char="11989">Institute</TOKEN>
<TOKEN end_char="12000" id="token-75-24" morph="none" pos="word" start_char="11999">of</TOKEN>
<TOKEN end_char="12008" id="token-75-25" morph="none" pos="word" start_char="12002">Allergy</TOKEN>
<TOKEN end_char="12012" id="token-75-26" morph="none" pos="word" start_char="12010">and</TOKEN>
<TOKEN end_char="12023" id="token-75-27" morph="none" pos="word" start_char="12014">Infectious</TOKEN>
<TOKEN end_char="12032" id="token-75-28" morph="none" pos="word" start_char="12025">Diseases</TOKEN>
<TOKEN end_char="12034" id="token-75-29" morph="none" pos="punct" start_char="12034">(</TOKEN>
<TOKEN end_char="12039" id="token-75-30" morph="none" pos="word" start_char="12035">NIAID</TOKEN>
<TOKEN end_char="12040" id="token-75-31" morph="none" pos="punct" start_char="12040">)</TOKEN>
<TOKEN end_char="12048" id="token-75-32" morph="none" pos="word" start_char="12042">Vaccine</TOKEN>
<TOKEN end_char="12057" id="token-75-33" morph="none" pos="word" start_char="12050">Research</TOKEN>
<TOKEN end_char="12064" id="token-75-34" morph="none" pos="word" start_char="12059">Center</TOKEN>
<TOKEN end_char="12065" id="token-75-35" morph="none" pos="punct" start_char="12065">.</TOKEN>
</SEG>
<SEG end_char="12174" id="segment-76" start_char="12067">
<ORIGINAL_TEXT>It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="12068" id="token-76-0" morph="none" pos="word" start_char="12067">It</TOKEN>
<TOKEN end_char="12072" id="token-76-1" morph="none" pos="word" start_char="12070">was</TOKEN>
<TOKEN end_char="12083" id="token-76-2" morph="none" pos="word" start_char="12074">identified</TOKEN>
<TOKEN end_char="12088" id="token-76-3" morph="none" pos="word" start_char="12085">from</TOKEN>
<TOKEN end_char="12090" id="token-76-4" morph="none" pos="word" start_char="12090">a</TOKEN>
<TOKEN end_char="12096" id="token-76-5" morph="none" pos="word" start_char="12092">blood</TOKEN>
<TOKEN end_char="12103" id="token-76-6" morph="none" pos="word" start_char="12098">sample</TOKEN>
<TOKEN end_char="12109" id="token-76-7" morph="none" pos="word" start_char="12105">taken</TOKEN>
<TOKEN end_char="12114" id="token-76-8" morph="none" pos="word" start_char="12111">from</TOKEN>
<TOKEN end_char="12118" id="token-76-9" morph="none" pos="word" start_char="12116">one</TOKEN>
<TOKEN end_char="12121" id="token-76-10" morph="none" pos="word" start_char="12120">of</TOKEN>
<TOKEN end_char="12125" id="token-76-11" morph="none" pos="word" start_char="12123">the</TOKEN>
<TOKEN end_char="12131" id="token-76-12" morph="none" pos="word" start_char="12127">first</TOKEN>
<TOKEN end_char="12135" id="token-76-13" morph="none" pos="unknown" start_char="12133">U.S</TOKEN>
<TOKEN end_char="12136" id="token-76-14" morph="none" pos="punct" start_char="12136">.</TOKEN>
<TOKEN end_char="12145" id="token-76-15" morph="none" pos="word" start_char="12138">patients</TOKEN>
<TOKEN end_char="12149" id="token-76-16" morph="none" pos="word" start_char="12147">who</TOKEN>
<TOKEN end_char="12159" id="token-76-17" morph="none" pos="word" start_char="12151">recovered</TOKEN>
<TOKEN end_char="12164" id="token-76-18" morph="none" pos="word" start_char="12161">from</TOKEN>
<TOKEN end_char="12173" id="token-76-19" morph="none" pos="unknown" start_char="12166">COVID-19</TOKEN>
<TOKEN end_char="12174" id="token-76-20" morph="none" pos="punct" start_char="12174">.</TOKEN>
</SEG>
<SEG end_char="12294" id="segment-77" start_char="12177">
<ORIGINAL_TEXT>Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628).</ORIGINAL_TEXT>
<TOKEN end_char="12181" id="token-77-0" morph="none" pos="word" start_char="12177">Lilly</TOKEN>
<TOKEN end_char="12185" id="token-77-1" morph="none" pos="word" start_char="12183">has</TOKEN>
<TOKEN end_char="12198" id="token-77-2" morph="none" pos="word" start_char="12187">successfully</TOKEN>
<TOKEN end_char="12208" id="token-77-3" morph="none" pos="word" start_char="12200">completed</TOKEN>
<TOKEN end_char="12210" id="token-77-4" morph="none" pos="word" start_char="12210">a</TOKEN>
<TOKEN end_char="12216" id="token-77-5" morph="none" pos="word" start_char="12212">Phase</TOKEN>
<TOKEN end_char="12218" id="token-77-6" morph="none" pos="word" start_char="12218">1</TOKEN>
<TOKEN end_char="12224" id="token-77-7" morph="none" pos="word" start_char="12220">study</TOKEN>
<TOKEN end_char="12227" id="token-77-8" morph="none" pos="word" start_char="12226">of</TOKEN>
<TOKEN end_char="12240" id="token-77-9" morph="none" pos="word" start_char="12229">bamlanivimab</TOKEN>
<TOKEN end_char="12243" id="token-77-10" morph="none" pos="word" start_char="12242">in</TOKEN>
<TOKEN end_char="12256" id="token-77-11" morph="none" pos="word" start_char="12245">hospitalized</TOKEN>
<TOKEN end_char="12265" id="token-77-12" morph="none" pos="word" start_char="12258">patients</TOKEN>
<TOKEN end_char="12270" id="token-77-13" morph="none" pos="word" start_char="12267">with</TOKEN>
<TOKEN end_char="12279" id="token-77-14" morph="none" pos="unknown" start_char="12272">COVID-19</TOKEN>
<TOKEN end_char="12281" id="token-77-15" morph="none" pos="punct" start_char="12281">(</TOKEN>
<TOKEN end_char="12292" id="token-77-16" morph="none" pos="word" start_char="12282">NCT04411628</TOKEN>
<TOKEN end_char="12294" id="token-77-17" morph="none" pos="punct" start_char="12293">).</TOKEN>
</SEG>
<SEG end_char="12416" id="segment-78" start_char="12296">
<ORIGINAL_TEXT>A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing.</ORIGINAL_TEXT>
<TOKEN end_char="12296" id="token-78-0" morph="none" pos="word" start_char="12296">A</TOKEN>
<TOKEN end_char="12302" id="token-78-1" morph="none" pos="word" start_char="12298">Phase</TOKEN>
<TOKEN end_char="12306" id="token-78-2" morph="none" pos="unknown" start_char="12304">2/3</TOKEN>
<TOKEN end_char="12312" id="token-78-3" morph="none" pos="word" start_char="12308">study</TOKEN>
<TOKEN end_char="12315" id="token-78-4" morph="none" pos="word" start_char="12314">in</TOKEN>
<TOKEN end_char="12322" id="token-78-5" morph="none" pos="word" start_char="12317">people</TOKEN>
<TOKEN end_char="12331" id="token-78-6" morph="none" pos="word" start_char="12324">recently</TOKEN>
<TOKEN end_char="12341" id="token-78-7" morph="none" pos="word" start_char="12333">diagnosed</TOKEN>
<TOKEN end_char="12346" id="token-78-8" morph="none" pos="word" start_char="12343">with</TOKEN>
<TOKEN end_char="12355" id="token-78-9" morph="none" pos="unknown" start_char="12348">COVID-19</TOKEN>
<TOKEN end_char="12358" id="token-78-10" morph="none" pos="word" start_char="12357">in</TOKEN>
<TOKEN end_char="12362" id="token-78-11" morph="none" pos="word" start_char="12360">the</TOKEN>
<TOKEN end_char="12373" id="token-78-12" morph="none" pos="word" start_char="12364">ambulatory</TOKEN>
<TOKEN end_char="12381" id="token-78-13" morph="none" pos="word" start_char="12375">setting</TOKEN>
<TOKEN end_char="12383" id="token-78-14" morph="none" pos="punct" start_char="12383">(</TOKEN>
<TOKEN end_char="12390" id="token-78-15" morph="none" pos="unknown" start_char="12384">BLAZE-1</TOKEN>
<TOKEN end_char="12391" id="token-78-16" morph="none" pos="punct" start_char="12391">,</TOKEN>
<TOKEN end_char="12403" id="token-78-17" morph="none" pos="word" start_char="12393">NCT04427501</TOKEN>
<TOKEN end_char="12404" id="token-78-18" morph="none" pos="punct" start_char="12404">)</TOKEN>
<TOKEN end_char="12407" id="token-78-19" morph="none" pos="word" start_char="12406">is</TOKEN>
<TOKEN end_char="12415" id="token-78-20" morph="none" pos="word" start_char="12409">ongoing</TOKEN>
<TOKEN end_char="12416" id="token-78-21" morph="none" pos="punct" start_char="12416">.</TOKEN>
</SEG>
<SEG end_char="12586" id="segment-79" start_char="12418">
<ORIGINAL_TEXT>A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.</ORIGINAL_TEXT>
<TOKEN end_char="12418" id="token-79-0" morph="none" pos="word" start_char="12418">A</TOKEN>
<TOKEN end_char="12424" id="token-79-1" morph="none" pos="word" start_char="12420">Phase</TOKEN>
<TOKEN end_char="12426" id="token-79-2" morph="none" pos="word" start_char="12426">3</TOKEN>
<TOKEN end_char="12432" id="token-79-3" morph="none" pos="word" start_char="12428">study</TOKEN>
<TOKEN end_char="12435" id="token-79-4" morph="none" pos="word" start_char="12434">of</TOKEN>
<TOKEN end_char="12448" id="token-79-5" morph="none" pos="word" start_char="12437">bamlanivimab</TOKEN>
<TOKEN end_char="12454" id="token-79-6" morph="none" pos="word" start_char="12450">alone</TOKEN>
<TOKEN end_char="12457" id="token-79-7" morph="none" pos="word" start_char="12456">or</TOKEN>
<TOKEN end_char="12470" id="token-79-8" morph="none" pos="word" start_char="12459">bamlanivimab</TOKEN>
<TOKEN end_char="12474" id="token-79-9" morph="none" pos="word" start_char="12472">and</TOKEN>
<TOKEN end_char="12485" id="token-79-10" morph="none" pos="word" start_char="12476">etesevimab</TOKEN>
<TOKEN end_char="12494" id="token-79-11" morph="none" pos="word" start_char="12487">together</TOKEN>
<TOKEN end_char="12497" id="token-79-12" morph="none" pos="word" start_char="12496">in</TOKEN>
<TOKEN end_char="12507" id="token-79-13" morph="none" pos="word" start_char="12499">residents</TOKEN>
<TOKEN end_char="12511" id="token-79-14" morph="none" pos="word" start_char="12509">and</TOKEN>
<TOKEN end_char="12517" id="token-79-15" morph="none" pos="word" start_char="12513">staff</TOKEN>
<TOKEN end_char="12520" id="token-79-16" morph="none" pos="word" start_char="12519">at</TOKEN>
<TOKEN end_char="12530" id="token-79-17" morph="none" pos="unknown" start_char="12522">long-term</TOKEN>
<TOKEN end_char="12535" id="token-79-18" morph="none" pos="word" start_char="12532">care</TOKEN>
<TOKEN end_char="12546" id="token-79-19" morph="none" pos="word" start_char="12537">facilities</TOKEN>
<TOKEN end_char="12548" id="token-79-20" morph="none" pos="punct" start_char="12548">(</TOKEN>
<TOKEN end_char="12555" id="token-79-21" morph="none" pos="unknown" start_char="12549">BLAZE-2</TOKEN>
<TOKEN end_char="12556" id="token-79-22" morph="none" pos="punct" start_char="12556">,</TOKEN>
<TOKEN end_char="12568" id="token-79-23" morph="none" pos="word" start_char="12558">NCT04497987</TOKEN>
<TOKEN end_char="12569" id="token-79-24" morph="none" pos="punct" start_char="12569">)</TOKEN>
<TOKEN end_char="12572" id="token-79-25" morph="none" pos="word" start_char="12571">is</TOKEN>
<TOKEN end_char="12577" id="token-79-26" morph="none" pos="word" start_char="12574">also</TOKEN>
<TOKEN end_char="12585" id="token-79-27" morph="none" pos="word" start_char="12579">ongoing</TOKEN>
<TOKEN end_char="12586" id="token-79-28" morph="none" pos="punct" start_char="12586">.</TOKEN>
</SEG>
<SEG end_char="12716" id="segment-80" start_char="12588">
<ORIGINAL_TEXT>In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.</ORIGINAL_TEXT>
<TOKEN end_char="12589" id="token-80-0" morph="none" pos="word" start_char="12588">In</TOKEN>
<TOKEN end_char="12598" id="token-80-1" morph="none" pos="word" start_char="12591">addition</TOKEN>
<TOKEN end_char="12599" id="token-80-2" morph="none" pos="punct" start_char="12599">,</TOKEN>
<TOKEN end_char="12612" id="token-80-3" morph="none" pos="word" start_char="12601">bamlanivimab</TOKEN>
<TOKEN end_char="12615" id="token-80-4" morph="none" pos="word" start_char="12614">is</TOKEN>
<TOKEN end_char="12621" id="token-80-5" morph="none" pos="word" start_char="12617">being</TOKEN>
<TOKEN end_char="12628" id="token-80-6" morph="none" pos="word" start_char="12623">tested</TOKEN>
<TOKEN end_char="12631" id="token-80-7" morph="none" pos="word" start_char="12630">in</TOKEN>
<TOKEN end_char="12635" id="token-80-8" morph="none" pos="word" start_char="12633">the</TOKEN>
<TOKEN end_char="12644" id="token-80-9" morph="none" pos="word" start_char="12637">National</TOKEN>
<TOKEN end_char="12655" id="token-80-10" morph="none" pos="word" start_char="12646">Institutes</TOKEN>
<TOKEN end_char="12658" id="token-80-11" morph="none" pos="word" start_char="12657">of</TOKEN>
<TOKEN end_char="12669" id="token-80-12" morph="none" pos="unknown" start_char="12660">Health-led</TOKEN>
<TOKEN end_char="12677" id="token-80-13" morph="none" pos="unknown" start_char="12671">ACTIV-2</TOKEN>
<TOKEN end_char="12683" id="token-80-14" morph="none" pos="word" start_char="12679">study</TOKEN>
<TOKEN end_char="12686" id="token-80-15" morph="none" pos="word" start_char="12685">in</TOKEN>
<TOKEN end_char="12697" id="token-80-16" morph="none" pos="word" start_char="12688">ambulatory</TOKEN>
<TOKEN end_char="12706" id="token-80-17" morph="none" pos="unknown" start_char="12699">COVID-19</TOKEN>
<TOKEN end_char="12715" id="token-80-18" morph="none" pos="word" start_char="12708">patients</TOKEN>
<TOKEN end_char="12716" id="token-80-19" morph="none" pos="punct" start_char="12716">.</TOKEN>
</SEG>
<SEG end_char="13028" id="segment-81" start_char="12719">
<ORIGINAL_TEXT>About etesevimab Etesevimab (LY-CoV016, also known as JS016) is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor.</ORIGINAL_TEXT>
<TOKEN end_char="12723" id="token-81-0" morph="none" pos="word" start_char="12719">About</TOKEN>
<TOKEN end_char="12734" id="token-81-1" morph="none" pos="word" start_char="12725">etesevimab</TOKEN>
<TOKEN end_char="12745" id="token-81-2" morph="none" pos="word" start_char="12736">Etesevimab</TOKEN>
<TOKEN end_char="12747" id="token-81-3" morph="none" pos="punct" start_char="12747">(</TOKEN>
<TOKEN end_char="12756" id="token-81-4" morph="none" pos="unknown" start_char="12748">LY-CoV016</TOKEN>
<TOKEN end_char="12757" id="token-81-5" morph="none" pos="punct" start_char="12757">,</TOKEN>
<TOKEN end_char="12762" id="token-81-6" morph="none" pos="word" start_char="12759">also</TOKEN>
<TOKEN end_char="12768" id="token-81-7" morph="none" pos="word" start_char="12764">known</TOKEN>
<TOKEN end_char="12771" id="token-81-8" morph="none" pos="word" start_char="12770">as</TOKEN>
<TOKEN end_char="12777" id="token-81-9" morph="none" pos="word" start_char="12773">JS016</TOKEN>
<TOKEN end_char="12778" id="token-81-10" morph="none" pos="punct" start_char="12778">)</TOKEN>
<TOKEN end_char="12781" id="token-81-11" morph="none" pos="word" start_char="12780">is</TOKEN>
<TOKEN end_char="12783" id="token-81-12" morph="none" pos="word" start_char="12783">a</TOKEN>
<TOKEN end_char="12795" id="token-81-13" morph="none" pos="word" start_char="12785">recombinant</TOKEN>
<TOKEN end_char="12801" id="token-81-14" morph="none" pos="word" start_char="12797">fully</TOKEN>
<TOKEN end_char="12807" id="token-81-15" morph="none" pos="word" start_char="12803">human</TOKEN>
<TOKEN end_char="12818" id="token-81-16" morph="none" pos="word" start_char="12809">monoclonal</TOKEN>
<TOKEN end_char="12831" id="token-81-17" morph="none" pos="word" start_char="12820">neutralizing</TOKEN>
<TOKEN end_char="12840" id="token-81-18" morph="none" pos="word" start_char="12833">antibody</TOKEN>
<TOKEN end_char="12841" id="token-81-19" morph="none" pos="punct" start_char="12841">,</TOKEN>
<TOKEN end_char="12847" id="token-81-20" morph="none" pos="word" start_char="12843">which</TOKEN>
<TOKEN end_char="12860" id="token-81-21" morph="none" pos="word" start_char="12849">specifically</TOKEN>
<TOKEN end_char="12866" id="token-81-22" morph="none" pos="word" start_char="12862">binds</TOKEN>
<TOKEN end_char="12869" id="token-81-23" morph="none" pos="word" start_char="12868">to</TOKEN>
<TOKEN end_char="12873" id="token-81-24" morph="none" pos="word" start_char="12871">the</TOKEN>
<TOKEN end_char="12884" id="token-81-25" morph="none" pos="unknown" start_char="12875">SARS-CoV-2</TOKEN>
<TOKEN end_char="12892" id="token-81-26" morph="none" pos="word" start_char="12886">surface</TOKEN>
<TOKEN end_char="12898" id="token-81-27" morph="none" pos="word" start_char="12894">spike</TOKEN>
<TOKEN end_char="12906" id="token-81-28" morph="none" pos="word" start_char="12900">protein</TOKEN>
<TOKEN end_char="12915" id="token-81-29" morph="none" pos="word" start_char="12908">receptor</TOKEN>
<TOKEN end_char="12923" id="token-81-30" morph="none" pos="word" start_char="12917">binding</TOKEN>
<TOKEN end_char="12930" id="token-81-31" morph="none" pos="word" start_char="12925">domain</TOKEN>
<TOKEN end_char="12935" id="token-81-32" morph="none" pos="word" start_char="12932">with</TOKEN>
<TOKEN end_char="12940" id="token-81-33" morph="none" pos="word" start_char="12937">high</TOKEN>
<TOKEN end_char="12949" id="token-81-34" morph="none" pos="word" start_char="12942">affinity</TOKEN>
<TOKEN end_char="12953" id="token-81-35" morph="none" pos="word" start_char="12951">and</TOKEN>
<TOKEN end_char="12957" id="token-81-36" morph="none" pos="word" start_char="12955">can</TOKEN>
<TOKEN end_char="12963" id="token-81-37" morph="none" pos="word" start_char="12959">block</TOKEN>
<TOKEN end_char="12967" id="token-81-38" morph="none" pos="word" start_char="12965">the</TOKEN>
<TOKEN end_char="12975" id="token-81-39" morph="none" pos="word" start_char="12969">binding</TOKEN>
<TOKEN end_char="12978" id="token-81-40" morph="none" pos="word" start_char="12977">of</TOKEN>
<TOKEN end_char="12982" id="token-81-41" morph="none" pos="word" start_char="12980">the</TOKEN>
<TOKEN end_char="12988" id="token-81-42" morph="none" pos="word" start_char="12984">virus</TOKEN>
<TOKEN end_char="12991" id="token-81-43" morph="none" pos="word" start_char="12990">to</TOKEN>
<TOKEN end_char="12995" id="token-81-44" morph="none" pos="word" start_char="12993">the</TOKEN>
<TOKEN end_char="13000" id="token-81-45" morph="none" pos="word" start_char="12997">ACE2</TOKEN>
<TOKEN end_char="13005" id="token-81-46" morph="none" pos="word" start_char="13002">host</TOKEN>
<TOKEN end_char="13010" id="token-81-47" morph="none" pos="word" start_char="13007">cell</TOKEN>
<TOKEN end_char="13018" id="token-81-48" morph="none" pos="word" start_char="13012">surface</TOKEN>
<TOKEN end_char="13027" id="token-81-49" morph="none" pos="word" start_char="13020">receptor</TOKEN>
<TOKEN end_char="13028" id="token-81-50" morph="none" pos="punct" start_char="13028">.</TOKEN>
</SEG>
<SEG end_char="13127" id="segment-82" start_char="13030">
<ORIGINAL_TEXT>Point mutations were introduced into the native human IgG1 antibody to mitigate effector function.</ORIGINAL_TEXT>
<TOKEN end_char="13034" id="token-82-0" morph="none" pos="word" start_char="13030">Point</TOKEN>
<TOKEN end_char="13044" id="token-82-1" morph="none" pos="word" start_char="13036">mutations</TOKEN>
<TOKEN end_char="13049" id="token-82-2" morph="none" pos="word" start_char="13046">were</TOKEN>
<TOKEN end_char="13060" id="token-82-3" morph="none" pos="word" start_char="13051">introduced</TOKEN>
<TOKEN end_char="13065" id="token-82-4" morph="none" pos="word" start_char="13062">into</TOKEN>
<TOKEN end_char="13069" id="token-82-5" morph="none" pos="word" start_char="13067">the</TOKEN>
<TOKEN end_char="13076" id="token-82-6" morph="none" pos="word" start_char="13071">native</TOKEN>
<TOKEN end_char="13082" id="token-82-7" morph="none" pos="word" start_char="13078">human</TOKEN>
<TOKEN end_char="13087" id="token-82-8" morph="none" pos="word" start_char="13084">IgG1</TOKEN>
<TOKEN end_char="13096" id="token-82-9" morph="none" pos="word" start_char="13089">antibody</TOKEN>
<TOKEN end_char="13099" id="token-82-10" morph="none" pos="word" start_char="13098">to</TOKEN>
<TOKEN end_char="13108" id="token-82-11" morph="none" pos="word" start_char="13101">mitigate</TOKEN>
<TOKEN end_char="13117" id="token-82-12" morph="none" pos="word" start_char="13110">effector</TOKEN>
<TOKEN end_char="13126" id="token-82-13" morph="none" pos="word" start_char="13119">function</TOKEN>
<TOKEN end_char="13127" id="token-82-14" morph="none" pos="punct" start_char="13127">.</TOKEN>
</SEG>
<SEG end_char="13301" id="segment-83" start_char="13129">
<ORIGINAL_TEXT>Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology, Chinese Academy of Science (IMCAS).</ORIGINAL_TEXT>
<TOKEN end_char="13133" id="token-83-0" morph="none" pos="word" start_char="13129">Lilly</TOKEN>
<TOKEN end_char="13142" id="token-83-1" morph="none" pos="word" start_char="13135">licensed</TOKEN>
<TOKEN end_char="13153" id="token-83-2" morph="none" pos="word" start_char="13144">etesevimab</TOKEN>
<TOKEN end_char="13158" id="token-83-3" morph="none" pos="word" start_char="13155">from</TOKEN>
<TOKEN end_char="13165" id="token-83-4" morph="none" pos="word" start_char="13160">Junshi</TOKEN>
<TOKEN end_char="13177" id="token-83-5" morph="none" pos="word" start_char="13167">Biosciences</TOKEN>
<TOKEN end_char="13183" id="token-83-6" morph="none" pos="word" start_char="13179">after</TOKEN>
<TOKEN end_char="13186" id="token-83-7" morph="none" pos="word" start_char="13185">it</TOKEN>
<TOKEN end_char="13190" id="token-83-8" morph="none" pos="word" start_char="13188">was</TOKEN>
<TOKEN end_char="13198" id="token-83-9" morph="none" pos="word" start_char="13192">jointly</TOKEN>
<TOKEN end_char="13208" id="token-83-10" morph="none" pos="word" start_char="13200">developed</TOKEN>
<TOKEN end_char="13211" id="token-83-11" morph="none" pos="word" start_char="13210">by</TOKEN>
<TOKEN end_char="13218" id="token-83-12" morph="none" pos="word" start_char="13213">Junshi</TOKEN>
<TOKEN end_char="13230" id="token-83-13" morph="none" pos="word" start_char="13220">Biosciences</TOKEN>
<TOKEN end_char="13234" id="token-83-14" morph="none" pos="word" start_char="13232">and</TOKEN>
<TOKEN end_char="13238" id="token-83-15" morph="none" pos="word" start_char="13236">the</TOKEN>
<TOKEN end_char="13248" id="token-83-16" morph="none" pos="word" start_char="13240">Institute</TOKEN>
<TOKEN end_char="13251" id="token-83-17" morph="none" pos="word" start_char="13250">of</TOKEN>
<TOKEN end_char="13264" id="token-83-18" morph="none" pos="word" start_char="13253">Microbiology</TOKEN>
<TOKEN end_char="13265" id="token-83-19" morph="none" pos="punct" start_char="13265">,</TOKEN>
<TOKEN end_char="13273" id="token-83-20" morph="none" pos="word" start_char="13267">Chinese</TOKEN>
<TOKEN end_char="13281" id="token-83-21" morph="none" pos="word" start_char="13275">Academy</TOKEN>
<TOKEN end_char="13284" id="token-83-22" morph="none" pos="word" start_char="13283">of</TOKEN>
<TOKEN end_char="13292" id="token-83-23" morph="none" pos="word" start_char="13286">Science</TOKEN>
<TOKEN end_char="13294" id="token-83-24" morph="none" pos="punct" start_char="13294">(</TOKEN>
<TOKEN end_char="13299" id="token-83-25" morph="none" pos="word" start_char="13295">IMCAS</TOKEN>
<TOKEN end_char="13301" id="token-83-26" morph="none" pos="punct" start_char="13300">).</TOKEN>
</SEG>
<SEG end_char="13412" id="segment-84" start_char="13303">
<ORIGINAL_TEXT>Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world.</ORIGINAL_TEXT>
<TOKEN end_char="13308" id="token-84-0" morph="none" pos="word" start_char="13303">Junshi</TOKEN>
<TOKEN end_char="13320" id="token-84-1" morph="none" pos="word" start_char="13310">Biosciences</TOKEN>
<TOKEN end_char="13326" id="token-84-2" morph="none" pos="word" start_char="13322">leads</TOKEN>
<TOKEN end_char="13338" id="token-84-3" morph="none" pos="word" start_char="13328">development</TOKEN>
<TOKEN end_char="13341" id="token-84-4" morph="none" pos="word" start_char="13340">in</TOKEN>
<TOKEN end_char="13349" id="token-84-5" morph="none" pos="word" start_char="13343">Greater</TOKEN>
<TOKEN end_char="13355" id="token-84-6" morph="none" pos="word" start_char="13351">China</TOKEN>
<TOKEN end_char="13356" id="token-84-7" morph="none" pos="punct" start_char="13356">,</TOKEN>
<TOKEN end_char="13362" id="token-84-8" morph="none" pos="word" start_char="13358">while</TOKEN>
<TOKEN end_char="13368" id="token-84-9" morph="none" pos="word" start_char="13364">Lilly</TOKEN>
<TOKEN end_char="13374" id="token-84-10" morph="none" pos="word" start_char="13370">leads</TOKEN>
<TOKEN end_char="13386" id="token-84-11" morph="none" pos="word" start_char="13376">development</TOKEN>
<TOKEN end_char="13389" id="token-84-12" morph="none" pos="word" start_char="13388">in</TOKEN>
<TOKEN end_char="13393" id="token-84-13" morph="none" pos="word" start_char="13391">the</TOKEN>
<TOKEN end_char="13398" id="token-84-14" morph="none" pos="word" start_char="13395">rest</TOKEN>
<TOKEN end_char="13401" id="token-84-15" morph="none" pos="word" start_char="13400">of</TOKEN>
<TOKEN end_char="13405" id="token-84-16" morph="none" pos="word" start_char="13403">the</TOKEN>
<TOKEN end_char="13411" id="token-84-17" morph="none" pos="word" start_char="13407">world</TOKEN>
<TOKEN end_char="13412" id="token-84-18" morph="none" pos="punct" start_char="13412">.</TOKEN>
</SEG>
<SEG end_char="13592" id="segment-85" start_char="13415">
<ORIGINAL_TEXT>Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.</ORIGINAL_TEXT>
<TOKEN end_char="13419" id="token-85-0" morph="none" pos="word" start_char="13415">Lilly</TOKEN>
<TOKEN end_char="13423" id="token-85-1" morph="none" pos="word" start_char="13421">has</TOKEN>
<TOKEN end_char="13436" id="token-85-2" morph="none" pos="word" start_char="13425">successfully</TOKEN>
<TOKEN end_char="13446" id="token-85-3" morph="none" pos="word" start_char="13438">completed</TOKEN>
<TOKEN end_char="13448" id="token-85-4" morph="none" pos="word" start_char="13448">a</TOKEN>
<TOKEN end_char="13454" id="token-85-5" morph="none" pos="word" start_char="13450">Phase</TOKEN>
<TOKEN end_char="13456" id="token-85-6" morph="none" pos="word" start_char="13456">1</TOKEN>
<TOKEN end_char="13462" id="token-85-7" morph="none" pos="word" start_char="13458">study</TOKEN>
<TOKEN end_char="13464" id="token-85-8" morph="none" pos="punct" start_char="13464">(</TOKEN>
<TOKEN end_char="13475" id="token-85-9" morph="none" pos="word" start_char="13465">NCT04441931</TOKEN>
<TOKEN end_char="13476" id="token-85-10" morph="none" pos="punct" start_char="13476">)</TOKEN>
<TOKEN end_char="13479" id="token-85-11" morph="none" pos="word" start_char="13478">of</TOKEN>
<TOKEN end_char="13490" id="token-85-12" morph="none" pos="word" start_char="13481">etesevimab</TOKEN>
<TOKEN end_char="13493" id="token-85-13" morph="none" pos="word" start_char="13492">in</TOKEN>
<TOKEN end_char="13501" id="token-85-14" morph="none" pos="word" start_char="13495">healthy</TOKEN>
<TOKEN end_char="13505" id="token-85-15" morph="none" pos="unknown" start_char="13503">U.S</TOKEN>
<TOKEN end_char="13506" id="token-85-16" morph="none" pos="punct" start_char="13506">.</TOKEN>
<TOKEN end_char="13517" id="token-85-17" morph="none" pos="word" start_char="13508">volunteers</TOKEN>
<TOKEN end_char="13520" id="token-85-18" morph="none" pos="word" start_char="13519">to</TOKEN>
<TOKEN end_char="13529" id="token-85-19" morph="none" pos="word" start_char="13522">evaluate</TOKEN>
<TOKEN end_char="13533" id="token-85-20" morph="none" pos="word" start_char="13531">the</TOKEN>
<TOKEN end_char="13540" id="token-85-21" morph="none" pos="word" start_char="13535">safety</TOKEN>
<TOKEN end_char="13541" id="token-85-22" morph="none" pos="punct" start_char="13541">,</TOKEN>
<TOKEN end_char="13554" id="token-85-23" morph="none" pos="word" start_char="13543">tolerability</TOKEN>
<TOKEN end_char="13555" id="token-85-24" morph="none" pos="punct" start_char="13555">,</TOKEN>
<TOKEN end_char="13572" id="token-85-25" morph="none" pos="word" start_char="13557">pharmacokinetics</TOKEN>
<TOKEN end_char="13576" id="token-85-26" morph="none" pos="word" start_char="13574">and</TOKEN>
<TOKEN end_char="13591" id="token-85-27" morph="none" pos="word" start_char="13578">immunogenicity</TOKEN>
<TOKEN end_char="13592" id="token-85-28" morph="none" pos="punct" start_char="13592">.</TOKEN>
</SEG>
<SEG end_char="13714" id="segment-86" start_char="13594">
<ORIGINAL_TEXT>A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing.</ORIGINAL_TEXT>
<TOKEN end_char="13594" id="token-86-0" morph="none" pos="word" start_char="13594">A</TOKEN>
<TOKEN end_char="13600" id="token-86-1" morph="none" pos="word" start_char="13596">Phase</TOKEN>
<TOKEN end_char="13604" id="token-86-2" morph="none" pos="unknown" start_char="13602">2/3</TOKEN>
<TOKEN end_char="13610" id="token-86-3" morph="none" pos="word" start_char="13606">study</TOKEN>
<TOKEN end_char="13613" id="token-86-4" morph="none" pos="word" start_char="13612">in</TOKEN>
<TOKEN end_char="13620" id="token-86-5" morph="none" pos="word" start_char="13615">people</TOKEN>
<TOKEN end_char="13629" id="token-86-6" morph="none" pos="word" start_char="13622">recently</TOKEN>
<TOKEN end_char="13639" id="token-86-7" morph="none" pos="word" start_char="13631">diagnosed</TOKEN>
<TOKEN end_char="13644" id="token-86-8" morph="none" pos="word" start_char="13641">with</TOKEN>
<TOKEN end_char="13653" id="token-86-9" morph="none" pos="unknown" start_char="13646">COVID-19</TOKEN>
<TOKEN end_char="13656" id="token-86-10" morph="none" pos="word" start_char="13655">in</TOKEN>
<TOKEN end_char="13660" id="token-86-11" morph="none" pos="word" start_char="13658">the</TOKEN>
<TOKEN end_char="13671" id="token-86-12" morph="none" pos="word" start_char="13662">ambulatory</TOKEN>
<TOKEN end_char="13679" id="token-86-13" morph="none" pos="word" start_char="13673">setting</TOKEN>
<TOKEN end_char="13681" id="token-86-14" morph="none" pos="punct" start_char="13681">(</TOKEN>
<TOKEN end_char="13688" id="token-86-15" morph="none" pos="unknown" start_char="13682">BLAZE-1</TOKEN>
<TOKEN end_char="13689" id="token-86-16" morph="none" pos="punct" start_char="13689">,</TOKEN>
<TOKEN end_char="13701" id="token-86-17" morph="none" pos="word" start_char="13691">NCT04427501</TOKEN>
<TOKEN end_char="13702" id="token-86-18" morph="none" pos="punct" start_char="13702">)</TOKEN>
<TOKEN end_char="13705" id="token-86-19" morph="none" pos="word" start_char="13704">is</TOKEN>
<TOKEN end_char="13713" id="token-86-20" morph="none" pos="word" start_char="13707">ongoing</TOKEN>
<TOKEN end_char="13714" id="token-86-21" morph="none" pos="punct" start_char="13714">.</TOKEN>
</SEG>
<SEG end_char="13869" id="segment-87" start_char="13716">
<ORIGINAL_TEXT>Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally.</ORIGINAL_TEXT>
<TOKEN end_char="13721" id="token-87-0" morph="none" pos="word" start_char="13716">Junshi</TOKEN>
<TOKEN end_char="13733" id="token-87-1" morph="none" pos="word" start_char="13723">Biosciences</TOKEN>
<TOKEN end_char="13737" id="token-87-2" morph="none" pos="word" start_char="13735">has</TOKEN>
<TOKEN end_char="13747" id="token-87-3" morph="none" pos="word" start_char="13739">completed</TOKEN>
<TOKEN end_char="13749" id="token-87-4" morph="none" pos="word" start_char="13749">a</TOKEN>
<TOKEN end_char="13757" id="token-87-5" morph="none" pos="word" start_char="13751">similar</TOKEN>
<TOKEN end_char="13763" id="token-87-6" morph="none" pos="word" start_char="13759">Phase</TOKEN>
<TOKEN end_char="13765" id="token-87-7" morph="none" pos="word" start_char="13765">1</TOKEN>
<TOKEN end_char="13771" id="token-87-8" morph="none" pos="word" start_char="13767">study</TOKEN>
<TOKEN end_char="13774" id="token-87-9" morph="none" pos="word" start_char="13773">in</TOKEN>
<TOKEN end_char="13782" id="token-87-10" morph="none" pos="word" start_char="13776">healthy</TOKEN>
<TOKEN end_char="13793" id="token-87-11" morph="none" pos="word" start_char="13784">volunteers</TOKEN>
<TOKEN end_char="13796" id="token-87-12" morph="none" pos="word" start_char="13795">in</TOKEN>
<TOKEN end_char="13802" id="token-87-13" morph="none" pos="word" start_char="13798">China</TOKEN>
<TOKEN end_char="13806" id="token-87-14" morph="none" pos="word" start_char="13804">and</TOKEN>
<TOKEN end_char="13810" id="token-87-15" morph="none" pos="word" start_char="13808">has</TOKEN>
<TOKEN end_char="13820" id="token-87-16" morph="none" pos="word" start_char="13812">initiated</TOKEN>
<TOKEN end_char="13826" id="token-87-17" morph="none" pos="word" start_char="13822">Phase</TOKEN>
<TOKEN end_char="13831" id="token-87-18" morph="none" pos="unknown" start_char="13828">1b/2</TOKEN>
<TOKEN end_char="13838" id="token-87-19" morph="none" pos="word" start_char="13833">trials</TOKEN>
<TOKEN end_char="13841" id="token-87-20" morph="none" pos="word" start_char="13840">in</TOKEN>
<TOKEN end_char="13850" id="token-87-21" morph="none" pos="unknown" start_char="13843">COVID-19</TOKEN>
<TOKEN end_char="13859" id="token-87-22" morph="none" pos="word" start_char="13852">patients</TOKEN>
<TOKEN end_char="13868" id="token-87-23" morph="none" pos="word" start_char="13861">globally</TOKEN>
<TOKEN end_char="13869" id="token-87-24" morph="none" pos="punct" start_char="13869">.</TOKEN>
</SEG>
<SEG end_char="14146" id="segment-88" start_char="13872">
<ORIGINAL_TEXT>About BLAZE-1 BLAZE-1 (NCT04427501) is a randomized, double-blind, placebo-controlled Phase 2/3 study designed to assess the efficacy and safety of bamlanivimab alone or bamlanivimab and etesevimab together for the treatment of symptomatic COVID-19 in the outpatient setting.</ORIGINAL_TEXT>
<TOKEN end_char="13876" id="token-88-0" morph="none" pos="word" start_char="13872">About</TOKEN>
<TOKEN end_char="13884" id="token-88-1" morph="none" pos="unknown" start_char="13878">BLAZE-1</TOKEN>
<TOKEN end_char="13892" id="token-88-2" morph="none" pos="unknown" start_char="13886">BLAZE-1</TOKEN>
<TOKEN end_char="13894" id="token-88-3" morph="none" pos="punct" start_char="13894">(</TOKEN>
<TOKEN end_char="13905" id="token-88-4" morph="none" pos="word" start_char="13895">NCT04427501</TOKEN>
<TOKEN end_char="13906" id="token-88-5" morph="none" pos="punct" start_char="13906">)</TOKEN>
<TOKEN end_char="13909" id="token-88-6" morph="none" pos="word" start_char="13908">is</TOKEN>
<TOKEN end_char="13911" id="token-88-7" morph="none" pos="word" start_char="13911">a</TOKEN>
<TOKEN end_char="13922" id="token-88-8" morph="none" pos="word" start_char="13913">randomized</TOKEN>
<TOKEN end_char="13923" id="token-88-9" morph="none" pos="punct" start_char="13923">,</TOKEN>
<TOKEN end_char="13936" id="token-88-10" morph="none" pos="unknown" start_char="13925">double-blind</TOKEN>
<TOKEN end_char="13937" id="token-88-11" morph="none" pos="punct" start_char="13937">,</TOKEN>
<TOKEN end_char="13956" id="token-88-12" morph="none" pos="unknown" start_char="13939">placebo-controlled</TOKEN>
<TOKEN end_char="13962" id="token-88-13" morph="none" pos="word" start_char="13958">Phase</TOKEN>
<TOKEN end_char="13966" id="token-88-14" morph="none" pos="unknown" start_char="13964">2/3</TOKEN>
<TOKEN end_char="13972" id="token-88-15" morph="none" pos="word" start_char="13968">study</TOKEN>
<TOKEN end_char="13981" id="token-88-16" morph="none" pos="word" start_char="13974">designed</TOKEN>
<TOKEN end_char="13984" id="token-88-17" morph="none" pos="word" start_char="13983">to</TOKEN>
<TOKEN end_char="13991" id="token-88-18" morph="none" pos="word" start_char="13986">assess</TOKEN>
<TOKEN end_char="13995" id="token-88-19" morph="none" pos="word" start_char="13993">the</TOKEN>
<TOKEN end_char="14004" id="token-88-20" morph="none" pos="word" start_char="13997">efficacy</TOKEN>
<TOKEN end_char="14008" id="token-88-21" morph="none" pos="word" start_char="14006">and</TOKEN>
<TOKEN end_char="14015" id="token-88-22" morph="none" pos="word" start_char="14010">safety</TOKEN>
<TOKEN end_char="14018" id="token-88-23" morph="none" pos="word" start_char="14017">of</TOKEN>
<TOKEN end_char="14031" id="token-88-24" morph="none" pos="word" start_char="14020">bamlanivimab</TOKEN>
<TOKEN end_char="14037" id="token-88-25" morph="none" pos="word" start_char="14033">alone</TOKEN>
<TOKEN end_char="14040" id="token-88-26" morph="none" pos="word" start_char="14039">or</TOKEN>
<TOKEN end_char="14053" id="token-88-27" morph="none" pos="word" start_char="14042">bamlanivimab</TOKEN>
<TOKEN end_char="14057" id="token-88-28" morph="none" pos="word" start_char="14055">and</TOKEN>
<TOKEN end_char="14068" id="token-88-29" morph="none" pos="word" start_char="14059">etesevimab</TOKEN>
<TOKEN end_char="14077" id="token-88-30" morph="none" pos="word" start_char="14070">together</TOKEN>
<TOKEN end_char="14081" id="token-88-31" morph="none" pos="word" start_char="14079">for</TOKEN>
<TOKEN end_char="14085" id="token-88-32" morph="none" pos="word" start_char="14083">the</TOKEN>
<TOKEN end_char="14095" id="token-88-33" morph="none" pos="word" start_char="14087">treatment</TOKEN>
<TOKEN end_char="14098" id="token-88-34" morph="none" pos="word" start_char="14097">of</TOKEN>
<TOKEN end_char="14110" id="token-88-35" morph="none" pos="word" start_char="14100">symptomatic</TOKEN>
<TOKEN end_char="14119" id="token-88-36" morph="none" pos="unknown" start_char="14112">COVID-19</TOKEN>
<TOKEN end_char="14122" id="token-88-37" morph="none" pos="word" start_char="14121">in</TOKEN>
<TOKEN end_char="14126" id="token-88-38" morph="none" pos="word" start_char="14124">the</TOKEN>
<TOKEN end_char="14137" id="token-88-39" morph="none" pos="word" start_char="14128">outpatient</TOKEN>
<TOKEN end_char="14145" id="token-88-40" morph="none" pos="word" start_char="14139">setting</TOKEN>
<TOKEN end_char="14146" id="token-88-41" morph="none" pos="punct" start_char="14146">.</TOKEN>
</SEG>
<SEG end_char="14345" id="segment-89" start_char="14148">
<ORIGINAL_TEXT>To be eligible, patients were required to have mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than three days prior to drug infusion.</ORIGINAL_TEXT>
<TOKEN end_char="14149" id="token-89-0" morph="none" pos="word" start_char="14148">To</TOKEN>
<TOKEN end_char="14152" id="token-89-1" morph="none" pos="word" start_char="14151">be</TOKEN>
<TOKEN end_char="14161" id="token-89-2" morph="none" pos="word" start_char="14154">eligible</TOKEN>
<TOKEN end_char="14162" id="token-89-3" morph="none" pos="punct" start_char="14162">,</TOKEN>
<TOKEN end_char="14171" id="token-89-4" morph="none" pos="word" start_char="14164">patients</TOKEN>
<TOKEN end_char="14176" id="token-89-5" morph="none" pos="word" start_char="14173">were</TOKEN>
<TOKEN end_char="14185" id="token-89-6" morph="none" pos="word" start_char="14178">required</TOKEN>
<TOKEN end_char="14188" id="token-89-7" morph="none" pos="word" start_char="14187">to</TOKEN>
<TOKEN end_char="14193" id="token-89-8" morph="none" pos="word" start_char="14190">have</TOKEN>
<TOKEN end_char="14198" id="token-89-9" morph="none" pos="word" start_char="14195">mild</TOKEN>
<TOKEN end_char="14201" id="token-89-10" morph="none" pos="word" start_char="14200">or</TOKEN>
<TOKEN end_char="14210" id="token-89-11" morph="none" pos="word" start_char="14203">moderate</TOKEN>
<TOKEN end_char="14219" id="token-89-12" morph="none" pos="word" start_char="14212">symptoms</TOKEN>
<TOKEN end_char="14222" id="token-89-13" morph="none" pos="word" start_char="14221">of</TOKEN>
<TOKEN end_char="14231" id="token-89-14" morph="none" pos="unknown" start_char="14224">COVID-19</TOKEN>
<TOKEN end_char="14234" id="token-89-15" morph="none" pos="word" start_char="14233">as</TOKEN>
<TOKEN end_char="14239" id="token-89-16" morph="none" pos="word" start_char="14236">well</TOKEN>
<TOKEN end_char="14242" id="token-89-17" morph="none" pos="word" start_char="14241">as</TOKEN>
<TOKEN end_char="14244" id="token-89-18" morph="none" pos="word" start_char="14244">a</TOKEN>
<TOKEN end_char="14253" id="token-89-19" morph="none" pos="word" start_char="14246">positive</TOKEN>
<TOKEN end_char="14264" id="token-89-20" morph="none" pos="unknown" start_char="14255">SARS-CoV-2</TOKEN>
<TOKEN end_char="14269" id="token-89-21" morph="none" pos="word" start_char="14266">test</TOKEN>
<TOKEN end_char="14275" id="token-89-22" morph="none" pos="word" start_char="14271">based</TOKEN>
<TOKEN end_char="14278" id="token-89-23" morph="none" pos="word" start_char="14277">on</TOKEN>
<TOKEN end_char="14280" id="token-89-24" morph="none" pos="word" start_char="14280">a</TOKEN>
<TOKEN end_char="14287" id="token-89-25" morph="none" pos="word" start_char="14282">sample</TOKEN>
<TOKEN end_char="14297" id="token-89-26" morph="none" pos="word" start_char="14289">collected</TOKEN>
<TOKEN end_char="14300" id="token-89-27" morph="none" pos="word" start_char="14299">no</TOKEN>
<TOKEN end_char="14305" id="token-89-28" morph="none" pos="word" start_char="14302">more</TOKEN>
<TOKEN end_char="14310" id="token-89-29" morph="none" pos="word" start_char="14307">than</TOKEN>
<TOKEN end_char="14316" id="token-89-30" morph="none" pos="word" start_char="14312">three</TOKEN>
<TOKEN end_char="14321" id="token-89-31" morph="none" pos="word" start_char="14318">days</TOKEN>
<TOKEN end_char="14327" id="token-89-32" morph="none" pos="word" start_char="14323">prior</TOKEN>
<TOKEN end_char="14330" id="token-89-33" morph="none" pos="word" start_char="14329">to</TOKEN>
<TOKEN end_char="14335" id="token-89-34" morph="none" pos="word" start_char="14332">drug</TOKEN>
<TOKEN end_char="14344" id="token-89-35" morph="none" pos="word" start_char="14337">infusion</TOKEN>
<TOKEN end_char="14345" id="token-89-36" morph="none" pos="punct" start_char="14345">.</TOKEN>
</SEG>
<SEG end_char="14591" id="segment-90" start_char="14348">
<ORIGINAL_TEXT>In the Phase 2 portion of BLAZE-1, cohorts of mild to moderate recently diagnosed COVID-19 patients, were randomized to one of three doses of bamlanivimab (700 mg, 2800 mg, and 7000 mg), bamlanivimab 2800 mg plus etesevimab 2800 mg, or placebo.</ORIGINAL_TEXT>
<TOKEN end_char="14349" id="token-90-0" morph="none" pos="word" start_char="14348">In</TOKEN>
<TOKEN end_char="14353" id="token-90-1" morph="none" pos="word" start_char="14351">the</TOKEN>
<TOKEN end_char="14359" id="token-90-2" morph="none" pos="word" start_char="14355">Phase</TOKEN>
<TOKEN end_char="14361" id="token-90-3" morph="none" pos="word" start_char="14361">2</TOKEN>
<TOKEN end_char="14369" id="token-90-4" morph="none" pos="word" start_char="14363">portion</TOKEN>
<TOKEN end_char="14372" id="token-90-5" morph="none" pos="word" start_char="14371">of</TOKEN>
<TOKEN end_char="14380" id="token-90-6" morph="none" pos="unknown" start_char="14374">BLAZE-1</TOKEN>
<TOKEN end_char="14381" id="token-90-7" morph="none" pos="punct" start_char="14381">,</TOKEN>
<TOKEN end_char="14389" id="token-90-8" morph="none" pos="word" start_char="14383">cohorts</TOKEN>
<TOKEN end_char="14392" id="token-90-9" morph="none" pos="word" start_char="14391">of</TOKEN>
<TOKEN end_char="14397" id="token-90-10" morph="none" pos="word" start_char="14394">mild</TOKEN>
<TOKEN end_char="14400" id="token-90-11" morph="none" pos="word" start_char="14399">to</TOKEN>
<TOKEN end_char="14409" id="token-90-12" morph="none" pos="word" start_char="14402">moderate</TOKEN>
<TOKEN end_char="14418" id="token-90-13" morph="none" pos="word" start_char="14411">recently</TOKEN>
<TOKEN end_char="14428" id="token-90-14" morph="none" pos="word" start_char="14420">diagnosed</TOKEN>
<TOKEN end_char="14437" id="token-90-15" morph="none" pos="unknown" start_char="14430">COVID-19</TOKEN>
<TOKEN end_char="14446" id="token-90-16" morph="none" pos="word" start_char="14439">patients</TOKEN>
<TOKEN end_char="14447" id="token-90-17" morph="none" pos="punct" start_char="14447">,</TOKEN>
<TOKEN end_char="14452" id="token-90-18" morph="none" pos="word" start_char="14449">were</TOKEN>
<TOKEN end_char="14463" id="token-90-19" morph="none" pos="word" start_char="14454">randomized</TOKEN>
<TOKEN end_char="14466" id="token-90-20" morph="none" pos="word" start_char="14465">to</TOKEN>
<TOKEN end_char="14470" id="token-90-21" morph="none" pos="word" start_char="14468">one</TOKEN>
<TOKEN end_char="14473" id="token-90-22" morph="none" pos="word" start_char="14472">of</TOKEN>
<TOKEN end_char="14479" id="token-90-23" morph="none" pos="word" start_char="14475">three</TOKEN>
<TOKEN end_char="14485" id="token-90-24" morph="none" pos="word" start_char="14481">doses</TOKEN>
<TOKEN end_char="14488" id="token-90-25" morph="none" pos="word" start_char="14487">of</TOKEN>
<TOKEN end_char="14501" id="token-90-26" morph="none" pos="word" start_char="14490">bamlanivimab</TOKEN>
<TOKEN end_char="14503" id="token-90-27" morph="none" pos="punct" start_char="14503">(</TOKEN>
<TOKEN end_char="14506" id="token-90-28" morph="none" pos="word" start_char="14504">700</TOKEN>
<TOKEN end_char="14509" id="token-90-29" morph="none" pos="word" start_char="14508">mg</TOKEN>
<TOKEN end_char="14510" id="token-90-30" morph="none" pos="punct" start_char="14510">,</TOKEN>
<TOKEN end_char="14515" id="token-90-31" morph="none" pos="word" start_char="14512">2800</TOKEN>
<TOKEN end_char="14518" id="token-90-32" morph="none" pos="word" start_char="14517">mg</TOKEN>
<TOKEN end_char="14519" id="token-90-33" morph="none" pos="punct" start_char="14519">,</TOKEN>
<TOKEN end_char="14523" id="token-90-34" morph="none" pos="word" start_char="14521">and</TOKEN>
<TOKEN end_char="14528" id="token-90-35" morph="none" pos="word" start_char="14525">7000</TOKEN>
<TOKEN end_char="14531" id="token-90-36" morph="none" pos="word" start_char="14530">mg</TOKEN>
<TOKEN end_char="14533" id="token-90-37" morph="none" pos="punct" start_char="14532">),</TOKEN>
<TOKEN end_char="14546" id="token-90-38" morph="none" pos="word" start_char="14535">bamlanivimab</TOKEN>
<TOKEN end_char="14551" id="token-90-39" morph="none" pos="word" start_char="14548">2800</TOKEN>
<TOKEN end_char="14554" id="token-90-40" morph="none" pos="word" start_char="14553">mg</TOKEN>
<TOKEN end_char="14559" id="token-90-41" morph="none" pos="word" start_char="14556">plus</TOKEN>
<TOKEN end_char="14570" id="token-90-42" morph="none" pos="word" start_char="14561">etesevimab</TOKEN>
<TOKEN end_char="14575" id="token-90-43" morph="none" pos="word" start_char="14572">2800</TOKEN>
<TOKEN end_char="14578" id="token-90-44" morph="none" pos="word" start_char="14577">mg</TOKEN>
<TOKEN end_char="14579" id="token-90-45" morph="none" pos="punct" start_char="14579">,</TOKEN>
<TOKEN end_char="14582" id="token-90-46" morph="none" pos="word" start_char="14581">or</TOKEN>
<TOKEN end_char="14590" id="token-90-47" morph="none" pos="word" start_char="14584">placebo</TOKEN>
<TOKEN end_char="14591" id="token-90-48" morph="none" pos="punct" start_char="14591">.</TOKEN>
</SEG>
<SEG end_char="14657" id="segment-91" start_char="14593">
<ORIGINAL_TEXT>Results from the Phase 2 cohorts of BLAZE-1 were published in the</ORIGINAL_TEXT>
<TOKEN end_char="14599" id="token-91-0" morph="none" pos="word" start_char="14593">Results</TOKEN>
<TOKEN end_char="14604" id="token-91-1" morph="none" pos="word" start_char="14601">from</TOKEN>
<TOKEN end_char="14608" id="token-91-2" morph="none" pos="word" start_char="14606">the</TOKEN>
<TOKEN end_char="14614" id="token-91-3" morph="none" pos="word" start_char="14610">Phase</TOKEN>
<TOKEN end_char="14616" id="token-91-4" morph="none" pos="word" start_char="14616">2</TOKEN>
<TOKEN end_char="14624" id="token-91-5" morph="none" pos="word" start_char="14618">cohorts</TOKEN>
<TOKEN end_char="14627" id="token-91-6" morph="none" pos="word" start_char="14626">of</TOKEN>
<TOKEN end_char="14635" id="token-91-7" morph="none" pos="unknown" start_char="14629">BLAZE-1</TOKEN>
<TOKEN end_char="14640" id="token-91-8" morph="none" pos="word" start_char="14637">were</TOKEN>
<TOKEN end_char="14650" id="token-91-9" morph="none" pos="word" start_char="14642">published</TOKEN>
<TOKEN end_char="14653" id="token-91-10" morph="none" pos="word" start_char="14652">in</TOKEN>
<TOKEN end_char="14657" id="token-91-11" morph="none" pos="word" start_char="14655">the</TOKEN>
</SEG>
<SEG end_char="14690" id="segment-92" start_char="14660">
<ORIGINAL_TEXT>New England Journal of Medicine</ORIGINAL_TEXT>
<TOKEN end_char="14662" id="token-92-0" morph="none" pos="word" start_char="14660">New</TOKEN>
<TOKEN end_char="14670" id="token-92-1" morph="none" pos="word" start_char="14664">England</TOKEN>
<TOKEN end_char="14678" id="token-92-2" morph="none" pos="word" start_char="14672">Journal</TOKEN>
<TOKEN end_char="14681" id="token-92-3" morph="none" pos="word" start_char="14680">of</TOKEN>
<TOKEN end_char="14690" id="token-92-4" morph="none" pos="word" start_char="14683">Medicine</TOKEN>
</SEG>
<SEG end_char="14695" id="segment-93" start_char="14693">
<ORIGINAL_TEXT>and</ORIGINAL_TEXT>
<TOKEN end_char="14695" id="token-93-0" morph="none" pos="word" start_char="14693">and</TOKEN>
</SEG>
<SEG end_char="14744" id="segment-94" start_char="14698">
<ORIGINAL_TEXT>The Journal of the American Medical Association</ORIGINAL_TEXT>
<TOKEN end_char="14700" id="token-94-0" morph="none" pos="word" start_char="14698">The</TOKEN>
<TOKEN end_char="14708" id="token-94-1" morph="none" pos="word" start_char="14702">Journal</TOKEN>
<TOKEN end_char="14711" id="token-94-2" morph="none" pos="word" start_char="14710">of</TOKEN>
<TOKEN end_char="14715" id="token-94-3" morph="none" pos="word" start_char="14713">the</TOKEN>
<TOKEN end_char="14724" id="token-94-4" morph="none" pos="word" start_char="14717">American</TOKEN>
<TOKEN end_char="14732" id="token-94-5" morph="none" pos="word" start_char="14726">Medical</TOKEN>
<TOKEN end_char="14744" id="token-94-6" morph="none" pos="word" start_char="14734">Association</TOKEN>
</SEG>
<SEG end_char="14747" id="segment-95" start_char="14747">
<ORIGINAL_TEXT>.</ORIGINAL_TEXT>
<TOKEN end_char="14747" id="token-95-0" morph="none" pos="punct" start_char="14747">.</TOKEN>
</SEG>
<SEG end_char="15091" id="segment-96" start_char="14751">
<ORIGINAL_TEXT>In the Phase 3 portion of BLAZE-1, the combination therapy arms enrolled mild to moderate, recently diagnosed COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization, studying bamlanivimab 2800 mg plus etesevimab 2800 mg versus placebo, and bamlanivimab 700 mg plus etesevimab 1400 mg versus placebo.</ORIGINAL_TEXT>
<TOKEN end_char="14752" id="token-96-0" morph="none" pos="word" start_char="14751">In</TOKEN>
<TOKEN end_char="14756" id="token-96-1" morph="none" pos="word" start_char="14754">the</TOKEN>
<TOKEN end_char="14762" id="token-96-2" morph="none" pos="word" start_char="14758">Phase</TOKEN>
<TOKEN end_char="14764" id="token-96-3" morph="none" pos="word" start_char="14764">3</TOKEN>
<TOKEN end_char="14772" id="token-96-4" morph="none" pos="word" start_char="14766">portion</TOKEN>
<TOKEN end_char="14775" id="token-96-5" morph="none" pos="word" start_char="14774">of</TOKEN>
<TOKEN end_char="14783" id="token-96-6" morph="none" pos="unknown" start_char="14777">BLAZE-1</TOKEN>
<TOKEN end_char="14784" id="token-96-7" morph="none" pos="punct" start_char="14784">,</TOKEN>
<TOKEN end_char="14788" id="token-96-8" morph="none" pos="word" start_char="14786">the</TOKEN>
<TOKEN end_char="14800" id="token-96-9" morph="none" pos="word" start_char="14790">combination</TOKEN>
<TOKEN end_char="14808" id="token-96-10" morph="none" pos="word" start_char="14802">therapy</TOKEN>
<TOKEN end_char="14813" id="token-96-11" morph="none" pos="word" start_char="14810">arms</TOKEN>
<TOKEN end_char="14822" id="token-96-12" morph="none" pos="word" start_char="14815">enrolled</TOKEN>
<TOKEN end_char="14827" id="token-96-13" morph="none" pos="word" start_char="14824">mild</TOKEN>
<TOKEN end_char="14830" id="token-96-14" morph="none" pos="word" start_char="14829">to</TOKEN>
<TOKEN end_char="14839" id="token-96-15" morph="none" pos="word" start_char="14832">moderate</TOKEN>
<TOKEN end_char="14840" id="token-96-16" morph="none" pos="punct" start_char="14840">,</TOKEN>
<TOKEN end_char="14849" id="token-96-17" morph="none" pos="word" start_char="14842">recently</TOKEN>
<TOKEN end_char="14859" id="token-96-18" morph="none" pos="word" start_char="14851">diagnosed</TOKEN>
<TOKEN end_char="14868" id="token-96-19" morph="none" pos="unknown" start_char="14861">COVID-19</TOKEN>
<TOKEN end_char="14877" id="token-96-20" morph="none" pos="word" start_char="14870">patients</TOKEN>
<TOKEN end_char="14881" id="token-96-21" morph="none" pos="word" start_char="14879">who</TOKEN>
<TOKEN end_char="14885" id="token-96-22" morph="none" pos="word" start_char="14883">are</TOKEN>
<TOKEN end_char="14888" id="token-96-23" morph="none" pos="word" start_char="14887">at</TOKEN>
<TOKEN end_char="14893" id="token-96-24" morph="none" pos="word" start_char="14890">high</TOKEN>
<TOKEN end_char="14898" id="token-96-25" morph="none" pos="word" start_char="14895">risk</TOKEN>
<TOKEN end_char="14902" id="token-96-26" morph="none" pos="word" start_char="14900">for</TOKEN>
<TOKEN end_char="14914" id="token-96-27" morph="none" pos="word" start_char="14904">progressing</TOKEN>
<TOKEN end_char="14917" id="token-96-28" morph="none" pos="word" start_char="14916">to</TOKEN>
<TOKEN end_char="14924" id="token-96-29" morph="none" pos="word" start_char="14919">severe</TOKEN>
<TOKEN end_char="14933" id="token-96-30" morph="none" pos="unknown" start_char="14926">COVID-19</TOKEN>
<TOKEN end_char="14940" id="token-96-31" morph="none" pos="unknown" start_char="14935">and/or</TOKEN>
<TOKEN end_char="14956" id="token-96-32" morph="none" pos="word" start_char="14942">hospitalization</TOKEN>
<TOKEN end_char="14957" id="token-96-33" morph="none" pos="punct" start_char="14957">,</TOKEN>
<TOKEN end_char="14966" id="token-96-34" morph="none" pos="word" start_char="14959">studying</TOKEN>
<TOKEN end_char="14979" id="token-96-35" morph="none" pos="word" start_char="14968">bamlanivimab</TOKEN>
<TOKEN end_char="14984" id="token-96-36" morph="none" pos="word" start_char="14981">2800</TOKEN>
<TOKEN end_char="14987" id="token-96-37" morph="none" pos="word" start_char="14986">mg</TOKEN>
<TOKEN end_char="14992" id="token-96-38" morph="none" pos="word" start_char="14989">plus</TOKEN>
<TOKEN end_char="15003" id="token-96-39" morph="none" pos="word" start_char="14994">etesevimab</TOKEN>
<TOKEN end_char="15008" id="token-96-40" morph="none" pos="word" start_char="15005">2800</TOKEN>
<TOKEN end_char="15011" id="token-96-41" morph="none" pos="word" start_char="15010">mg</TOKEN>
<TOKEN end_char="15018" id="token-96-42" morph="none" pos="word" start_char="15013">versus</TOKEN>
<TOKEN end_char="15026" id="token-96-43" morph="none" pos="word" start_char="15020">placebo</TOKEN>
<TOKEN end_char="15027" id="token-96-44" morph="none" pos="punct" start_char="15027">,</TOKEN>
<TOKEN end_char="15031" id="token-96-45" morph="none" pos="word" start_char="15029">and</TOKEN>
<TOKEN end_char="15044" id="token-96-46" morph="none" pos="word" start_char="15033">bamlanivimab</TOKEN>
<TOKEN end_char="15048" id="token-96-47" morph="none" pos="word" start_char="15046">700</TOKEN>
<TOKEN end_char="15051" id="token-96-48" morph="none" pos="word" start_char="15050">mg</TOKEN>
<TOKEN end_char="15056" id="token-96-49" morph="none" pos="word" start_char="15053">plus</TOKEN>
<TOKEN end_char="15067" id="token-96-50" morph="none" pos="word" start_char="15058">etesevimab</TOKEN>
<TOKEN end_char="15072" id="token-96-51" morph="none" pos="word" start_char="15069">1400</TOKEN>
<TOKEN end_char="15075" id="token-96-52" morph="none" pos="word" start_char="15074">mg</TOKEN>
<TOKEN end_char="15082" id="token-96-53" morph="none" pos="word" start_char="15077">versus</TOKEN>
<TOKEN end_char="15090" id="token-96-54" morph="none" pos="word" start_char="15084">placebo</TOKEN>
<TOKEN end_char="15091" id="token-96-55" morph="none" pos="punct" start_char="15091">.</TOKEN>
</SEG>
<SEG end_char="15280" id="segment-97" start_char="15093">
<ORIGINAL_TEXT>The primary outcome measure for the Phase 3 portion of the BLAZE-1 trial was the percentage of participants who experience COVID-related hospitalizations or death from any cause by day 29.</ORIGINAL_TEXT>
<TOKEN end_char="15095" id="token-97-0" morph="none" pos="word" start_char="15093">The</TOKEN>
<TOKEN end_char="15103" id="token-97-1" morph="none" pos="word" start_char="15097">primary</TOKEN>
<TOKEN end_char="15111" id="token-97-2" morph="none" pos="word" start_char="15105">outcome</TOKEN>
<TOKEN end_char="15119" id="token-97-3" morph="none" pos="word" start_char="15113">measure</TOKEN>
<TOKEN end_char="15123" id="token-97-4" morph="none" pos="word" start_char="15121">for</TOKEN>
<TOKEN end_char="15127" id="token-97-5" morph="none" pos="word" start_char="15125">the</TOKEN>
<TOKEN end_char="15133" id="token-97-6" morph="none" pos="word" start_char="15129">Phase</TOKEN>
<TOKEN end_char="15135" id="token-97-7" morph="none" pos="word" start_char="15135">3</TOKEN>
<TOKEN end_char="15143" id="token-97-8" morph="none" pos="word" start_char="15137">portion</TOKEN>
<TOKEN end_char="15146" id="token-97-9" morph="none" pos="word" start_char="15145">of</TOKEN>
<TOKEN end_char="15150" id="token-97-10" morph="none" pos="word" start_char="15148">the</TOKEN>
<TOKEN end_char="15158" id="token-97-11" morph="none" pos="unknown" start_char="15152">BLAZE-1</TOKEN>
<TOKEN end_char="15164" id="token-97-12" morph="none" pos="word" start_char="15160">trial</TOKEN>
<TOKEN end_char="15168" id="token-97-13" morph="none" pos="word" start_char="15166">was</TOKEN>
<TOKEN end_char="15172" id="token-97-14" morph="none" pos="word" start_char="15170">the</TOKEN>
<TOKEN end_char="15183" id="token-97-15" morph="none" pos="word" start_char="15174">percentage</TOKEN>
<TOKEN end_char="15186" id="token-97-16" morph="none" pos="word" start_char="15185">of</TOKEN>
<TOKEN end_char="15199" id="token-97-17" morph="none" pos="word" start_char="15188">participants</TOKEN>
<TOKEN end_char="15203" id="token-97-18" morph="none" pos="word" start_char="15201">who</TOKEN>
<TOKEN end_char="15214" id="token-97-19" morph="none" pos="word" start_char="15205">experience</TOKEN>
<TOKEN end_char="15228" id="token-97-20" morph="none" pos="unknown" start_char="15216">COVID-related</TOKEN>
<TOKEN end_char="15245" id="token-97-21" morph="none" pos="word" start_char="15230">hospitalizations</TOKEN>
<TOKEN end_char="15248" id="token-97-22" morph="none" pos="word" start_char="15247">or</TOKEN>
<TOKEN end_char="15254" id="token-97-23" morph="none" pos="word" start_char="15250">death</TOKEN>
<TOKEN end_char="15259" id="token-97-24" morph="none" pos="word" start_char="15256">from</TOKEN>
<TOKEN end_char="15263" id="token-97-25" morph="none" pos="word" start_char="15261">any</TOKEN>
<TOKEN end_char="15269" id="token-97-26" morph="none" pos="word" start_char="15265">cause</TOKEN>
<TOKEN end_char="15272" id="token-97-27" morph="none" pos="word" start_char="15271">by</TOKEN>
<TOKEN end_char="15276" id="token-97-28" morph="none" pos="word" start_char="15274">day</TOKEN>
<TOKEN end_char="15279" id="token-97-29" morph="none" pos="word" start_char="15278">29</TOKEN>
<TOKEN end_char="15280" id="token-97-30" morph="none" pos="punct" start_char="15280">.</TOKEN>
</SEG>
<SEG end_char="15550" id="segment-98" start_char="15282">
<ORIGINAL_TEXT>The key secondary endpoints were change from baseline to day 7 in SARS-CoV-2 viral load, persistently high SARS-CoV-2 viral load on day 7, time to sustained symptom resolution, and COVID-related hospitalization, ER visit or death from any cause from baseline by day 29.</ORIGINAL_TEXT>
<TOKEN end_char="15284" id="token-98-0" morph="none" pos="word" start_char="15282">The</TOKEN>
<TOKEN end_char="15288" id="token-98-1" morph="none" pos="word" start_char="15286">key</TOKEN>
<TOKEN end_char="15298" id="token-98-2" morph="none" pos="word" start_char="15290">secondary</TOKEN>
<TOKEN end_char="15308" id="token-98-3" morph="none" pos="word" start_char="15300">endpoints</TOKEN>
<TOKEN end_char="15313" id="token-98-4" morph="none" pos="word" start_char="15310">were</TOKEN>
<TOKEN end_char="15320" id="token-98-5" morph="none" pos="word" start_char="15315">change</TOKEN>
<TOKEN end_char="15325" id="token-98-6" morph="none" pos="word" start_char="15322">from</TOKEN>
<TOKEN end_char="15334" id="token-98-7" morph="none" pos="word" start_char="15327">baseline</TOKEN>
<TOKEN end_char="15337" id="token-98-8" morph="none" pos="word" start_char="15336">to</TOKEN>
<TOKEN end_char="15341" id="token-98-9" morph="none" pos="word" start_char="15339">day</TOKEN>
<TOKEN end_char="15343" id="token-98-10" morph="none" pos="word" start_char="15343">7</TOKEN>
<TOKEN end_char="15346" id="token-98-11" morph="none" pos="word" start_char="15345">in</TOKEN>
<TOKEN end_char="15357" id="token-98-12" morph="none" pos="unknown" start_char="15348">SARS-CoV-2</TOKEN>
<TOKEN end_char="15363" id="token-98-13" morph="none" pos="word" start_char="15359">viral</TOKEN>
<TOKEN end_char="15368" id="token-98-14" morph="none" pos="word" start_char="15365">load</TOKEN>
<TOKEN end_char="15369" id="token-98-15" morph="none" pos="punct" start_char="15369">,</TOKEN>
<TOKEN end_char="15382" id="token-98-16" morph="none" pos="word" start_char="15371">persistently</TOKEN>
<TOKEN end_char="15387" id="token-98-17" morph="none" pos="word" start_char="15384">high</TOKEN>
<TOKEN end_char="15398" id="token-98-18" morph="none" pos="unknown" start_char="15389">SARS-CoV-2</TOKEN>
<TOKEN end_char="15404" id="token-98-19" morph="none" pos="word" start_char="15400">viral</TOKEN>
<TOKEN end_char="15409" id="token-98-20" morph="none" pos="word" start_char="15406">load</TOKEN>
<TOKEN end_char="15412" id="token-98-21" morph="none" pos="word" start_char="15411">on</TOKEN>
<TOKEN end_char="15416" id="token-98-22" morph="none" pos="word" start_char="15414">day</TOKEN>
<TOKEN end_char="15418" id="token-98-23" morph="none" pos="word" start_char="15418">7</TOKEN>
<TOKEN end_char="15419" id="token-98-24" morph="none" pos="punct" start_char="15419">,</TOKEN>
<TOKEN end_char="15424" id="token-98-25" morph="none" pos="word" start_char="15421">time</TOKEN>
<TOKEN end_char="15427" id="token-98-26" morph="none" pos="word" start_char="15426">to</TOKEN>
<TOKEN end_char="15437" id="token-98-27" morph="none" pos="word" start_char="15429">sustained</TOKEN>
<TOKEN end_char="15445" id="token-98-28" morph="none" pos="word" start_char="15439">symptom</TOKEN>
<TOKEN end_char="15456" id="token-98-29" morph="none" pos="word" start_char="15447">resolution</TOKEN>
<TOKEN end_char="15457" id="token-98-30" morph="none" pos="punct" start_char="15457">,</TOKEN>
<TOKEN end_char="15461" id="token-98-31" morph="none" pos="word" start_char="15459">and</TOKEN>
<TOKEN end_char="15475" id="token-98-32" morph="none" pos="unknown" start_char="15463">COVID-related</TOKEN>
<TOKEN end_char="15491" id="token-98-33" morph="none" pos="word" start_char="15477">hospitalization</TOKEN>
<TOKEN end_char="15492" id="token-98-34" morph="none" pos="punct" start_char="15492">,</TOKEN>
<TOKEN end_char="15495" id="token-98-35" morph="none" pos="word" start_char="15494">ER</TOKEN>
<TOKEN end_char="15501" id="token-98-36" morph="none" pos="word" start_char="15497">visit</TOKEN>
<TOKEN end_char="15504" id="token-98-37" morph="none" pos="word" start_char="15503">or</TOKEN>
<TOKEN end_char="15510" id="token-98-38" morph="none" pos="word" start_char="15506">death</TOKEN>
<TOKEN end_char="15515" id="token-98-39" morph="none" pos="word" start_char="15512">from</TOKEN>
<TOKEN end_char="15519" id="token-98-40" morph="none" pos="word" start_char="15517">any</TOKEN>
<TOKEN end_char="15525" id="token-98-41" morph="none" pos="word" start_char="15521">cause</TOKEN>
<TOKEN end_char="15530" id="token-98-42" morph="none" pos="word" start_char="15527">from</TOKEN>
<TOKEN end_char="15539" id="token-98-43" morph="none" pos="word" start_char="15532">baseline</TOKEN>
<TOKEN end_char="15542" id="token-98-44" morph="none" pos="word" start_char="15541">by</TOKEN>
<TOKEN end_char="15546" id="token-98-45" morph="none" pos="word" start_char="15544">day</TOKEN>
<TOKEN end_char="15549" id="token-98-46" morph="none" pos="word" start_char="15548">29</TOKEN>
<TOKEN end_char="15550" id="token-98-47" morph="none" pos="punct" start_char="15550">.</TOKEN>
</SEG>
<SEG end_char="15696" id="segment-99" start_char="15552">
<ORIGINAL_TEXT>Additional endpoints include change from baseline in viral load at other time points, symptom improvement, symptom resolution, as well as safety.</ORIGINAL_TEXT>
<TOKEN end_char="15561" id="token-99-0" morph="none" pos="word" start_char="15552">Additional</TOKEN>
<TOKEN end_char="15571" id="token-99-1" morph="none" pos="word" start_char="15563">endpoints</TOKEN>
<TOKEN end_char="15579" id="token-99-2" morph="none" pos="word" start_char="15573">include</TOKEN>
<TOKEN end_char="15586" id="token-99-3" morph="none" pos="word" start_char="15581">change</TOKEN>
<TOKEN end_char="15591" id="token-99-4" morph="none" pos="word" start_char="15588">from</TOKEN>
<TOKEN end_char="15600" id="token-99-5" morph="none" pos="word" start_char="15593">baseline</TOKEN>
<TOKEN end_char="15603" id="token-99-6" morph="none" pos="word" start_char="15602">in</TOKEN>
<TOKEN end_char="15609" id="token-99-7" morph="none" pos="word" start_char="15605">viral</TOKEN>
<TOKEN end_char="15614" id="token-99-8" morph="none" pos="word" start_char="15611">load</TOKEN>
<TOKEN end_char="15617" id="token-99-9" morph="none" pos="word" start_char="15616">at</TOKEN>
<TOKEN end_char="15623" id="token-99-10" morph="none" pos="word" start_char="15619">other</TOKEN>
<TOKEN end_char="15628" id="token-99-11" morph="none" pos="word" start_char="15625">time</TOKEN>
<TOKEN end_char="15635" id="token-99-12" morph="none" pos="word" start_char="15630">points</TOKEN>
<TOKEN end_char="15636" id="token-99-13" morph="none" pos="punct" start_char="15636">,</TOKEN>
<TOKEN end_char="15644" id="token-99-14" morph="none" pos="word" start_char="15638">symptom</TOKEN>
<TOKEN end_char="15656" id="token-99-15" morph="none" pos="word" start_char="15646">improvement</TOKEN>
<TOKEN end_char="15657" id="token-99-16" morph="none" pos="punct" start_char="15657">,</TOKEN>
<TOKEN end_char="15665" id="token-99-17" morph="none" pos="word" start_char="15659">symptom</TOKEN>
<TOKEN end_char="15676" id="token-99-18" morph="none" pos="word" start_char="15667">resolution</TOKEN>
<TOKEN end_char="15677" id="token-99-19" morph="none" pos="punct" start_char="15677">,</TOKEN>
<TOKEN end_char="15680" id="token-99-20" morph="none" pos="word" start_char="15679">as</TOKEN>
<TOKEN end_char="15685" id="token-99-21" morph="none" pos="word" start_char="15682">well</TOKEN>
<TOKEN end_char="15688" id="token-99-22" morph="none" pos="word" start_char="15687">as</TOKEN>
<TOKEN end_char="15695" id="token-99-23" morph="none" pos="word" start_char="15690">safety</TOKEN>
<TOKEN end_char="15696" id="token-99-24" morph="none" pos="punct" start_char="15696">.</TOKEN>
</SEG>
<SEG end_char="15750" id="segment-100" start_char="15699">
<ORIGINAL_TEXT>The study is ongoing with additional treatment arms.</ORIGINAL_TEXT>
<TOKEN end_char="15701" id="token-100-0" morph="none" pos="word" start_char="15699">The</TOKEN>
<TOKEN end_char="15707" id="token-100-1" morph="none" pos="word" start_char="15703">study</TOKEN>
<TOKEN end_char="15710" id="token-100-2" morph="none" pos="word" start_char="15709">is</TOKEN>
<TOKEN end_char="15718" id="token-100-3" morph="none" pos="word" start_char="15712">ongoing</TOKEN>
<TOKEN end_char="15723" id="token-100-4" morph="none" pos="word" start_char="15720">with</TOKEN>
<TOKEN end_char="15734" id="token-100-5" morph="none" pos="word" start_char="15725">additional</TOKEN>
<TOKEN end_char="15744" id="token-100-6" morph="none" pos="word" start_char="15736">treatment</TOKEN>
<TOKEN end_char="15749" id="token-100-7" morph="none" pos="word" start_char="15746">arms</TOKEN>
<TOKEN end_char="15750" id="token-100-8" morph="none" pos="punct" start_char="15750">.</TOKEN>
</SEG>
<SEG end_char="15908" id="segment-101" start_char="15753">
<ORIGINAL_TEXT>About Lilly's COVID-19 Efforts Lilly is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world.</ORIGINAL_TEXT>
<TOKEN end_char="15757" id="token-101-0" morph="none" pos="word" start_char="15753">About</TOKEN>
<TOKEN end_char="15765" id="token-101-1" morph="none" pos="word" start_char="15759">Lilly's</TOKEN>
<TOKEN end_char="15774" id="token-101-2" morph="none" pos="unknown" start_char="15767">COVID-19</TOKEN>
<TOKEN end_char="15782" id="token-101-3" morph="none" pos="word" start_char="15776">Efforts</TOKEN>
<TOKEN end_char="15788" id="token-101-4" morph="none" pos="word" start_char="15784">Lilly</TOKEN>
<TOKEN end_char="15791" id="token-101-5" morph="none" pos="word" start_char="15790">is</TOKEN>
<TOKEN end_char="15800" id="token-101-6" morph="none" pos="word" start_char="15793">bringing</TOKEN>
<TOKEN end_char="15804" id="token-101-7" morph="none" pos="word" start_char="15802">the</TOKEN>
<TOKEN end_char="15809" id="token-101-8" morph="none" pos="word" start_char="15806">full</TOKEN>
<TOKEN end_char="15815" id="token-101-9" morph="none" pos="word" start_char="15811">force</TOKEN>
<TOKEN end_char="15818" id="token-101-10" morph="none" pos="word" start_char="15817">of</TOKEN>
<TOKEN end_char="15822" id="token-101-11" morph="none" pos="word" start_char="15820">its</TOKEN>
<TOKEN end_char="15833" id="token-101-12" morph="none" pos="word" start_char="15824">scientific</TOKEN>
<TOKEN end_char="15837" id="token-101-13" morph="none" pos="word" start_char="15835">and</TOKEN>
<TOKEN end_char="15845" id="token-101-14" morph="none" pos="word" start_char="15839">medical</TOKEN>
<TOKEN end_char="15855" id="token-101-15" morph="none" pos="word" start_char="15847">expertise</TOKEN>
<TOKEN end_char="15858" id="token-101-16" morph="none" pos="word" start_char="15857">to</TOKEN>
<TOKEN end_char="15865" id="token-101-17" morph="none" pos="word" start_char="15860">attack</TOKEN>
<TOKEN end_char="15869" id="token-101-18" morph="none" pos="word" start_char="15867">the</TOKEN>
<TOKEN end_char="15881" id="token-101-19" morph="none" pos="word" start_char="15871">coronavirus</TOKEN>
<TOKEN end_char="15890" id="token-101-20" morph="none" pos="word" start_char="15883">pandemic</TOKEN>
<TOKEN end_char="15897" id="token-101-21" morph="none" pos="word" start_char="15892">around</TOKEN>
<TOKEN end_char="15901" id="token-101-22" morph="none" pos="word" start_char="15899">the</TOKEN>
<TOKEN end_char="15907" id="token-101-23" morph="none" pos="word" start_char="15903">world</TOKEN>
<TOKEN end_char="15908" id="token-101-24" morph="none" pos="punct" start_char="15908">.</TOKEN>
</SEG>
<SEG end_char="16140" id="segment-102" start_char="15910">
<ORIGINAL_TEXT>Existing Lilly medicines are being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with partner companies to discover and develop novel antibody treatments for COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="15917" id="token-102-0" morph="none" pos="word" start_char="15910">Existing</TOKEN>
<TOKEN end_char="15923" id="token-102-1" morph="none" pos="word" start_char="15919">Lilly</TOKEN>
<TOKEN end_char="15933" id="token-102-2" morph="none" pos="word" start_char="15925">medicines</TOKEN>
<TOKEN end_char="15937" id="token-102-3" morph="none" pos="word" start_char="15935">are</TOKEN>
<TOKEN end_char="15943" id="token-102-4" morph="none" pos="word" start_char="15939">being</TOKEN>
<TOKEN end_char="15951" id="token-102-5" morph="none" pos="word" start_char="15945">studied</TOKEN>
<TOKEN end_char="15954" id="token-102-6" morph="none" pos="word" start_char="15953">to</TOKEN>
<TOKEN end_char="15965" id="token-102-7" morph="none" pos="word" start_char="15956">understand</TOKEN>
<TOKEN end_char="15971" id="token-102-8" morph="none" pos="word" start_char="15967">their</TOKEN>
<TOKEN end_char="15981" id="token-102-9" morph="none" pos="word" start_char="15973">potential</TOKEN>
<TOKEN end_char="15984" id="token-102-10" morph="none" pos="word" start_char="15983">in</TOKEN>
<TOKEN end_char="15993" id="token-102-11" morph="none" pos="word" start_char="15986">treating</TOKEN>
<TOKEN end_char="16007" id="token-102-12" morph="none" pos="word" start_char="15995">complications</TOKEN>
<TOKEN end_char="16010" id="token-102-13" morph="none" pos="word" start_char="16009">of</TOKEN>
<TOKEN end_char="16019" id="token-102-14" morph="none" pos="unknown" start_char="16012">COVID-19</TOKEN>
<TOKEN end_char="16020" id="token-102-15" morph="none" pos="punct" start_char="16020">,</TOKEN>
<TOKEN end_char="16024" id="token-102-16" morph="none" pos="word" start_char="16022">and</TOKEN>
<TOKEN end_char="16028" id="token-102-17" morph="none" pos="word" start_char="16026">the</TOKEN>
<TOKEN end_char="16036" id="token-102-18" morph="none" pos="word" start_char="16030">company</TOKEN>
<TOKEN end_char="16039" id="token-102-19" morph="none" pos="word" start_char="16038">is</TOKEN>
<TOKEN end_char="16053" id="token-102-20" morph="none" pos="word" start_char="16041">collaborating</TOKEN>
<TOKEN end_char="16058" id="token-102-21" morph="none" pos="word" start_char="16055">with</TOKEN>
<TOKEN end_char="16066" id="token-102-22" morph="none" pos="word" start_char="16060">partner</TOKEN>
<TOKEN end_char="16076" id="token-102-23" morph="none" pos="word" start_char="16068">companies</TOKEN>
<TOKEN end_char="16079" id="token-102-24" morph="none" pos="word" start_char="16078">to</TOKEN>
<TOKEN end_char="16088" id="token-102-25" morph="none" pos="word" start_char="16081">discover</TOKEN>
<TOKEN end_char="16092" id="token-102-26" morph="none" pos="word" start_char="16090">and</TOKEN>
<TOKEN end_char="16100" id="token-102-27" morph="none" pos="word" start_char="16094">develop</TOKEN>
<TOKEN end_char="16106" id="token-102-28" morph="none" pos="word" start_char="16102">novel</TOKEN>
<TOKEN end_char="16115" id="token-102-29" morph="none" pos="word" start_char="16108">antibody</TOKEN>
<TOKEN end_char="16126" id="token-102-30" morph="none" pos="word" start_char="16117">treatments</TOKEN>
<TOKEN end_char="16130" id="token-102-31" morph="none" pos="word" start_char="16128">for</TOKEN>
<TOKEN end_char="16139" id="token-102-32" morph="none" pos="unknown" start_char="16132">COVID-19</TOKEN>
<TOKEN end_char="16140" id="token-102-33" morph="none" pos="punct" start_char="16140">.</TOKEN>
</SEG>
<SEG end_char="16264" id="segment-103" start_char="16142">
<ORIGINAL_TEXT>Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="16146" id="token-103-0" morph="none" pos="word" start_char="16142">Lilly</TOKEN>
<TOKEN end_char="16149" id="token-103-1" morph="none" pos="word" start_char="16148">is</TOKEN>
<TOKEN end_char="16157" id="token-103-2" morph="none" pos="word" start_char="16151">testing</TOKEN>
<TOKEN end_char="16162" id="token-103-3" morph="none" pos="word" start_char="16159">both</TOKEN>
<TOKEN end_char="16169" id="token-103-4" morph="none" pos="word" start_char="16164">single</TOKEN>
<TOKEN end_char="16178" id="token-103-5" morph="none" pos="word" start_char="16171">antibody</TOKEN>
<TOKEN end_char="16186" id="token-103-6" morph="none" pos="word" start_char="16180">therapy</TOKEN>
<TOKEN end_char="16189" id="token-103-7" morph="none" pos="word" start_char="16188">as</TOKEN>
<TOKEN end_char="16194" id="token-103-8" morph="none" pos="word" start_char="16191">well</TOKEN>
<TOKEN end_char="16197" id="token-103-9" morph="none" pos="word" start_char="16196">as</TOKEN>
<TOKEN end_char="16210" id="token-103-10" morph="none" pos="word" start_char="16199">combinations</TOKEN>
<TOKEN end_char="16213" id="token-103-11" morph="none" pos="word" start_char="16212">of</TOKEN>
<TOKEN end_char="16224" id="token-103-12" morph="none" pos="word" start_char="16215">antibodies</TOKEN>
<TOKEN end_char="16227" id="token-103-13" morph="none" pos="word" start_char="16226">as</TOKEN>
<TOKEN end_char="16237" id="token-103-14" morph="none" pos="word" start_char="16229">potential</TOKEN>
<TOKEN end_char="16250" id="token-103-15" morph="none" pos="word" start_char="16239">therapeutics</TOKEN>
<TOKEN end_char="16254" id="token-103-16" morph="none" pos="word" start_char="16252">for</TOKEN>
<TOKEN end_char="16263" id="token-103-17" morph="none" pos="unknown" start_char="16256">COVID-19</TOKEN>
<TOKEN end_char="16264" id="token-103-18" morph="none" pos="punct" start_char="16264">.</TOKEN>
</SEG>
<SEG end_char="16326" id="segment-104" start_char="16266">
<ORIGINAL_TEXT>Click here for resources related to Lilly's COVID-19 efforts.</ORIGINAL_TEXT>
<TOKEN end_char="16270" id="token-104-0" morph="none" pos="word" start_char="16266">Click</TOKEN>
<TOKEN end_char="16275" id="token-104-1" morph="none" pos="word" start_char="16272">here</TOKEN>
<TOKEN end_char="16279" id="token-104-2" morph="none" pos="word" start_char="16277">for</TOKEN>
<TOKEN end_char="16289" id="token-104-3" morph="none" pos="word" start_char="16281">resources</TOKEN>
<TOKEN end_char="16297" id="token-104-4" morph="none" pos="word" start_char="16291">related</TOKEN>
<TOKEN end_char="16300" id="token-104-5" morph="none" pos="word" start_char="16299">to</TOKEN>
<TOKEN end_char="16308" id="token-104-6" morph="none" pos="word" start_char="16302">Lilly's</TOKEN>
<TOKEN end_char="16317" id="token-104-7" morph="none" pos="unknown" start_char="16310">COVID-19</TOKEN>
<TOKEN end_char="16325" id="token-104-8" morph="none" pos="word" start_char="16319">efforts</TOKEN>
<TOKEN end_char="16326" id="token-104-9" morph="none" pos="punct" start_char="16326">.</TOKEN>
</SEG>
<SEG end_char="16496" id="segment-105" start_char="16329">
<ORIGINAL_TEXT>About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.</ORIGINAL_TEXT>
<TOKEN end_char="16333" id="token-105-0" morph="none" pos="word" start_char="16329">About</TOKEN>
<TOKEN end_char="16337" id="token-105-1" morph="none" pos="word" start_char="16335">Eli</TOKEN>
<TOKEN end_char="16343" id="token-105-2" morph="none" pos="word" start_char="16339">Lilly</TOKEN>
<TOKEN end_char="16347" id="token-105-3" morph="none" pos="word" start_char="16345">and</TOKEN>
<TOKEN end_char="16355" id="token-105-4" morph="none" pos="word" start_char="16349">Company</TOKEN>
<TOKEN end_char="16361" id="token-105-5" morph="none" pos="word" start_char="16357">Lilly</TOKEN>
<TOKEN end_char="16364" id="token-105-6" morph="none" pos="word" start_char="16363">is</TOKEN>
<TOKEN end_char="16366" id="token-105-7" morph="none" pos="word" start_char="16366">a</TOKEN>
<TOKEN end_char="16373" id="token-105-8" morph="none" pos="word" start_char="16368">global</TOKEN>
<TOKEN end_char="16384" id="token-105-9" morph="none" pos="word" start_char="16375">healthcare</TOKEN>
<TOKEN end_char="16391" id="token-105-10" morph="none" pos="word" start_char="16386">leader</TOKEN>
<TOKEN end_char="16396" id="token-105-11" morph="none" pos="word" start_char="16393">that</TOKEN>
<TOKEN end_char="16403" id="token-105-12" morph="none" pos="word" start_char="16398">unites</TOKEN>
<TOKEN end_char="16410" id="token-105-13" morph="none" pos="word" start_char="16405">caring</TOKEN>
<TOKEN end_char="16415" id="token-105-14" morph="none" pos="word" start_char="16412">with</TOKEN>
<TOKEN end_char="16425" id="token-105-15" morph="none" pos="word" start_char="16417">discovery</TOKEN>
<TOKEN end_char="16428" id="token-105-16" morph="none" pos="word" start_char="16427">to</TOKEN>
<TOKEN end_char="16435" id="token-105-17" morph="none" pos="word" start_char="16430">create</TOKEN>
<TOKEN end_char="16445" id="token-105-18" morph="none" pos="word" start_char="16437">medicines</TOKEN>
<TOKEN end_char="16450" id="token-105-19" morph="none" pos="word" start_char="16447">that</TOKEN>
<TOKEN end_char="16455" id="token-105-20" morph="none" pos="word" start_char="16452">make</TOKEN>
<TOKEN end_char="16460" id="token-105-21" morph="none" pos="word" start_char="16457">life</TOKEN>
<TOKEN end_char="16467" id="token-105-22" morph="none" pos="word" start_char="16462">better</TOKEN>
<TOKEN end_char="16471" id="token-105-23" morph="none" pos="word" start_char="16469">for</TOKEN>
<TOKEN end_char="16478" id="token-105-24" morph="none" pos="word" start_char="16473">people</TOKEN>
<TOKEN end_char="16485" id="token-105-25" morph="none" pos="word" start_char="16480">around</TOKEN>
<TOKEN end_char="16489" id="token-105-26" morph="none" pos="word" start_char="16487">the</TOKEN>
<TOKEN end_char="16495" id="token-105-27" morph="none" pos="word" start_char="16491">world</TOKEN>
<TOKEN end_char="16496" id="token-105-28" morph="none" pos="punct" start_char="16496">.</TOKEN>
</SEG>
<SEG end_char="16670" id="segment-106" start_char="16498">
<ORIGINAL_TEXT>We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.</ORIGINAL_TEXT>
<TOKEN end_char="16499" id="token-106-0" morph="none" pos="word" start_char="16498">We</TOKEN>
<TOKEN end_char="16504" id="token-106-1" morph="none" pos="word" start_char="16501">were</TOKEN>
<TOKEN end_char="16512" id="token-106-2" morph="none" pos="word" start_char="16506">founded</TOKEN>
<TOKEN end_char="16517" id="token-106-3" morph="none" pos="word" start_char="16514">more</TOKEN>
<TOKEN end_char="16522" id="token-106-4" morph="none" pos="word" start_char="16519">than</TOKEN>
<TOKEN end_char="16524" id="token-106-5" morph="none" pos="word" start_char="16524">a</TOKEN>
<TOKEN end_char="16532" id="token-106-6" morph="none" pos="word" start_char="16526">century</TOKEN>
<TOKEN end_char="16536" id="token-106-7" morph="none" pos="word" start_char="16534">ago</TOKEN>
<TOKEN end_char="16539" id="token-106-8" morph="none" pos="word" start_char="16538">by</TOKEN>
<TOKEN end_char="16541" id="token-106-9" morph="none" pos="word" start_char="16541">a</TOKEN>
<TOKEN end_char="16545" id="token-106-10" morph="none" pos="word" start_char="16543">man</TOKEN>
<TOKEN end_char="16555" id="token-106-11" morph="none" pos="word" start_char="16547">committed</TOKEN>
<TOKEN end_char="16558" id="token-106-12" morph="none" pos="word" start_char="16557">to</TOKEN>
<TOKEN end_char="16567" id="token-106-13" morph="none" pos="word" start_char="16560">creating</TOKEN>
<TOKEN end_char="16580" id="token-106-14" morph="none" pos="unknown" start_char="16569">high-quality</TOKEN>
<TOKEN end_char="16590" id="token-106-15" morph="none" pos="word" start_char="16582">medicines</TOKEN>
<TOKEN end_char="16595" id="token-106-16" morph="none" pos="word" start_char="16592">that</TOKEN>
<TOKEN end_char="16600" id="token-106-17" morph="none" pos="word" start_char="16597">meet</TOKEN>
<TOKEN end_char="16605" id="token-106-18" morph="none" pos="word" start_char="16602">real</TOKEN>
<TOKEN end_char="16611" id="token-106-19" morph="none" pos="word" start_char="16607">needs</TOKEN>
<TOKEN end_char="16612" id="token-106-20" morph="none" pos="punct" start_char="16612">,</TOKEN>
<TOKEN end_char="16616" id="token-106-21" morph="none" pos="word" start_char="16614">and</TOKEN>
<TOKEN end_char="16622" id="token-106-22" morph="none" pos="word" start_char="16618">today</TOKEN>
<TOKEN end_char="16625" id="token-106-23" morph="none" pos="word" start_char="16624">we</TOKEN>
<TOKEN end_char="16632" id="token-106-24" morph="none" pos="word" start_char="16627">remain</TOKEN>
<TOKEN end_char="16637" id="token-106-25" morph="none" pos="word" start_char="16634">true</TOKEN>
<TOKEN end_char="16640" id="token-106-26" morph="none" pos="word" start_char="16639">to</TOKEN>
<TOKEN end_char="16645" id="token-106-27" morph="none" pos="word" start_char="16642">that</TOKEN>
<TOKEN end_char="16653" id="token-106-28" morph="none" pos="word" start_char="16647">mission</TOKEN>
<TOKEN end_char="16656" id="token-106-29" morph="none" pos="word" start_char="16655">in</TOKEN>
<TOKEN end_char="16660" id="token-106-30" morph="none" pos="word" start_char="16658">all</TOKEN>
<TOKEN end_char="16664" id="token-106-31" morph="none" pos="word" start_char="16662">our</TOKEN>
<TOKEN end_char="16669" id="token-106-32" morph="none" pos="word" start_char="16666">work</TOKEN>
<TOKEN end_char="16670" id="token-106-33" morph="none" pos="punct" start_char="16670">.</TOKEN>
</SEG>
<SEG end_char="16900" id="segment-107" start_char="16672">
<ORIGINAL_TEXT>Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.</ORIGINAL_TEXT>
<TOKEN end_char="16677" id="token-107-0" morph="none" pos="word" start_char="16672">Across</TOKEN>
<TOKEN end_char="16681" id="token-107-1" morph="none" pos="word" start_char="16679">the</TOKEN>
<TOKEN end_char="16687" id="token-107-2" morph="none" pos="word" start_char="16683">globe</TOKEN>
<TOKEN end_char="16688" id="token-107-3" morph="none" pos="punct" start_char="16688">,</TOKEN>
<TOKEN end_char="16694" id="token-107-4" morph="none" pos="word" start_char="16690">Lilly</TOKEN>
<TOKEN end_char="16704" id="token-107-5" morph="none" pos="word" start_char="16696">employees</TOKEN>
<TOKEN end_char="16709" id="token-107-6" morph="none" pos="word" start_char="16706">work</TOKEN>
<TOKEN end_char="16712" id="token-107-7" morph="none" pos="word" start_char="16711">to</TOKEN>
<TOKEN end_char="16721" id="token-107-8" morph="none" pos="word" start_char="16714">discover</TOKEN>
<TOKEN end_char="16725" id="token-107-9" morph="none" pos="word" start_char="16723">and</TOKEN>
<TOKEN end_char="16731" id="token-107-10" morph="none" pos="word" start_char="16727">bring</TOKEN>
<TOKEN end_char="16745" id="token-107-11" morph="none" pos="unknown" start_char="16733">life-changing</TOKEN>
<TOKEN end_char="16755" id="token-107-12" morph="none" pos="word" start_char="16747">medicines</TOKEN>
<TOKEN end_char="16758" id="token-107-13" morph="none" pos="word" start_char="16757">to</TOKEN>
<TOKEN end_char="16764" id="token-107-14" morph="none" pos="word" start_char="16760">those</TOKEN>
<TOKEN end_char="16768" id="token-107-15" morph="none" pos="word" start_char="16766">who</TOKEN>
<TOKEN end_char="16773" id="token-107-16" morph="none" pos="word" start_char="16770">need</TOKEN>
<TOKEN end_char="16778" id="token-107-17" morph="none" pos="word" start_char="16775">them</TOKEN>
<TOKEN end_char="16779" id="token-107-18" morph="none" pos="punct" start_char="16779">,</TOKEN>
<TOKEN end_char="16787" id="token-107-19" morph="none" pos="word" start_char="16781">improve</TOKEN>
<TOKEN end_char="16791" id="token-107-20" morph="none" pos="word" start_char="16789">the</TOKEN>
<TOKEN end_char="16805" id="token-107-21" morph="none" pos="word" start_char="16793">understanding</TOKEN>
<TOKEN end_char="16809" id="token-107-22" morph="none" pos="word" start_char="16807">and</TOKEN>
<TOKEN end_char="16820" id="token-107-23" morph="none" pos="word" start_char="16811">management</TOKEN>
<TOKEN end_char="16823" id="token-107-24" morph="none" pos="word" start_char="16822">of</TOKEN>
<TOKEN end_char="16831" id="token-107-25" morph="none" pos="word" start_char="16825">disease</TOKEN>
<TOKEN end_char="16832" id="token-107-26" morph="none" pos="punct" start_char="16832">,</TOKEN>
<TOKEN end_char="16836" id="token-107-27" morph="none" pos="word" start_char="16834">and</TOKEN>
<TOKEN end_char="16841" id="token-107-28" morph="none" pos="word" start_char="16838">give</TOKEN>
<TOKEN end_char="16846" id="token-107-29" morph="none" pos="word" start_char="16843">back</TOKEN>
<TOKEN end_char="16849" id="token-107-30" morph="none" pos="word" start_char="16848">to</TOKEN>
<TOKEN end_char="16861" id="token-107-31" morph="none" pos="word" start_char="16851">communities</TOKEN>
<TOKEN end_char="16869" id="token-107-32" morph="none" pos="word" start_char="16863">through</TOKEN>
<TOKEN end_char="16882" id="token-107-33" morph="none" pos="word" start_char="16871">philanthropy</TOKEN>
<TOKEN end_char="16886" id="token-107-34" morph="none" pos="word" start_char="16884">and</TOKEN>
<TOKEN end_char="16899" id="token-107-35" morph="none" pos="word" start_char="16888">volunteerism</TOKEN>
<TOKEN end_char="16900" id="token-107-36" morph="none" pos="punct" start_char="16900">.</TOKEN>
</SEG>
<SEG end_char="16946" id="segment-108" start_char="16902">
<ORIGINAL_TEXT>To learn more about Lilly, please visit us at</ORIGINAL_TEXT>
<TOKEN end_char="16903" id="token-108-0" morph="none" pos="word" start_char="16902">To</TOKEN>
<TOKEN end_char="16909" id="token-108-1" morph="none" pos="word" start_char="16905">learn</TOKEN>
<TOKEN end_char="16914" id="token-108-2" morph="none" pos="word" start_char="16911">more</TOKEN>
<TOKEN end_char="16920" id="token-108-3" morph="none" pos="word" start_char="16916">about</TOKEN>
<TOKEN end_char="16926" id="token-108-4" morph="none" pos="word" start_char="16922">Lilly</TOKEN>
<TOKEN end_char="16927" id="token-108-5" morph="none" pos="punct" start_char="16927">,</TOKEN>
<TOKEN end_char="16934" id="token-108-6" morph="none" pos="word" start_char="16929">please</TOKEN>
<TOKEN end_char="16940" id="token-108-7" morph="none" pos="word" start_char="16936">visit</TOKEN>
<TOKEN end_char="16943" id="token-108-8" morph="none" pos="word" start_char="16942">us</TOKEN>
<TOKEN end_char="16946" id="token-108-9" morph="none" pos="word" start_char="16945">at</TOKEN>
</SEG>
<SEG end_char="16961" id="segment-109" start_char="16949">
<ORIGINAL_TEXT>www.lilly.com</ORIGINAL_TEXT>
<TOKEN end_char="16961" id="token-109-0" morph="none" pos="url" start_char="16949">www.lilly.com</TOKEN>
</SEG>
<SEG end_char="16966" id="segment-110" start_char="16964">
<ORIGINAL_TEXT>and</ORIGINAL_TEXT>
<TOKEN end_char="16966" id="token-110-0" morph="none" pos="word" start_char="16964">and</TOKEN>
</SEG>
<SEG end_char="16986" id="segment-111" start_char="16969">
<ORIGINAL_TEXT>www.lilly.com/news</ORIGINAL_TEXT>
<TOKEN end_char="16986" id="token-111-0" morph="none" pos="url" start_char="16969">www.lilly.com/news</TOKEN>
</SEG>
<SEG end_char="16989" id="segment-112" start_char="16989">
<ORIGINAL_TEXT>.</ORIGINAL_TEXT>
<TOKEN end_char="16989" id="token-112-0" morph="none" pos="punct" start_char="16989">.</TOKEN>
</SEG>
<SEG end_char="16995" id="segment-113" start_char="16991">
<ORIGINAL_TEXT>P-LLY</ORIGINAL_TEXT>
<TOKEN end_char="16995" id="token-113-0" morph="none" pos="unknown" start_char="16991">P-LLY</TOKEN>
</SEG>
<SEG end_char="17060" id="segment-114" start_char="16998">
<ORIGINAL_TEXT>Lilly Cautionary Statement Regarding Forward-Looking Statements</ORIGINAL_TEXT>
<TOKEN end_char="17002" id="token-114-0" morph="none" pos="word" start_char="16998">Lilly</TOKEN>
<TOKEN end_char="17013" id="token-114-1" morph="none" pos="word" start_char="17004">Cautionary</TOKEN>
<TOKEN end_char="17023" id="token-114-2" morph="none" pos="word" start_char="17015">Statement</TOKEN>
<TOKEN end_char="17033" id="token-114-3" morph="none" pos="word" start_char="17025">Regarding</TOKEN>
<TOKEN end_char="17049" id="token-114-4" morph="none" pos="unknown" start_char="17035">Forward-Looking</TOKEN>
<TOKEN end_char="17060" id="token-114-5" morph="none" pos="word" start_char="17051">Statements</TOKEN>
</SEG>
<SEG end_char="17434" id="segment-115" start_char="17063">
<ORIGINAL_TEXT>This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about bamlanivimab (LY-CoV555) alone or bamlanivimab and etesevimab (LY-CoV016) together as potential treatments for patients with COVID-19, as well as its supply and distribution, and reflects Lilly's current beliefs and expectations.</ORIGINAL_TEXT>
<TOKEN end_char="17066" id="token-115-0" morph="none" pos="word" start_char="17063">This</TOKEN>
<TOKEN end_char="17072" id="token-115-1" morph="none" pos="word" start_char="17068">press</TOKEN>
<TOKEN end_char="17080" id="token-115-2" morph="none" pos="word" start_char="17074">release</TOKEN>
<TOKEN end_char="17089" id="token-115-3" morph="none" pos="word" start_char="17082">contains</TOKEN>
<TOKEN end_char="17105" id="token-115-4" morph="none" pos="unknown" start_char="17091">forward-looking</TOKEN>
<TOKEN end_char="17116" id="token-115-5" morph="none" pos="word" start_char="17107">statements</TOKEN>
<TOKEN end_char="17118" id="token-115-6" morph="none" pos="punct" start_char="17118">(</TOKEN>
<TOKEN end_char="17120" id="token-115-7" morph="none" pos="word" start_char="17119">as</TOKEN>
<TOKEN end_char="17125" id="token-115-8" morph="none" pos="word" start_char="17122">that</TOKEN>
<TOKEN end_char="17130" id="token-115-9" morph="none" pos="word" start_char="17127">term</TOKEN>
<TOKEN end_char="17133" id="token-115-10" morph="none" pos="word" start_char="17132">is</TOKEN>
<TOKEN end_char="17141" id="token-115-11" morph="none" pos="word" start_char="17135">defined</TOKEN>
<TOKEN end_char="17144" id="token-115-12" morph="none" pos="word" start_char="17143">in</TOKEN>
<TOKEN end_char="17148" id="token-115-13" morph="none" pos="word" start_char="17146">the</TOKEN>
<TOKEN end_char="17156" id="token-115-14" morph="none" pos="word" start_char="17150">Private</TOKEN>
<TOKEN end_char="17167" id="token-115-15" morph="none" pos="word" start_char="17158">Securities</TOKEN>
<TOKEN end_char="17178" id="token-115-16" morph="none" pos="word" start_char="17169">Litigation</TOKEN>
<TOKEN end_char="17185" id="token-115-17" morph="none" pos="word" start_char="17180">Reform</TOKEN>
<TOKEN end_char="17189" id="token-115-18" morph="none" pos="word" start_char="17187">Act</TOKEN>
<TOKEN end_char="17192" id="token-115-19" morph="none" pos="word" start_char="17191">of</TOKEN>
<TOKEN end_char="17197" id="token-115-20" morph="none" pos="word" start_char="17194">1995</TOKEN>
<TOKEN end_char="17198" id="token-115-21" morph="none" pos="punct" start_char="17198">)</TOKEN>
<TOKEN end_char="17204" id="token-115-22" morph="none" pos="word" start_char="17200">about</TOKEN>
<TOKEN end_char="17217" id="token-115-23" morph="none" pos="word" start_char="17206">bamlanivimab</TOKEN>
<TOKEN end_char="17219" id="token-115-24" morph="none" pos="punct" start_char="17219">(</TOKEN>
<TOKEN end_char="17228" id="token-115-25" morph="none" pos="unknown" start_char="17220">LY-CoV555</TOKEN>
<TOKEN end_char="17229" id="token-115-26" morph="none" pos="punct" start_char="17229">)</TOKEN>
<TOKEN end_char="17235" id="token-115-27" morph="none" pos="word" start_char="17231">alone</TOKEN>
<TOKEN end_char="17238" id="token-115-28" morph="none" pos="word" start_char="17237">or</TOKEN>
<TOKEN end_char="17251" id="token-115-29" morph="none" pos="word" start_char="17240">bamlanivimab</TOKEN>
<TOKEN end_char="17255" id="token-115-30" morph="none" pos="word" start_char="17253">and</TOKEN>
<TOKEN end_char="17266" id="token-115-31" morph="none" pos="word" start_char="17257">etesevimab</TOKEN>
<TOKEN end_char="17268" id="token-115-32" morph="none" pos="punct" start_char="17268">(</TOKEN>
<TOKEN end_char="17277" id="token-115-33" morph="none" pos="unknown" start_char="17269">LY-CoV016</TOKEN>
<TOKEN end_char="17278" id="token-115-34" morph="none" pos="punct" start_char="17278">)</TOKEN>
<TOKEN end_char="17287" id="token-115-35" morph="none" pos="word" start_char="17280">together</TOKEN>
<TOKEN end_char="17290" id="token-115-36" morph="none" pos="word" start_char="17289">as</TOKEN>
<TOKEN end_char="17300" id="token-115-37" morph="none" pos="word" start_char="17292">potential</TOKEN>
<TOKEN end_char="17311" id="token-115-38" morph="none" pos="word" start_char="17302">treatments</TOKEN>
<TOKEN end_char="17315" id="token-115-39" morph="none" pos="word" start_char="17313">for</TOKEN>
<TOKEN end_char="17324" id="token-115-40" morph="none" pos="word" start_char="17317">patients</TOKEN>
<TOKEN end_char="17329" id="token-115-41" morph="none" pos="word" start_char="17326">with</TOKEN>
<TOKEN end_char="17338" id="token-115-42" morph="none" pos="unknown" start_char="17331">COVID-19</TOKEN>
<TOKEN end_char="17339" id="token-115-43" morph="none" pos="punct" start_char="17339">,</TOKEN>
<TOKEN end_char="17342" id="token-115-44" morph="none" pos="word" start_char="17341">as</TOKEN>
<TOKEN end_char="17347" id="token-115-45" morph="none" pos="word" start_char="17344">well</TOKEN>
<TOKEN end_char="17350" id="token-115-46" morph="none" pos="word" start_char="17349">as</TOKEN>
<TOKEN end_char="17354" id="token-115-47" morph="none" pos="word" start_char="17352">its</TOKEN>
<TOKEN end_char="17361" id="token-115-48" morph="none" pos="word" start_char="17356">supply</TOKEN>
<TOKEN end_char="17365" id="token-115-49" morph="none" pos="word" start_char="17363">and</TOKEN>
<TOKEN end_char="17378" id="token-115-50" morph="none" pos="word" start_char="17367">distribution</TOKEN>
<TOKEN end_char="17379" id="token-115-51" morph="none" pos="punct" start_char="17379">,</TOKEN>
<TOKEN end_char="17383" id="token-115-52" morph="none" pos="word" start_char="17381">and</TOKEN>
<TOKEN end_char="17392" id="token-115-53" morph="none" pos="word" start_char="17385">reflects</TOKEN>
<TOKEN end_char="17400" id="token-115-54" morph="none" pos="word" start_char="17394">Lilly's</TOKEN>
<TOKEN end_char="17408" id="token-115-55" morph="none" pos="word" start_char="17402">current</TOKEN>
<TOKEN end_char="17416" id="token-115-56" morph="none" pos="word" start_char="17410">beliefs</TOKEN>
<TOKEN end_char="17420" id="token-115-57" morph="none" pos="word" start_char="17418">and</TOKEN>
<TOKEN end_char="17433" id="token-115-58" morph="none" pos="word" start_char="17422">expectations</TOKEN>
<TOKEN end_char="17434" id="token-115-59" morph="none" pos="punct" start_char="17434">.</TOKEN>
</SEG>
<SEG end_char="17577" id="segment-116" start_char="17436">
<ORIGINAL_TEXT>However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization.</ORIGINAL_TEXT>
<TOKEN end_char="17442" id="token-116-0" morph="none" pos="word" start_char="17436">However</TOKEN>
<TOKEN end_char="17443" id="token-116-1" morph="none" pos="punct" start_char="17443">,</TOKEN>
<TOKEN end_char="17446" id="token-116-2" morph="none" pos="word" start_char="17445">as</TOKEN>
<TOKEN end_char="17451" id="token-116-3" morph="none" pos="word" start_char="17448">with</TOKEN>
<TOKEN end_char="17455" id="token-116-4" morph="none" pos="word" start_char="17453">any</TOKEN>
<TOKEN end_char="17460" id="token-116-5" morph="none" pos="word" start_char="17457">such</TOKEN>
<TOKEN end_char="17472" id="token-116-6" morph="none" pos="word" start_char="17462">undertaking</TOKEN>
<TOKEN end_char="17473" id="token-116-7" morph="none" pos="punct" start_char="17473">,</TOKEN>
<TOKEN end_char="17479" id="token-116-8" morph="none" pos="word" start_char="17475">there</TOKEN>
<TOKEN end_char="17483" id="token-116-9" morph="none" pos="word" start_char="17481">are</TOKEN>
<TOKEN end_char="17495" id="token-116-10" morph="none" pos="word" start_char="17485">substantial</TOKEN>
<TOKEN end_char="17501" id="token-116-11" morph="none" pos="word" start_char="17497">risks</TOKEN>
<TOKEN end_char="17505" id="token-116-12" morph="none" pos="word" start_char="17503">and</TOKEN>
<TOKEN end_char="17519" id="token-116-13" morph="none" pos="word" start_char="17507">uncertainties</TOKEN>
<TOKEN end_char="17522" id="token-116-14" morph="none" pos="word" start_char="17521">in</TOKEN>
<TOKEN end_char="17526" id="token-116-15" morph="none" pos="word" start_char="17524">the</TOKEN>
<TOKEN end_char="17534" id="token-116-16" morph="none" pos="word" start_char="17528">process</TOKEN>
<TOKEN end_char="17537" id="token-116-17" morph="none" pos="word" start_char="17536">of</TOKEN>
<TOKEN end_char="17542" id="token-116-18" morph="none" pos="word" start_char="17539">drug</TOKEN>
<TOKEN end_char="17554" id="token-116-19" morph="none" pos="word" start_char="17544">development</TOKEN>
<TOKEN end_char="17558" id="token-116-20" morph="none" pos="word" start_char="17556">and</TOKEN>
<TOKEN end_char="17576" id="token-116-21" morph="none" pos="word" start_char="17560">commercialization</TOKEN>
<TOKEN end_char="17577" id="token-116-22" morph="none" pos="punct" start_char="17577">.</TOKEN>
</SEG>
<SEG end_char="18113" id="segment-117" start_char="17579">
<ORIGINAL_TEXT>Among other things, there can be no guarantee that future study results will be consistent with the results to date, that bamlanivimab alone or bamlanivimab and etesevimab together will prove to be safe and effective treatments or successful preventative therapies for COVID-19, that bamlanivimab alone or bamlanivimab and etesevimab together will receive regulatory approvals or additional authorizations, or that Lilly can provide an adequate supply of bamlanivimab alone or bamlanivimab and etesevimab together in all circumstances.</ORIGINAL_TEXT>
<TOKEN end_char="17583" id="token-117-0" morph="none" pos="word" start_char="17579">Among</TOKEN>
<TOKEN end_char="17589" id="token-117-1" morph="none" pos="word" start_char="17585">other</TOKEN>
<TOKEN end_char="17596" id="token-117-2" morph="none" pos="word" start_char="17591">things</TOKEN>
<TOKEN end_char="17597" id="token-117-3" morph="none" pos="punct" start_char="17597">,</TOKEN>
<TOKEN end_char="17603" id="token-117-4" morph="none" pos="word" start_char="17599">there</TOKEN>
<TOKEN end_char="17607" id="token-117-5" morph="none" pos="word" start_char="17605">can</TOKEN>
<TOKEN end_char="17610" id="token-117-6" morph="none" pos="word" start_char="17609">be</TOKEN>
<TOKEN end_char="17613" id="token-117-7" morph="none" pos="word" start_char="17612">no</TOKEN>
<TOKEN end_char="17623" id="token-117-8" morph="none" pos="word" start_char="17615">guarantee</TOKEN>
<TOKEN end_char="17628" id="token-117-9" morph="none" pos="word" start_char="17625">that</TOKEN>
<TOKEN end_char="17635" id="token-117-10" morph="none" pos="word" start_char="17630">future</TOKEN>
<TOKEN end_char="17641" id="token-117-11" morph="none" pos="word" start_char="17637">study</TOKEN>
<TOKEN end_char="17649" id="token-117-12" morph="none" pos="word" start_char="17643">results</TOKEN>
<TOKEN end_char="17654" id="token-117-13" morph="none" pos="word" start_char="17651">will</TOKEN>
<TOKEN end_char="17657" id="token-117-14" morph="none" pos="word" start_char="17656">be</TOKEN>
<TOKEN end_char="17668" id="token-117-15" morph="none" pos="word" start_char="17659">consistent</TOKEN>
<TOKEN end_char="17673" id="token-117-16" morph="none" pos="word" start_char="17670">with</TOKEN>
<TOKEN end_char="17677" id="token-117-17" morph="none" pos="word" start_char="17675">the</TOKEN>
<TOKEN end_char="17685" id="token-117-18" morph="none" pos="word" start_char="17679">results</TOKEN>
<TOKEN end_char="17688" id="token-117-19" morph="none" pos="word" start_char="17687">to</TOKEN>
<TOKEN end_char="17693" id="token-117-20" morph="none" pos="word" start_char="17690">date</TOKEN>
<TOKEN end_char="17694" id="token-117-21" morph="none" pos="punct" start_char="17694">,</TOKEN>
<TOKEN end_char="17699" id="token-117-22" morph="none" pos="word" start_char="17696">that</TOKEN>
<TOKEN end_char="17712" id="token-117-23" morph="none" pos="word" start_char="17701">bamlanivimab</TOKEN>
<TOKEN end_char="17718" id="token-117-24" morph="none" pos="word" start_char="17714">alone</TOKEN>
<TOKEN end_char="17721" id="token-117-25" morph="none" pos="word" start_char="17720">or</TOKEN>
<TOKEN end_char="17734" id="token-117-26" morph="none" pos="word" start_char="17723">bamlanivimab</TOKEN>
<TOKEN end_char="17738" id="token-117-27" morph="none" pos="word" start_char="17736">and</TOKEN>
<TOKEN end_char="17749" id="token-117-28" morph="none" pos="word" start_char="17740">etesevimab</TOKEN>
<TOKEN end_char="17758" id="token-117-29" morph="none" pos="word" start_char="17751">together</TOKEN>
<TOKEN end_char="17763" id="token-117-30" morph="none" pos="word" start_char="17760">will</TOKEN>
<TOKEN end_char="17769" id="token-117-31" morph="none" pos="word" start_char="17765">prove</TOKEN>
<TOKEN end_char="17772" id="token-117-32" morph="none" pos="word" start_char="17771">to</TOKEN>
<TOKEN end_char="17775" id="token-117-33" morph="none" pos="word" start_char="17774">be</TOKEN>
<TOKEN end_char="17780" id="token-117-34" morph="none" pos="word" start_char="17777">safe</TOKEN>
<TOKEN end_char="17784" id="token-117-35" morph="none" pos="word" start_char="17782">and</TOKEN>
<TOKEN end_char="17794" id="token-117-36" morph="none" pos="word" start_char="17786">effective</TOKEN>
<TOKEN end_char="17805" id="token-117-37" morph="none" pos="word" start_char="17796">treatments</TOKEN>
<TOKEN end_char="17808" id="token-117-38" morph="none" pos="word" start_char="17807">or</TOKEN>
<TOKEN end_char="17819" id="token-117-39" morph="none" pos="word" start_char="17810">successful</TOKEN>
<TOKEN end_char="17832" id="token-117-40" morph="none" pos="word" start_char="17821">preventative</TOKEN>
<TOKEN end_char="17842" id="token-117-41" morph="none" pos="word" start_char="17834">therapies</TOKEN>
<TOKEN end_char="17846" id="token-117-42" morph="none" pos="word" start_char="17844">for</TOKEN>
<TOKEN end_char="17855" id="token-117-43" morph="none" pos="unknown" start_char="17848">COVID-19</TOKEN>
<TOKEN end_char="17856" id="token-117-44" morph="none" pos="punct" start_char="17856">,</TOKEN>
<TOKEN end_char="17861" id="token-117-45" morph="none" pos="word" start_char="17858">that</TOKEN>
<TOKEN end_char="17874" id="token-117-46" morph="none" pos="word" start_char="17863">bamlanivimab</TOKEN>
<TOKEN end_char="17880" id="token-117-47" morph="none" pos="word" start_char="17876">alone</TOKEN>
<TOKEN end_char="17883" id="token-117-48" morph="none" pos="word" start_char="17882">or</TOKEN>
<TOKEN end_char="17896" id="token-117-49" morph="none" pos="word" start_char="17885">bamlanivimab</TOKEN>
<TOKEN end_char="17900" id="token-117-50" morph="none" pos="word" start_char="17898">and</TOKEN>
<TOKEN end_char="17911" id="token-117-51" morph="none" pos="word" start_char="17902">etesevimab</TOKEN>
<TOKEN end_char="17920" id="token-117-52" morph="none" pos="word" start_char="17913">together</TOKEN>
<TOKEN end_char="17925" id="token-117-53" morph="none" pos="word" start_char="17922">will</TOKEN>
<TOKEN end_char="17933" id="token-117-54" morph="none" pos="word" start_char="17927">receive</TOKEN>
<TOKEN end_char="17944" id="token-117-55" morph="none" pos="word" start_char="17935">regulatory</TOKEN>
<TOKEN end_char="17954" id="token-117-56" morph="none" pos="word" start_char="17946">approvals</TOKEN>
<TOKEN end_char="17957" id="token-117-57" morph="none" pos="word" start_char="17956">or</TOKEN>
<TOKEN end_char="17968" id="token-117-58" morph="none" pos="word" start_char="17959">additional</TOKEN>
<TOKEN end_char="17983" id="token-117-59" morph="none" pos="word" start_char="17970">authorizations</TOKEN>
<TOKEN end_char="17984" id="token-117-60" morph="none" pos="punct" start_char="17984">,</TOKEN>
<TOKEN end_char="17987" id="token-117-61" morph="none" pos="word" start_char="17986">or</TOKEN>
<TOKEN end_char="17992" id="token-117-62" morph="none" pos="word" start_char="17989">that</TOKEN>
<TOKEN end_char="17998" id="token-117-63" morph="none" pos="word" start_char="17994">Lilly</TOKEN>
<TOKEN end_char="18002" id="token-117-64" morph="none" pos="word" start_char="18000">can</TOKEN>
<TOKEN end_char="18010" id="token-117-65" morph="none" pos="word" start_char="18004">provide</TOKEN>
<TOKEN end_char="18013" id="token-117-66" morph="none" pos="word" start_char="18012">an</TOKEN>
<TOKEN end_char="18022" id="token-117-67" morph="none" pos="word" start_char="18015">adequate</TOKEN>
<TOKEN end_char="18029" id="token-117-68" morph="none" pos="word" start_char="18024">supply</TOKEN>
<TOKEN end_char="18032" id="token-117-69" morph="none" pos="word" start_char="18031">of</TOKEN>
<TOKEN end_char="18045" id="token-117-70" morph="none" pos="word" start_char="18034">bamlanivimab</TOKEN>
<TOKEN end_char="18051" id="token-117-71" morph="none" pos="word" start_char="18047">alone</TOKEN>
<TOKEN end_char="18054" id="token-117-72" morph="none" pos="word" start_char="18053">or</TOKEN>
<TOKEN end_char="18067" id="token-117-73" morph="none" pos="word" start_char="18056">bamlanivimab</TOKEN>
<TOKEN end_char="18071" id="token-117-74" morph="none" pos="word" start_char="18069">and</TOKEN>
<TOKEN end_char="18082" id="token-117-75" morph="none" pos="word" start_char="18073">etesevimab</TOKEN>
<TOKEN end_char="18091" id="token-117-76" morph="none" pos="word" start_char="18084">together</TOKEN>
<TOKEN end_char="18094" id="token-117-77" morph="none" pos="word" start_char="18093">in</TOKEN>
<TOKEN end_char="18098" id="token-117-78" morph="none" pos="word" start_char="18096">all</TOKEN>
<TOKEN end_char="18112" id="token-117-79" morph="none" pos="word" start_char="18100">circumstances</TOKEN>
<TOKEN end_char="18113" id="token-117-80" morph="none" pos="punct" start_char="18113">.</TOKEN>
</SEG>
<SEG end_char="18357" id="segment-118" start_char="18115">
<ORIGINAL_TEXT>For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.</ORIGINAL_TEXT>
<TOKEN end_char="18117" id="token-118-0" morph="none" pos="word" start_char="18115">For</TOKEN>
<TOKEN end_char="18119" id="token-118-1" morph="none" pos="word" start_char="18119">a</TOKEN>
<TOKEN end_char="18127" id="token-118-2" morph="none" pos="word" start_char="18121">further</TOKEN>
<TOKEN end_char="18138" id="token-118-3" morph="none" pos="word" start_char="18129">discussion</TOKEN>
<TOKEN end_char="18141" id="token-118-4" morph="none" pos="word" start_char="18140">of</TOKEN>
<TOKEN end_char="18147" id="token-118-5" morph="none" pos="word" start_char="18143">these</TOKEN>
<TOKEN end_char="18151" id="token-118-6" morph="none" pos="word" start_char="18149">and</TOKEN>
<TOKEN end_char="18157" id="token-118-7" morph="none" pos="word" start_char="18153">other</TOKEN>
<TOKEN end_char="18163" id="token-118-8" morph="none" pos="word" start_char="18159">risks</TOKEN>
<TOKEN end_char="18167" id="token-118-9" morph="none" pos="word" start_char="18165">and</TOKEN>
<TOKEN end_char="18181" id="token-118-10" morph="none" pos="word" start_char="18169">uncertainties</TOKEN>
<TOKEN end_char="18186" id="token-118-11" morph="none" pos="word" start_char="18183">that</TOKEN>
<TOKEN end_char="18192" id="token-118-12" morph="none" pos="word" start_char="18188">could</TOKEN>
<TOKEN end_char="18198" id="token-118-13" morph="none" pos="word" start_char="18194">cause</TOKEN>
<TOKEN end_char="18205" id="token-118-14" morph="none" pos="word" start_char="18200">actual</TOKEN>
<TOKEN end_char="18213" id="token-118-15" morph="none" pos="word" start_char="18207">results</TOKEN>
<TOKEN end_char="18216" id="token-118-16" morph="none" pos="word" start_char="18215">to</TOKEN>
<TOKEN end_char="18223" id="token-118-17" morph="none" pos="word" start_char="18218">differ</TOKEN>
<TOKEN end_char="18228" id="token-118-18" morph="none" pos="word" start_char="18225">from</TOKEN>
<TOKEN end_char="18236" id="token-118-19" morph="none" pos="word" start_char="18230">Lilly's</TOKEN>
<TOKEN end_char="18249" id="token-118-20" morph="none" pos="word" start_char="18238">expectations</TOKEN>
<TOKEN end_char="18250" id="token-118-21" morph="none" pos="punct" start_char="18250">,</TOKEN>
<TOKEN end_char="18257" id="token-118-22" morph="none" pos="word" start_char="18252">please</TOKEN>
<TOKEN end_char="18261" id="token-118-23" morph="none" pos="word" start_char="18259">see</TOKEN>
<TOKEN end_char="18269" id="token-118-24" morph="none" pos="word" start_char="18263">Lilly's</TOKEN>
<TOKEN end_char="18274" id="token-118-25" morph="none" pos="word" start_char="18271">most</TOKEN>
<TOKEN end_char="18281" id="token-118-26" morph="none" pos="word" start_char="18276">recent</TOKEN>
<TOKEN end_char="18287" id="token-118-27" morph="none" pos="word" start_char="18283">Forms</TOKEN>
<TOKEN end_char="18292" id="token-118-28" morph="none" pos="unknown" start_char="18289">10-K</TOKEN>
<TOKEN end_char="18296" id="token-118-29" morph="none" pos="word" start_char="18294">and</TOKEN>
<TOKEN end_char="18301" id="token-118-30" morph="none" pos="unknown" start_char="18298">10-Q</TOKEN>
<TOKEN end_char="18307" id="token-118-31" morph="none" pos="word" start_char="18303">filed</TOKEN>
<TOKEN end_char="18312" id="token-118-32" morph="none" pos="word" start_char="18309">with</TOKEN>
<TOKEN end_char="18316" id="token-118-33" morph="none" pos="word" start_char="18314">the</TOKEN>
<TOKEN end_char="18320" id="token-118-34" morph="none" pos="unknown" start_char="18318">U.S</TOKEN>
<TOKEN end_char="18321" id="token-118-35" morph="none" pos="punct" start_char="18321">.</TOKEN>
<TOKEN end_char="18332" id="token-118-36" morph="none" pos="word" start_char="18323">Securities</TOKEN>
<TOKEN end_char="18336" id="token-118-37" morph="none" pos="word" start_char="18334">and</TOKEN>
<TOKEN end_char="18345" id="token-118-38" morph="none" pos="word" start_char="18338">Exchange</TOKEN>
<TOKEN end_char="18356" id="token-118-39" morph="none" pos="word" start_char="18347">Commission</TOKEN>
<TOKEN end_char="18357" id="token-118-40" morph="none" pos="punct" start_char="18357">.</TOKEN>
</SEG>
<SEG end_char="18420" id="segment-119" start_char="18359">
<ORIGINAL_TEXT>Lilly undertakes no duty to update forward-looking statements.</ORIGINAL_TEXT>
<TOKEN end_char="18363" id="token-119-0" morph="none" pos="word" start_char="18359">Lilly</TOKEN>
<TOKEN end_char="18374" id="token-119-1" morph="none" pos="word" start_char="18365">undertakes</TOKEN>
<TOKEN end_char="18377" id="token-119-2" morph="none" pos="word" start_char="18376">no</TOKEN>
<TOKEN end_char="18382" id="token-119-3" morph="none" pos="word" start_char="18379">duty</TOKEN>
<TOKEN end_char="18385" id="token-119-4" morph="none" pos="word" start_char="18384">to</TOKEN>
<TOKEN end_char="18392" id="token-119-5" morph="none" pos="word" start_char="18387">update</TOKEN>
<TOKEN end_char="18408" id="token-119-6" morph="none" pos="unknown" start_char="18394">forward-looking</TOKEN>
<TOKEN end_char="18419" id="token-119-7" morph="none" pos="word" start_char="18410">statements</TOKEN>
<TOKEN end_char="18420" id="token-119-8" morph="none" pos="punct" start_char="18420">.</TOKEN>
</SEG>
<SEG end_char="18450" id="segment-120" start_char="18424">
<ORIGINAL_TEXT>Eli Lilly and Company logo.</ORIGINAL_TEXT>
<TOKEN end_char="18426" id="token-120-0" morph="none" pos="word" start_char="18424">Eli</TOKEN>
<TOKEN end_char="18432" id="token-120-1" morph="none" pos="word" start_char="18428">Lilly</TOKEN>
<TOKEN end_char="18436" id="token-120-2" morph="none" pos="word" start_char="18434">and</TOKEN>
<TOKEN end_char="18444" id="token-120-3" morph="none" pos="word" start_char="18438">Company</TOKEN>
<TOKEN end_char="18449" id="token-120-4" morph="none" pos="word" start_char="18446">logo</TOKEN>
<TOKEN end_char="18450" id="token-120-5" morph="none" pos="punct" start_char="18450">.</TOKEN>
</SEG>
<SEG end_char="18521" id="segment-121" start_char="18452">
<ORIGINAL_TEXT>(PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)</ORIGINAL_TEXT>
<TOKEN end_char="18452" id="token-121-0" morph="none" pos="punct" start_char="18452">(</TOKEN>
<TOKEN end_char="18462" id="token-121-1" morph="none" pos="word" start_char="18453">PRNewsFoto</TOKEN>
<TOKEN end_char="18463" id="token-121-2" morph="none" pos="punct" start_char="18463">,</TOKEN>
<TOKEN end_char="18467" id="token-121-3" morph="none" pos="word" start_char="18465">Eli</TOKEN>
<TOKEN end_char="18473" id="token-121-4" morph="none" pos="word" start_char="18469">Lilly</TOKEN>
<TOKEN end_char="18477" id="token-121-5" morph="none" pos="word" start_char="18475">and</TOKEN>
<TOKEN end_char="18485" id="token-121-6" morph="none" pos="word" start_char="18479">Company</TOKEN>
<TOKEN end_char="18486" id="token-121-7" morph="none" pos="punct" start_char="18486">)</TOKEN>
<TOKEN end_char="18488" id="token-121-8" morph="none" pos="punct" start_char="18488">(</TOKEN>
<TOKEN end_char="18502" id="token-121-9" morph="none" pos="unknown" start_char="18489">PRNewsfoto/Eli</TOKEN>
<TOKEN end_char="18508" id="token-121-10" morph="none" pos="word" start_char="18504">Lilly</TOKEN>
<TOKEN end_char="18512" id="token-121-11" morph="none" pos="word" start_char="18510">and</TOKEN>
<TOKEN end_char="18520" id="token-121-12" morph="none" pos="word" start_char="18514">Company</TOKEN>
<TOKEN end_char="18521" id="token-121-13" morph="none" pos="punct" start_char="18521">)</TOKEN>
</SEG>
<SEG end_char="18738" id="segment-122" start_char="18525">
<ORIGINAL_TEXT>View original content to download multimedia:http://www.prnewswire.com/news-releases/lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-trial-for-early-covid-19-301243984.html</ORIGINAL_TEXT>
<TOKEN end_char="18528" id="token-122-0" morph="none" pos="word" start_char="18525">View</TOKEN>
<TOKEN end_char="18537" id="token-122-1" morph="none" pos="word" start_char="18530">original</TOKEN>
<TOKEN end_char="18545" id="token-122-2" morph="none" pos="word" start_char="18539">content</TOKEN>
<TOKEN end_char="18548" id="token-122-3" morph="none" pos="word" start_char="18547">to</TOKEN>
<TOKEN end_char="18557" id="token-122-4" morph="none" pos="word" start_char="18550">download</TOKEN>
<TOKEN end_char="18738" id="token-122-5" morph="none" pos="unknown" start_char="18559">multimedia:http://www.prnewswire.com/news-releases/lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-trial-for-early-covid-19-301243984.html</TOKEN>
</SEG>
<SEG end_char="18768" id="segment-123" start_char="18741">
<ORIGINAL_TEXT>SOURCE Eli Lilly and Company</ORIGINAL_TEXT>
<TOKEN end_char="18746" id="token-123-0" morph="none" pos="word" start_char="18741">SOURCE</TOKEN>
<TOKEN end_char="18750" id="token-123-1" morph="none" pos="word" start_char="18748">Eli</TOKEN>
<TOKEN end_char="18756" id="token-123-2" morph="none" pos="word" start_char="18752">Lilly</TOKEN>
<TOKEN end_char="18760" id="token-123-3" morph="none" pos="word" start_char="18758">and</TOKEN>
<TOKEN end_char="18768" id="token-123-4" morph="none" pos="word" start_char="18762">Company</TOKEN>
</SEG>
</TEXT>
</DOC>
</LCTL_TEXT>